<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Laser therapy for treating hypertrophic and keloid scars - Leszczynski, R - 2022 | Cochrane Library</title> <meta content="Laser therapy for treating hypertrophic and keloid scars - Leszczynski, R - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011642.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Laser therapy for treating hypertrophic and keloid scars - Leszczynski, R - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011642.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011642.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Laser therapy for treating hypertrophic and keloid scars" name="citation_title"/> <meta content="Rafael Leszczynski" name="citation_author"/> <meta content="Inderma" name="citation_author_institution"/> <meta content="Carolina AP da Silva" name="citation_author"/> <meta content="Health Technology Assessment Center" name="citation_author_institution"/> <meta content="Ana Carolina Pereira Nunes Pinto" name="citation_author"/> <meta content="anacarolinapnp@hotmail.com" name="citation_author_email"/> <meta content="Uliana Kuczynski" name="citation_author"/> <meta content="Universidade Federal do Paraná" name="citation_author_institution"/> <meta content="Edina MK da Silva" name="citation_author"/> <meta content="Universidade Federal de São Paulo" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD011642.pub2" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/09/26" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011642.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011642.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011642.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenal Cortex Hormones [therapeutic use]; Aluminum; Atrophy; Carbon Dioxide; *Cicatrix, Hypertrophic [etiology, radiotherapy]; Dimethylpolysiloxanes; Erbium; Fluorouracil; Helium; Hypertrophy; *Hypopigmentation [etiology]; *Keloid [etiology, radiotherapy]; *Laser Therapy [adverse effects]; Neodymium; Neon; Pain [etiology]; Silicone Gels; *Telangiectasis [etiology]; Triamcinolone Acetonide; Verapamil; Wound Healing; Yttrium" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011642.pub2&amp;doi=10.1002/14651858.CD011642.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011642.pub2&amp;doi=10.1002/14651858.CD011642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011642.pub2&amp;doi=10.1002/14651858.CD011642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011642.pub2&amp;doi=10.1002/14651858.CD011642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011642.pub2&amp;doi=10.1002/14651858.CD011642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011642.pub2&amp;doi=10.1002/14651858.CD011642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011642.pub2&amp;doi=10.1002/14651858.CD011642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011642.pub2&amp;doi=10.1002/14651858.CD011642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011642.pub2&amp;doi=10.1002/14651858.CD011642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011642.pub2&amp;doi=10.1002/14651858.CD011642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011642.pub2&amp;doi=10.1002/14651858.CD011642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011642.pub2&amp;doi=10.1002/14651858.CD011642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011642.pub2&amp;doi=10.1002/14651858.CD011642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011642.pub2&amp;doi=10.1002/14651858.CD011642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011642.pub2&amp;doi=10.1002/14651858.CD011642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011642.pub2&amp;doi=10.1002/14651858.CD011642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011642.pub2&amp;doi=10.1002/14651858.CD011642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011642.pub2&amp;doi=10.1002/14651858.CD011642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011642.pub2&amp;doi=10.1002/14651858.CD011642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011642.pub2&amp;doi=10.1002/14651858.CD011642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011642.pub2&amp;doi=10.1002/14651858.CD011642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011642.pub2&amp;doi=10.1002/14651858.CD011642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011642.pub2&amp;doi=10.1002/14651858.CD011642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="FKeXZrqu";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011642\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011642\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011642\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011642\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","pt","ko","ms","ja","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011642.pub2",title:"Laser therapy for treating hypertrophic and keloid scars",firstPublishedDate:"Sep 26, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Wounds Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=FKeXZrqu&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011642.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011642.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011642.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011642.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011642.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011642.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011642.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011642.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011642.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011642.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>10672 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011642.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011642.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011642.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011642.pub2/full#CD011642-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011642.pub2/full#CD011642-sec-0121"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011642.pub2/full#CD011642-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011642.pub2/full#CD011642-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011642.pub2/full#CD011642-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011642.pub2/full#CD011642-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011642.pub2/full#CD011642-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011642.pub2/full#CD011642-sec-0115"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011642.pub2/appendices#CD011642-sec-0126"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/table_n/CD011642StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/table_n/CD011642StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011642.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011642.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011642.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011642.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011642.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011642.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Laser therapy for treating hypertrophic and keloid scars</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011642.pub2/information#CD011642-cr-0004">Rafael Leszczynski</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011642.pub2/information#CD011642-cr-0005">Carolina AP da Silva</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011642.pub2/information#CD011642-cr-0006"><i class="icon corresponding-author fa fa-envelope"></i>Ana Carolina Pereira Nunes Pinto</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011642.pub2/information#CD011642-cr-0007">Uliana Kuczynski</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011642.pub2/information#CD011642-cr-0008">Edina MK da Silva</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/information/en#CD011642-sec-0156">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 26 September 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011642.pub2">https://doi.org/10.1002/14651858.CD011642.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011642-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011642-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011642-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011642-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011642-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD011642-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/pt#CD011642-abs-0006">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011642-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011642-abs-0001" lang="en"> <section id="CD011642-sec-0001"> <h3 class="title" id="CD011642-sec-0001">Background</h3> <p>Hypertrophic and keloid scars are common skin conditions resulting from abnormal wound healing. They can cause itching, pain and have a negative physical and psychological impact on patients’ lives. Different approaches are used aiming to improve these scars, including intralesional corticosteroids, surgery and more recently, laser therapy. Since laser therapy is expensive and may have adverse effects, it is critical to evaluate the potential benefits and harms of this therapy for treating hypertrophic and keloid scars. </p> </section> <section id="CD011642-sec-0002"> <h3 class="title" id="CD011642-sec-0002">Objectives</h3> <p>To assess the effects of laser therapy for treating hypertrophic and keloid scars.</p> </section> <section id="CD011642-sec-0003"> <h3 class="title" id="CD011642-sec-0003">Search methods</h3> <p>In March 2021 we searched the Cochrane Wounds Specialised Register, CENTRAL, MEDLINE, Embase, CINAHL EBSCO Plus and LILACS. To identify additional studies, we also searched clinical trials registries for ongoing and unpublished studies, and scanned reference lists of relevant included studies as well as reviews, meta‐analyses, and health technology reports. There were no restrictions with respect to language, date of publication, or study setting. </p> </section> <section id="CD011642-sec-0004"> <h3 class="title" id="CD011642-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) for treating hypertrophic or keloid scars (or both), comparing laser therapy with placebo, no intervention or another intervention. </p> </section> <section id="CD011642-sec-0005"> <h3 class="title" id="CD011642-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected studies, extracted the data, assessed the risk of bias of included studies and carried out GRADE assessments to assess the certainty of evidence. A third review author arbitrated if there were disagreements. </p> </section> <section id="CD011642-sec-0006"> <h3 class="title" id="CD011642-sec-0006">Main results</h3> <p>We included 15 RCTs, involving 604 participants (children and adults) with study sample sizes ranging from 10 to 120 participants (mean 40.27). Where studies randomised different parts of the same scar, each scar segment was the unit of analysis (906 scar segments). The length of participant follow‐up varied from 12 weeks to 12 months. All included trials had a high risk of bias for at least one domain: all studies were deemed at high risk of bias due to lack of blinding of participants and personnel. The variability of intervention types, controls, follow‐up periods and limitations with report data meant we pooled data for one comparison (and only two outcomes within this). Several review secondary outcomes ‐ cosmesis, tolerance, preference for different modes of treatment, adherence, and change in quality of life ‐ were not reported in any of the included studies. </p> <p>Laser versus no treatment: </p> <p>We found low‐certainty evidence suggesting there may be more hypertrophic and keloid scar improvement (that is scars are less severe) in 585‐nm pulsed‐dye laser (PDL) ‐treated scars compared with no treatment (risk ratio (RR) 1.96; 95% confidence interval (CI): 1.11 to 3.45; two studies, 60 scar segments). </p> <p>It is unclear whether non‐ablative fractional laser (NAFL) impacts on hypertrophic scar severity when compared with no treatment (very low‐certainty evidence). </p> <p>It is unclear whether fractional carbon dioxide (CO<sub>2</sub>) laser impacts on hypertrophic and keloid scar severity compared with no treatment (very low‐certainty evidence). </p> <p>Eight studies reported treatment‐related adverse effects but did not provide enough data for further analyses. </p> <p>Laser versus other treatments: </p> <p>We are uncertain whether treatment with 585‐nm PDL impacts on hypertrophic and keloid scar severity compared with intralesional corticosteroid triamcinolone acetonide (TAC), intralesional Fluorouracil (5‐FU) or combined use of TAC plus 5‐FU (very low‐certainty evidence). It is also uncertain whether erbium laser impacts on hypertrophic scar severity when compared with TAC (very low‐certainty evidence). </p> <p>Other comparisons included 585‐nm PDL versus silicone gel sheeting, fractional CO<sub>2</sub> laser versus TAC and fractional CO<sub>2</sub> laser versus verapamil. However, the authors did not report enough data regarding the severity of scars to compare the interventions. </p> <p>As only very low‐certainty evidence is available on treatment‐related adverse effects, including pain, charring (skin burning so that the surface becomes blackened), telangiectasia (a condition in which tiny blood vessels cause thread‐like red lines on the skin), skin atrophy (skin thinning), purpuric discolorations, hypopigmentation (skin colour becomes lighter), and erosion (loss of part of the top layer of skin, leaving a denuded surface) secondary to blistering, we are not able to draw conclusions as to how these treatments compare. </p> <p>Laser plus other treatment versus other treatment: </p> <p>It is unclear whether 585‐nm PDL plus TAC plus 5‐FU leads to a higher percentage of good to excellent improvement in hypertrophic and keloid scar severity compared with TAC plus 5‐FU, as the certainty of evidence has been assessed as very low. </p> <p>Due to very low‐certainty evidence, it is also uncertain whether CO<sub>2</sub> laser plus TAC impacts on keloid scar severity compared with cryosurgery plus TAC. </p> <p>The evidence is also very uncertain about the effect of neodymium‐doped yttrium aluminium garnet (Nd:YAG) laser plus intralesional corticosteroid diprospan plus 5‐FU on scar severity compared with diprospan plus 5‐FU and about the effect of helium‐neon (He‐Ne) laser plus decamethyltetrasiloxane, polydimethylsiloxane and cyclopentasiloxane cream on scar severity compared with decamethyltetrasiloxane, polydimethylsiloxane and cyclopentasiloxane cream. </p> <p>Only very low‐certainty evidence is available on treatment‐related adverse effects, including pain, atrophy, erythema, telangiectasia, hypopigmentation, regrowth, hyperpigmentation (skin colour becomes darker), and depigmentation (loss of colour from the skin). Therefore, we are not able to draw conclusions as to how these treatments compare.  </p> </section> <section id="CD011642-sec-0007"> <h3 class="title" id="CD011642-sec-0007">Authors' conclusions</h3> <p>There is insufficient evidence to support or refute the effectiveness of laser therapy for treating hypertrophic and keloid scars. The available information is also insufficient to perform a more accurate analysis on treatment‐related adverse effects related to laser therapy. Due to the heterogeneity of the studies, conflicting results, study design issues and small sample sizes, further high‐quality trials, with validated scales and core outcome sets should be developed. These trials should take into consideration the consumers' opinion and values, the need for long‐term follow‐up and the necessity of reporting the rate of recurrence of scars to determine whether lasers may achieve superior results when compared with other therapies for treating hypertrophic and keloid scars. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011642-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011642-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011642-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011642-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011642-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD011642-abs-0011">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD011642-abs-0009">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011642-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD011642-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011642-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD011642-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011642-abs-0002" lang="en"> <h3>Laser therapy for hypertrophic and keloid scars</h3> <p><b>What was studied in the review?</b> </p> <p>Hypertrophic and keloid scars are raised and bumpy scars that form when a wound does not heal correctly. These scars can be discoloured or reddened and can also cause pain and itching. A range of treatments are available, including silicone gels and steroids. </p> <p>Laser therapy may be an alternative treatment for these types of scars. During laser therapy, areas of skin are targeted by a powerful beam of light which can break down damaged tissue. Different types of laser therapy are available depending on the patient's skin type and the nature of the scar. Laser therapy is expensive and has potentially harmful side effects, so it is important to establish whether it is safe and effective. </p> <p><b>What is the aim of this review?</b> </p> <p>The aim of this review was to investigate whether laser therapy is an effective treatment for people with hypertrophic and keloid scars. To answer this question, researchers from Cochrane collected and analysed all relevant studies to answer this question and found 15 randomised controlled trials. </p> <p><b>What are the main results of the review?</b> </p> <p>We included 15 studies dating from 1999 to 2019, involving 604 participants (children and adults of both sexes). The study sizes were small (10 to 120 participants), with the length of participant follow‐up varying from 12 weeks to 12 months. The studies analysed the change in the severity of scars assessed by health professionals or participants. </p> <p>In the studies, different kinds of laser devices were compared with no treatment and with other treatment methods. Laser therapy combined with another treatment was also compared with this treatment alone. </p> <p>We cannot be sure whether laser therapy alone or combined with other treatments improves hypertrophic or keloid scars severity when compared with no treatment or other treatments, as the certainty of all available evidence is low or very low. This is due to the small number of studies, different comparisons, conflicting results, small number of participants, and lack of available data. </p> <p>Some side effects of laser treatment such as damage to the skin or underlying blood vessels, redness, and numbness were reported. However, the certainty of the evidence is too low to be sure how common these side effects are. </p> <p><b>Key messages</b> </p> <p>Taken together, the results of these studies do not allow us to be sure if using any kind of laser therapy is more or less effective than other available treatments for hypertrophic and keloid scars. As the studies provided only very low‐certainty evidence regarding possible side effects, we are not very confident in the results of the currently available studies, and we cannot be sure whether any type of laser therapy leads to more harm than benefits compared with no treatment or other treatments. </p> <p><b>How up to date is this review?</b> </p> <p>We searched for studies published up to 23 March 2021.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011642-sec-0121" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011642-sec-0121"></div> <h3 class="title" id="CD011642-sec-0122">Implications for practice</h3> <section id="CD011642-sec-0122"> <p>There is currently limited research evidence about the impact of laser therapy on severity of hypertrophic and keloid scars. Due to the heterogeneity of the studies and conflicting results, we cannot draw any conclusions on whether lasers offer net benefit when compared with traditional therapies for treating hypertrophic and keloid scars. Further high‐quality trials, with long‐term follow‐up, and which report the rate of scar recurrence, are needed to better understand the potential impacts of laser as a treatment for these scar types and to guide future clinical practice. </p> </section> <h3 class="title" id="CD011642-sec-0123">Implications for research</h3> <section id="CD011642-sec-0123"> <p>A broad range of different laser devices and protocols were used to treat hypertrophic scars and keloids resulting in multiple comparisons, often with limited evidence. As this is a high‐priority clinical decision uncertainty in the field, more randomised controlled trials (RCTs) assessing laser therapy for treating these types of scars are needed. Given the number of comparisons, focusing research on treatments where there is a signal of effectiveness, such as on 585‐nm pulsed‐dye laser (PDL), should be considered. </p> <p>New studies should be standardised, in order to provide more homogeneous and reliable data for a proper comparison of the results. For example, studies should evaluate the same laser device (e.g. 585‐nm PDL), delivered with the same fluency, in an equal regimen for treating similar scars (including the same scar age, size, and body region) of participants with the same phototype, and keloids and hypertrophic scars should be assessed separately (and their cause described, e.g. surgical wounds and post‐burn scars), as they are physiologically different and could respond distinctly to different treatment modalities. The follow‐up period should be suitably long to allow evaluation of the long‐term effects of laser therapy, recurrence events, or even worsening after treatment. Validated scales and forms (including quality of life forms) should be used. Also, to ensure a "spill‐over" of the treatment from one scar segment to the other is avoided, it may be useful for further trials ‐ if using a split‐scar design ‐ to leave treatment‐free areas (e.g. 2‐3 centimetres (cm)) between the treated scar segments. </p> <p>Of note, there are no current core outcome sets in this area and they should be developed taking into consideration consumers' opinion and values. The validated scale chosen should be one that evaluates both objective (measured by blinded observers, colorimeters, ultrasound, graduated callipers etc) and subjective (participant opinion about the overall improvement of the scar severity, symptoms, cosmesis, pain during treatment etc) characteristics. The Patient and Observer Scar Assessment Scale (POSAS) scale is an example. In addition, there is a need for clear and complete reporting of outcome data for the interventions being compared and reporting of the rate of recurrence of scars during the follow‐up periods. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011642-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011642-sec-0008"></div> <div class="table" id="CD011642-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Laser therapy compared with no treatment for treating hypertrophic and keloid scars</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Laser therapy</b> <b>compared with no treatment for treating hypertrophic and keloid scars</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with hypertrophic and keloid scars<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> laser therapy (various types ‐ 585‐nm Pulsed‐Dye Laser (PDL), Non‐Ablative Fractional Laser (NAFL), Fractional CO<sub>2</sub>)<br/><b>Comparison:</b> no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of scar segment<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with no treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Laser therapy</b> </p> </th> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Scar severity ‐ 585‐nm Pulsed‐Dye Laser (PDL) versus no treatment ‐ patient self‐assessment of scar improvement of 50% or higher ‐ hypertrophic and keloid scars ‐ follow‐up: 32 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.96<br/>(1.11 to 3.45) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>60<br/>(2 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<sup>1,2</sup><br/>Low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> <p>There may be more hypertrophic and keloid scar improvement (that is scars are less severe) in 585‐nm PDL‐treated scars compared with no treatment after 32 weeks. </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>400 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>784 per 1000<br/>  </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ 585‐nm PDL versus no treatment ‐ mild to moderate discomfort or pain related to treatment ‐ hypertrophic and keloid scars ‐follow‐up: 32 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Two split‐scar trials (n = 60) reported this outcome. In these studies, participants reported mild to moderate discomfort or pain in 10 out of 30 (10/30) (33%) PDL treated areas versus 0 out of 30 (0/30) (0%) no treatment areas (RR 8.62; 1.10 to 67.39). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>2,3</sup><br/>Very low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p> It is uncertain whether there is any difference in the incidence and severity of treatment‐related adverse effects in 585‐nm PDL‐treated hypertrophic and keloid scars compared with no treatment after 32 weeks. </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ 585‐nm PDL versus no treatment ‐ purpura ‐ hypertrophic and keloid scars ‐ follow‐up: 32 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Two split‐scar trials (n = 60) reported this outcome. In these studies, purpura was observed in 40 out of 40 (40/40) (100%) PDL treated areas versus 0 out of 20 (0/20) (0%) no treatment areas (RR 21.32; 3.14 to 144.86). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>2,3</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Scar severity ‐ Non‐Ablative Fractional Laser (NAFL) versus no treatment ‐ health professional global assessment measured on a visual analogue scale (VAS) ranging from 0 to 100 mm (0 = as normal skin and 100 = worst possible scar) ‐ hypertrophic scars ‐ follow‐up: 3 months </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 2.00</p> <p>(0.85 to 4.69)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>36</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>3,4 </sup><br/>Very low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>It is uncertain whether there is any difference in the scar severity in NAFL‐treated hypertrophic scars compared with no treatment after 3 months. </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>278 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>556 per 1000</p> <p> </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity ‐ NAFL versus no treatment ‐ patient global assessment measured on a VAS ranging from 0 to 100 mm (0 = as normal skin and 100 = worst possible scar) ‐ hypertrophic scars ‐ follow‐up: 3 months </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One split‐scar trial (n = 36) reported this outcome. In this study, the authors reported an improvement in scar severity in NAFL treated hypertrophic scars compared with no treatment on the patient global assessment at 1 month (reported P = 0.006) and 3 months (reported P = 0.02). </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>5,6</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity ‐ NAFL versus no treatment ‐ Patient and Observer Scar Assessment Scale (POSAS) (higher scores = worse scar appearance) ‐ hypertrophic scars ‐ follow‐up: up to 3 months </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One split‐scar trial (n = 36) reported this outcome. In this study, the authors reported an improvement in scar severity in NAFL treated hypertrophic scars compared with no treatment on the participant part of the scale at 1 month and 3 months. The size of the difference was not reported and no data for the observer part of the scale was presented. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>5,6</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ NAFL versus no treatment ‐ scar worsening ‐ hypertrophic scars ‐ follow‐up: 3 months </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One split‐scar trial (n = 20) reported this outcome. In this study, 3 out of 10 (3/10) (30%) NAFL treated areas versus 0 out of 10 (0/10) (0%) no treatment areas were considered by the patients to have worsened (RR 7.00; 0.41 to 120.16). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>3,7</sup><br/>Very low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>It is uncertain whether there is any difference in the incidence and severity of treatment‐related adverse effects in NAFL‐treated hypertrophic scars compared with no treatment after 3 months. </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ NAFL versus no treatment ‐ hyperpigmentation ‐ hypertrophic scars ‐ follow‐up: 3 months </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One split‐scar trial (n = 36) reported this outcome. In this study, hyperpigmentation was observed in 1 out of 18 (1/18) (6%) NAFL treated areas versus 0 out of 18 (0/18) (0%) no treatment areas (RR 3.00; 0.13 to 69.09). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>3,5 </sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Scar severity ‐ Fractional Carbon Dioxide (CO<sub>2</sub>) Laser versus no treatment ‐ Vancouver Burn Scar (VBS) scale (higher scores = worse scar appearance) ‐ hypertrophic scars ‐ follow‐up: up to 3 months </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>104</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>6,8</sup><br/>Very low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>It is uncertain whether there is any difference in the scar severity in Fractional CO<sub>2</sub>‐treated hypertrophic and keloid scars compared with no treatment after up to 3 months, and in Fractional CO<sub>2</sub>‐treated hypertrophic scars compared with no treatment after at least 1 month. </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Baseline mean in the no treatment group was 7.6</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD 1.30 lower<br/>(4.32 lower to 1.71 higher) </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Scar severity ‐ Fractional CO<sub>2</sub> Laser versus no treatment ‐ VBS (higher scores = worse scar appearance) ‐ keloid scars ‐ follow‐up: 3 months </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>24</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>6,9</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Baseline mean in the no treatment group was 7.6</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD 1.90 lower<br/>(3.02 lower to 0.78 lower) </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Scar severity ‐ Fractional CO<sub>2</sub> Laser versus no treatment ‐ POSAS scale (higher scores = worse scar appearance) ‐ hypertrophic scars ‐ follow‐up: at least 1 month </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>80</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>6,10</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Baseline mean in the no treatment group was 29.9</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD 4.13 higher (1.24 lower to 9.50 higher)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% confidence interval) is based on the mean risk in the comparison group and the relative effect of the intervention (and its 95% CI). </p> <p>ƚThe assumed risk in the comparison group is based on the event rate observed in the control arms of included trials. Where no events occurred, the risk was not calculated. </p> <p> </p> <p>VAS: visual analogue scale ‐ ranging from 0 to 100 mm (0 = normal skin and 100 = worst possible scar); </p> <p>Patient self‐assessment ‐ based on a 4‐point scale (1 = 0 to 25% improvement, 2 = 25 to 50% improvement, 3 = 50 to 75% improvement, and 4 = 75% or greater improvement); </p> <p>POSAS: Patient and Observer Scar Assessment Scale ‐ the lowest score (6) reflects normal skin, and the highest score (60) reflects the worst imaginable scar; </p> <p>VBS: Vancouver Burn Scar Assessment Scale ‐ severity of scar was determined by numeric value from a minimum of 0 to 13 as the most severe form. </p> <p><b>CI:</b> Confidence Interval; <b>CO<sub>2</sub>:</b> carbon dioxide;<b>LDTA:</b> (Low‐Density Treatment Arm of NAFL), <b>HDTA:</b> (High‐Density Treatment Arm of NAFL); <b>MD:</b> Mean Difference; <b>NAFL:</b> Non‐Ablative Fractional Laser ;<b>PDL:</b> Pulsed‐Dye Laser; <b>RR:</b> Risk Ratio; <b>VBS:</b> Vancouver Burn Scar Assessment Scale. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded 1 level for serious imprecision due to small number of events. </p> <p><sup>2</sup> Downgraded 1 level for serious risk of bias (lack of blinding of participants and assessors (patient‐reported outcome), and unclear sequence generation and allocation concealment). </p> <p><sup>3</sup> Downgraded 2 levels for very serious imprecision due to small number of events and large confidence interval. </p> <p><sup>4</sup> Downgraded 1 level for serious risk of bias (lack of blinding of participants). </p> <p><sup>5</sup> Downgraded 1 level for serious risk of bias (lack of blinding of participants and assessors (patient‐reported outcome)). </p> <p><sup>6</sup> Downgraded 2 levels for very serious imprecision due to small sample size and large confidence interval. </p> <p><sup>7</sup> Downgraded 1 level for serious risk of bias (lack of blinding of participants and assessors (patient‐reported outcome), incomplete outcome data, and unclear allocation concealment). </p> <p><sup>8</sup> Downgraded 1 level for serious risk of bias (selective reporting in one study, and lack of blinding of participants and incomplete outcome data in 2 studies). </p> <p><sup>9</sup> Downgraded 1 level for serious risk of bias (lack of blinding of participants, incomplete outcome data and selective reporting). </p> <p><sup>10</sup> Downgraded 1 level for serious risk of bias (lack of blinding of participants and assessors (patient‐reported outcome) and incomplete outcome data). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011642-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Laser therapy compared with other treatments for treating hypertrophic and keloid scars</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Laser therapy compared with other treatments for treating hypertrophic and keloid scars</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with hypertrophic and keloid scars<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> laser therapy (various types ‐ 585‐nm Pulsed‐Dye Laser (PDL), Erbium Laser, Fractional Carbon Dioxide (CO<sub>2</sub>) Laser)<br/><b>Comparison:</b> other treatments (various types ‐ triamcinolone acetonide (TAC), 5‐Fluorouracil (5‐FU), verapamil) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of scar segments<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with other treatments</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Laser therapy</b> </p> </th> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Scar severity ‐ 585‐nm Pulsed‐Dye Laser (PDL) versus Triamcinolone acetonide (TAC) ‐ Vancouver Burn Scar (VBS) (Higher score = worse scar appearance) ‐ hypertrophic scars ‐ follow‐up: up to 12 months </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>80<br/>(1 study) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>1,2</sup><br/>Very low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>It is uncertain whether there is any difference in the scar severity in PDL‐treated hypertrophic and keloid scars compared with TAC after up to 12 months. </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Baseline mean in the other treatment group was 6.7</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.5 lower<br/>(3.2 lower to 1.8 lower) </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity ‐ 585‐nm PDL versus TAC ‐ patient self‐assessment of scar improvement of 50% or higher, or patients considering the scar better or much better ‐ hypertrophic and keloid scars ‐ follow‐up: up to 12 months </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One split‐scar trial (n = 20) and one parallel trial (n = 80) reported this outcome. In the split scar trial, 8 out of 10 (8/10) (80%) PDL treated areas versus 10 out of 10 (10/10) (100%) TAC treated areas were considered to have improved 50% or more by participants (RR 0.81; 0.57 to 1.14), and in the parallel trial, 28 out of 40 participants (28/40) (70%) treated with PDL and 12 out of 40 participants (12/40) (30%) treated with TAC considered their scars better or much better (RR 2.33; 1.39 to 3.91). </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>3,4</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ 585‐nm PDL versus TAC: sequelae ‐ hypertrophic and keloid scars ‐ follow‐up: 32 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.09<br/>(0.01 to 1.45) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>20<br/>(1 study) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>3,5</sup><br/>Very low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>It is uncertain whether there is any difference in the incidence and severity of treatment‐related adverse effects in PDL‐treated hypertrophic and keloid scars compared with TAC after 32 weeks.   </p> <p> </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>500 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>45 per 1000<br/>  </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ 585‐nm PDL versus TAC ‐ mild to moderate pain related to treatment ‐ hypertrophic and keloid scars ‐ follow‐up: 32 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One split‐scar trial (n = 20) reported this outcome. In this study, participants reported to have felt mild to moderate pain during the intervention in 10 out of 10 (10/10) (100%) TAC treated areas versus in 9 out of 10 (9/10) (90%) PDL treated areas (RR 0.90; 0.69 to 1.18).  </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>3,5</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity ‐ 585‐nm PDL versus 5‐FU ‐ patient self‐assessment of scar improvement of 50% or higher ‐ hypertrophic and keloid scars ‐ follow‐up: 32 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One split‐scar trial (n = 20) reported this outcome. In this study, 8 out of 10 (8/10) (80%) PDL treated areas versus 10 out of 10 (10/10) (100%) 5‐FU treated areas were reported by the participants to have improved 50% or more (RR 0.81; 0.57 to 1.14). </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>3,5</sup><br/>Very low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>It is uncertain whether there is any difference in the scar severity in PDL‐treated hypertrophic and keloid scars compared with 5‐FU after 32 weeks.  </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ 585‐nm PDL versus 5‐FU ‐ mild to moderate pain related to treatment ‐ hypertrophic and keloid scars ‐ follow‐up: 32 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One split‐scar trial (n = 20) reported this outcome. In this study, participants reported to have felt mild to moderate pain during the intervention in 9 out of 10 (9/10) (90%) PDL treated areas versus in 10 out of 10 (10/10) (100%) 5‐FU treated areas (RR 0.90; 0.69 to 1.18). </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>3,5</sup><br/>Very low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>It is uncertain whether there is any difference in the incidence and severity of treatment‐related adverse effects in PDL‐treated hypertrophic and keloid scars compared with 5‐FU after 32 weeks. </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ 585‐nm PDL versus 5‐FU ‐ purpura ‐ hypertrophic and keloid scars ‐ follow‐up: 32 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One split‐scar trial (n = 20) reported this outcome. In this study, purpura was observed in 10 out of 10 (10/10) (100%) PDL treated areas versus in 2 out of 10 (2/10) (20%) 5‐FU treated areas (RR 4.20; 1.40 to 12.58). </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>3,5</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Scar severity ‐ 585‐nm PDL versus TAC plus 5‐FU ‐ patient self‐assessment of scar improvement of 50% or higher ‐ hypertrophic and keloid scars ‐ follow‐up: 32 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.89<br/>(0.61 to 1.29) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>20<br/>(1 study) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>3,5</sup><br/>Very low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p> It is uncertain whether there is any difference in the scar severity in PDL‐treated hypertrophic and keloid scars compared with TAC plus 5‐FU after 32 weeks. </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>900 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>801 per 1000</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ 585‐nm PDL versus TAC plus 5‐FU ‐ mild to moderate pain related to treatment ‐ hypertrophic and keloid scars ‐ follow‐up: 32 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One split‐scar trial (n = 20) reported this outcome. In this study, participants reported to have felt mild to moderate pain during the intervention in 9 out of 10 (9/10) (90%) PDL treated areas versus in 10 out of 10 (10/10) (100%) TAC plus 5‐FU treated areas (RR 0.90; 0.69 to 1.18). </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>3,5</sup><br/>Very low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>It is uncertain whether there is any difference in the incidence and severity of treatment‐related adverse effects in PDL‐treated hypertrophic and keloid scars compared with TAC plus 5‐FU after 32 weeks. </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ 585‐nm PDL versus TAC plus 5‐FU ‐ purpura ‐ hypertrophic and keloid scars ‐ follow‐up: 32 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One split‐scar trial (n = 20) reported this outcome. In this study, purpura was observed in 10 out of 10 (10/10) (100%) PDL treated areas versus in 3 out of 10 (3/10) (30%) TAC plus 5‐FU treated areas (RR 3.00; 1.25 to 7.19). </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>3,5</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ 585‐nm PDL versus silicone gel sheeting ‐ pain during laser treatments ‐ hypertrophic scars ‐ follow‐up: 24 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One split‐scar trial (n = 40) reported this outcome. In this study, participants reported to have felt pain during laser treatment in 1 out of 20 (1/20) (5%) PDL treated areas versus in 0 out of 20 (0/20) (0%) silicone gel sheeting treated areas (RR 3.00; 0.13 to 69.52). </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>3,6</sup><br/>Very low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>It is uncertain whether there is any difference in the incidence and severity of treatment‐related adverse effects in PDL‐treated hypertrophic scars compared with silicone gel sheeting after 24 weeks.   </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ 585‐nm PDL versus silicone gel sheeting ‐ skin irritation ‐ hypertrophic scars ‐ follow‐up: 24 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One split‐scar trial (n = 40) reported this outcome. In this study, participants reported to have felt skin irritation related to laser treatment in 0 out of 20 (0/20) (0%) PDL treated areas versus in 1 out of 20 (1/20) (5%) silicone gel sheeting treated areas (RR 0.33; 0.01 to 7.72). </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>3,6</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Scar severity ‐ erbium laser versus TAC ‐ VBS (Higher scores = worse scar appearance) ‐ hypertrophic scars ‐ follow‐up: up to 12 months </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Baseline mean in the other treatment group was 6.7</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.10 lower<br/>(2.87 lower to 1.33 lower) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(1 study) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>1,2</sup><br/>Very low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p> It is uncertain whether there is any difference in the scar severity in erbium‐treated hypertrophic scars compared with TAC after up to 12 months. </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Scar severity ‐ erbium laser versus TAC ‐ patient self‐assessment ‐ patients considering the scar much better ‐ hypertrophic scars ‐ follow‐up: up to 12 months </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.17<br/>(1.28 to 3.66) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>80<br/>(1 study) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<sup>3,7</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>651 per 1000<br/>  </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ fractional carbon dioxide (CO<sub>2</sub>) laser versus TAC ‐ pain at injection site ‐ keloid scars ‐ follow‐up: 24 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.25</p> <p>(0.06 to 1.03)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>40<br/>(1 study) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>3,8</sup><br/>Very low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p>It is uncertain whether there is any difference in the incidence and severity of treatment‐related adverse effects in fractional CO<sub>2</sub>‐treated keloid scars compared with TAC after 24 weeks.  </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>400 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>100 per 1000</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ fractional CO<sub>2</sub> laser versus TAC ‐ telangectasia ‐ keloid scars ‐ follow‐up: 24 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.20</p> <p>(0.01 to 3.92)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>40<br/>(1 study) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>3,8</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>100 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>20 per 1000</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ fractional CO<sub>2</sub> laser versus TAC ‐ skin atrophy ‐ keloid scars ‐ follow‐up: 24 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.33</p> <p>(0.01 to 7.72)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>40<br/>(1 study) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>3,8</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>50 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>17 per 1000</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ fractional CO<sub>2</sub> laser versus TAC ‐ charring ‐ keloid scars ‐ follow‐up: 24 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One parallel trial (n = 40) reported this outcome. In this study, charring was observed in 3 out of 20 (3/20) (15%) participants treated with fractional CO<sub>2</sub> laser and 0 out of 20 (0/20) (0%) participants treated with TAC (RR 7.00; 0.38 to 127.32). </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>3,8</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ fractional CO<sub>2</sub> laser versus verapamil ‐ pain at injection site ‐ keloid scars ‐ follow‐up: 24 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One parallel trial (n = 40) reported this outcome. In this study, pain at injection site was reported by 2 out of 20 (2/20) (10%) participants treated with fractional CO<sub>2</sub> laser group and 0 out of 20 (0/20) (0%) participants treated with verapamil (RR 5.00; 0.26 to 98.00). </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>3,8</sup><br/>Very low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p> It is uncertain whether there is any difference in the incidence and severity of treatment‐related adverse effects in fractional CO<sub>2</sub>‐treated keloid scars compared with verapamil after 24 weeks. </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ fractional CO<sub>2</sub> laser versus verapamil ‐ charring ‐ keloid scars ‐ follow‐up: 24 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One parallel trial (n = 40) reported this outcome. In this study, charring was observed in 3 out of 20 (3/20) (15%) participants treated with fractional CO<sub>2</sub> laser group and 0 out of 20 (0/20) (0%) participants treated with verapamil group (RR 7.0; 0.38 to 127.32) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>3,8</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% confidence interval) is based on the mean risk in the comparison group and the relative effect of the intervention (and its 95% CI). </p> <p>ƚThe assumed risk in the comparison group is based on the event rate observed in the control arms of included trials. Where no events occurred, the risk was not calculated. </p> <p> </p> <p>Vancouver Burn Scar (VBS) Assessment Scale ‐ severity of scar was determined by numeric value from a minimum of 0 to 13 as the most severe form. </p> <p>Patient self‐assessment ‐ based on a 4‐point scale (1 = 0 to 25% improvement, 2 = 25 to 50% improvement, 3 = 50 to 75% improvement, and 4 = 75% or greater improvement). </p> <p><b>CI:</b> Confidence Interval; <b>CO<sub>2</sub>:</b> carbon dioxide; <b>MD:</b> Mean Difference; <b>PDL:</b> Pulsed‐Dye Laser;<b>RR:</b> Risk Ratio; <b>TAC:</b> Triamcinolone acetonide;<b>5‐FU:</b> 5‐fluorouracil;<b>VBS:</b> Vancouver Burn Scar Assessment Scale;. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded 2 levels for very serious imprecision due to small sample size and large confidence interval. </p> <p><sup>2</sup> Downgraded 1 level due to serious risk of bias (lack of blinding of participants, selective reporting, and unclear sequence generation and allocation concealment). </p> <p><sup>3</sup> Downgraded 2 levels for very serious imprecision due to small number of events and large confidence interval. </p> <p><sup>4</sup> Downgraded 1 level due to serious risk of bias (lack of blinding of participants and assessors (patient‐reported outcome) and unclear sequence generation and allocation concealment in 2 studies, and selective reporting in 1 study). </p> <p><sup>5</sup> Downgraded 1 level due to serious risk of bias (lack of blinding of participants and assessors (patient‐reported outcome) and unclear sequence generation and allocation concealment). </p> <p><sup>6</sup> Downgraded 1 level due to serious risk of bias (lack of blinding of participants and assessors (patient‐reported outcome) and unclear allocation concealment). </p> <p><sup>7</sup> Downgraded 1 level due to serious risk of bias (lack of blinding of participants and assessors (patient‐reported outcome) and selective reporting, and unclear sequence generation and allocation concealment). </p> <p><sup>8</sup> Downgraded 1 level due to serious risk of bias (lack of blinding of participants and assessors (patient‐reported outcome), and unclear allocation concealment and selective reporting). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011642-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Laser therapy plus other treatment compared with other treatment for treating hypertrophic and keloid scars</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Laser therapy plus other treatment compared with other treatment for treating hypertrophic and keloid scars</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with hypertrophic and keloid scars<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> laser therapy (various types ‐ 585‐nm Pulsed‐Dye Laser (PDL), erbium laser, carbon dioxide (CO<sub>2</sub>) laser, Neodymium‐doped yttrium aluminium garnet (Nd:YAG) laser, Helium‐Neon (He‐Ne) laser) plus other treatments (various types ‐ triamcinolone acetonide (TAC), 5‐Fluorouracil (5‐FU), Diprospan, decamethyltetrasiloxane, polydimethylsiloxane and cyclopentasiloxane cream and verapamil)<br/><b>Comparison:</b> other treatments (various types ‐ triamcinolone acetonide (TAC), 5‐Fluorouracil (5‐FU), Diprospan, decamethyltetrasiloxane, polydimethylsiloxane and cyclopentasiloxane cream, cryosurgery and verapamil) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of scar segments<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with other treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Laser therapy plus other treatment</b> </p> </th> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Scar severity ‐ 585‐nm pulsed‐dye laser (PDL) plus triamcinolone acetonide (TAC) plus 5‐Fluorouracil (5‐FU) versus TAC plus 5‐FU ‐ blinded observer assessment of good to excellent scar improvement ‐ hypertrophic and keloid scars ‐ follow‐up: 12 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.75</p> <p>(0.95 to 3.22)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>40<br/>(1 study) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<sup>1,2</sup><br/>Very low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p> It is uncertain whether there is any difference in the scar severity in PDL plus TAC plus 5‐FU‐treated hypertrophic and keloid scars compared with TAC plus 5‐FU after 12 weeks. </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>400 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>700 per 1000<br/>  </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Scar severity ‐ 585‐nm PDL plus TAC plus 5 FU versus TAC plus 5‐FU ‐ patient self‐assessment of good to excellent scar improvement ‐ hypertrophic and keloid scars ‐ follow‐up: 12 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.36</p> <p>(0.85 to 2.18)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>40<br/>(1 study) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<sup>1,3</sup><br/>Very low </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>550 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>748 per 1000<br/>  </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Scar severity ‐ carbon dioxide (CO<sub>2</sub>) laser plus TAC versus cryosurgery plus TAC. Mean percentage reduction ‐ blinded observer assessment ‐ keloid scars ‐ follow‐up: 12 months </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>60</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>4,5</sup><br/>Very low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p> It is uncertain whether there is any difference in the scar severity in CO<sub>2</sub> plus TAC‐treated keloid scars compared with cryosurgery plus TAC after 12 months. </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Baseline mean in the other treatment group was 74.44</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD 16.11 lower<br/>(34.49 lower to 2.27 higher) </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Scar severity ‐ CO<sub>2</sub> laser plus TAC versus cryosurgery plus TAC Mean percentage reduction ‐ patient self‐assessment score (higher scores = worse scar appearance) ‐ keloid scars ‐ follow‐up: 12 months </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>60</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>4,6</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Baseline mean in the other treatment group was 74.26</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD 7.59 lower<br/>(22.83 lower to 7.65 higher) </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Incidence of treatment‐related adverse effects: CO<sub>2</sub> laser plus TAC versus cryosurgery plus TAC ‐ atrophy ‐ keloid scars ‐ follow‐up: 12 months </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.13</p> <p>(0.70 to 1.82)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>60</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>4,6</sup><br/>Very low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p>It is uncertain whether there is any difference in the incidence and severity of treatment‐related adverse effects in CO<sub>2</sub> plus TAC‐treated keloid scars compared with cryosurgery plus TAC after 12 months.   </p> <p> </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>500 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>565 per 1000</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Incidence of treatment‐related adverse effects ‐ CO<sub>2</sub> laser plus TAC versus cryosurgery plus TAC ‐ erythema ‐ keloid scars ‐ follow‐up: 12 months </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.50</p> <p>(0.47 to 4.78)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>60</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>4,6</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>133 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>200 per 1000</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Incidence of treatment‐related adverse effects ‐ CO<sub>2</sub> laser plus TAC versus cryosurgery plus TAC ‐ telangiectasia ‐ keloid scars ‐ follow‐up: 12 months </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.33</p> <p>(0.07 to 1.52)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>60</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>4,6</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>200 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>66 per 1000</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Incidence of treatment‐related adverse effects ‐ CO<sub>2</sub> laser plus TAC versus cryosurgery plus TAC ‐ hypopigmentation ‐ keloid scars ‐ follow‐up: 12 months </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.60</p> <p>(0.16 to 2.29)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>60</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>4,6</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>167 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>100 per 1000</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Scar severity ‐ Neodymium‐doped yttrium aluminium garnet (Nd:YAG) laser plus Diprospan plus 5‐FU versus Diprospan plus 5‐FU ‐ blinded observer assessment of good to excellent scar improvement ‐ keloid scars ‐ follow‐up: 3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.45</p> <p>(0.88 to 2.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>46</p> <p>(1study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>1,7</sup><br/>Very low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p> It is uncertain whether there is any difference in the scar severity in Nd:YAG plus Diprospan plus 5‐FU‐treated keloid scars compared with Diprospan plus 5‐FU after 3 months. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>478 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>693 per 1000</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Scar severity: Nd:YAG laser plus Diprospan plus 5‐FU versus Diprospan plus 5‐FU ‐ patient self‐assessment of scar improvement of 50% or higher ‐ keloid scars ‐ follow‐up: 3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.38</p> <p>(0.91 to 2.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>46</p> <p>(1study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>1,8</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>565 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>780 per 1000</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects: Nd:YAG laser plus Diprospan plus 5‐FU versus Diprospan plus 5‐FU ‐ keloid scars ‐ follow‐up: 3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One parallel trial (n = 46) reported this outcome. In this study, almost all injections were reported by participants as being painful, and the sites treated by Nd:YAG laser became purpuric (which lasted for 7 to 10 days). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>1,8</sup><br/>Very low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>It is uncertain whether there is any difference in the incidence and severity of treatment‐related adverse effects in Nd:YAG plus Diprospan plus 5‐FU‐treated keloid scars compared with Diprospan plus 5‐FU after 3 months. </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity ‐ Helium‐Neon (He‐Ne) laser plus decamethyltetrasiloxane, polydimethylsiloxane and cyclopentasiloxane cream versus decamethyltetrasiloxane, polydimethylsiloxane and cyclopentasiloxane cream ‐ Vancouver Scar scale (VSS) (higher scores = worse scar appearance) ‐ hypertrophic scars ‐ follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One split‐scar trial (n = 30) reported this outcome. In this study, a significant decrease in the median values of VSS of the intervention area compared with the control area (P = 0.003) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>4,9</sup><br/>Very low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> It is uncertain whether there is any difference in the scar severity in He‐Ne plus decamethyltetrasiloxane, polydimethylsiloxane and cyclopentasiloxane cream‐treated hypertrophic scars compared with decamethyltetrasiloxane, polydimethylsiloxane and cyclopentasiloxane cream after 12 weeks. </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ regrowth ‐ keloid scars ‐ follow‐up: 24 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.50</p> <p>(0.27 to 8.22)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>50</p> <p>(1study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>1,10</sup><br/>Very low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="9" valign=""> <p> It is uncertain whether there is any difference in the incidence and severity of treatment‐related adverse effects in PDL plus verapamil‐treated keloid scars compared with verapamil after 24 weeks. </p> <p> </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>80 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>120 per 1000</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ pain related to treatment ‐ keloid scars ‐ follow‐up: 24 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One parallel trial (n = 50) reported this outcome. In this study, pain at injection site was reported by 1 out of 25 (1/25) (4%) participants treated with 595‐nm PDL plus verapamil and by 0 out of 25 (0/15) (0%) participants treated with verapamil (RR 3.00; 0.13 to 70.30) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>1,10</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ hyperpigmentation ‐ keloid scars ‐ follow‐up: 24 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One parallel trial (n = 50) reported this outcome. In this study, hyperpigmentation was observed in 2 out of 25 (2/25) (8%) participants treated with 595‐nm PDL plus verapamil and by 0 out of 25 (0/15) (0%) participants treated with verapamil (RR 5.00; 0.25 to 99.16) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>1,10</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ depigmentation ‐ keloid scars ‐ follow‐up: 24 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.00</p> <p>(0.07 to 15.12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>50</p> <p>(1study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>1,10</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>40 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>40 per 1000</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ purpura ‐ keloid scars ‐ follow‐up: 24 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One parallel trial (n = 50) reported this outcome. In this study, hyperpigmentation was observed in 7 out of 25 (7/25) (28%) participants treated with 595‐nm PDL plus verapamil and by 0 out of 25 (0/15) (0%) participants treated with verapamil (RR 15.00; 0.90 to 249.30) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>1,10</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ total ‐ keloid scars ‐ follow‐up: 24 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 4.67</p> <p>(1.53 to 14.26)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>50</p> <p>(1study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>1,10</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>120 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>560 per 1000</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% confidence interval) is based on the mean risk in the comparison group and the relative effect of the intervention (and its 95% CI). </p> <p>ƚThe assumed risk in the comparison group is based on the event rate observed in the control arms of included trials. Where no events occurred, the risk was not calculated. </p> <p>‐ Diprospan contains betamethasone disodium phosphate plus betamethasone dipropionate.</p> <p> </p> <p>Patient self‐assessment ‐ based on a 4‐point scale (1 = 0 to 25% improvement, 2 = 25 to 50% improvement, 3 = 50 to 75% improvement, and 4 = 75% or greater improvement); </p> <p>VBS: Vancouver Burn Scar Assessment Scale ‐ severity of scar was determined by numeric value from a minimum of 0 to 13 as the most severe form. </p> <p><b>CI:</b> Confidence Interval; ; <b>CO:<sub>2</sub> </b> carbon dioxide;<b>5‐FU:</b> 5‐fluorouracil; <b>He‐Ne:</b> Helium‐Neon; <b>NdYAG: </b> neodymium‐doped yttrium aluminium garnet; <b>PDL:</b> Pulsed‐Dye Laser; <b>RR:</b> Risk Ratio; <b>TAC:</b> Triamcinolone acetonide. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded 2 levels for very serious imprecision due to small number of events and large confidence interval. </p> <p><sup>2</sup> Downgraded 1 level due to serious risk of bias (lack of blinding of participants, incomplete outcome data and selective reporting, and unclear sequence generation and allocation concealment). </p> <p><sup>3</sup> Downgraded 1 level due to serious risk of bias (lack of blinding of participants and assessors (patient‐reported outcome), incomplete outcome data and selective reporting, and unclear sequence generation and allocation concealment) </p> <p><sup>4</sup> Downgraded 2 levels for very serious imprecision due to small sample size and large confidence interval. </p> <p><sup>5</sup> Downgraded 1 level due to serious risk of bias (lack of blinding of participants and incomplete outcome data, and unclear selective reporting). </p> <p><sup>6</sup> Downgraded 1 level due to serious risk of bias (lack of blinding of participants and assessors (patient‐reported outcome) and incomplete outcome data, and unclear selective reporting). </p> <p><sup>7</sup> Downgraded 1 level due to serious risk of bias (lack of blinding of participants and incomplete outcome data, and unclear sequence generation and allocation concealment). </p> <p><sup>8</sup> Downgraded 1 level due to serious risk of bias (lack of blinding of participants and assessors (patient‐reported outcome) and incomplete outcome data, and unclear sequence generation and allocation concealment). </p> <p><sup>9</sup> Downgraded 1 level due to serious risk of bias (lack of blinding of participants and selective reporting, and unclear sequence generation, allocation concealment and incomplete outcome data). </p> <p><sup>10</sup> Downgraded 1 level due to serious risk of bias (lack of blinding of participants and assessors (patient‐reported outcome), and unclear sequence generation, allocation concealment and incomplete outcome data). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011642-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011642-sec-0009"></div> <section id="CD011642-sec-0010"> <h3 class="title" id="CD011642-sec-0010">Description of the condition</h3> <p>Hypertrophic and keloid scars (usually referred to as keloids) represent common skin conditions (<a href="./references#CD011642-bbs2-0049" title="BouzariN , DavisSC , NouriK . Laser treatment of keloids and hypertrophic scars. International Journal of Dermatology2007;46(1):80-8.">Bouzari 2007</a>) which result from abnormal wound healing (<a href="./references#CD011642-bbs2-0068" title="SeifertO , MrowietzU . Keloid scarring: bench and bedside. Archives of Dermatologic Research2009;301(4):259-72.">Seifert 2009</a>). They can affect any part of the skin's surface that has suffered traumatic or infectious injury (<a href="./references#CD011642-bbs2-0059" title="KöseO , WaseemA . Keloids and hypertrophic scars: are they two different sides of the same coin?Dermatologic Surgery2008;34(3):336-46.">Köse 2008</a>), however, those areas of the skin where there is increased stretching tension (e.g. trunk, upper arm/shoulder (deltoid region), and knees) are more susceptible to the appearance of keloid and hypertrophic scars. They present as raised scars with a smooth surface, firm when palpitated, and their colour can vary from pink‐purple to pale (hypopigmented) or dark (hyperpigmented). They can be associated with symptoms such as itching (pruritus) and pain (<a href="./references#CD011642-bbs2-0002" title="AsilianA , DaroughehA , ShariatiF . New combination of triamcinolone, 5-fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars. Dermatologic Surgery2006;32(7):907-15. ">Asilian 2006</a>). In some cases, due to the physical and psychological impacts caused by these scars, patients with keloid and hypertrophic scars may report impairment in their quality of life (<a href="./references#CD011642-bbs2-0048" title="BockO , Schmid-OttG , MalewskiP , MrowietzU . Quality of life of patients with keloid and hypertrophic scarring. Archives of Dermatological Research2006;297(10):433-81.">Bock 2006</a>). </p> <p>The anatomical location of the initial skin lesion, a history of trauma or infection associated with the initial injury, a burn injury, sutures under tension, adolescence, pregnancy, and family history are considered to be risk factors for the appearance of hypertrophic scars and keloids (<a href="./references#CD011642-bbs2-0045" title="AlsterTS , TanziEL . Hypertrophic scars and keloids. Etiology and management. American Journal of Clinical Dermatology2003;4(4):235-43.">Alster 2003</a>; <a href="./references#CD011642-bbs2-0068" title="SeifertO , MrowietzU . Keloid scarring: bench and bedside. Archives of Dermatologic Research2009;301(4):259-72.">Seifert 2009</a>). During the normal healing process, several cells and chemical substances work together to promote tissue repair. In this process the production and subsequent degradation of collagen usually act in equilibrium, resulting in a scar healing normally. This balance is altered in keloids and hypertrophic scars, where there is higher production of collagen and lower levels of collagen degradation (<a href="./references#CD011642-bbs2-0052" title="ChoSB , LeeJH , LeeSH , LeeSJ , BangD , OhSH . Efﬁcacy and safety of 1064-nm Q-switched Nd:YAG laser with low ﬂuence for keloids and hypertrophic scars. Journal of the European Academy of Dermatology and Venereology2010;24(9):1070-4.">Cho 2010</a>). The collagen accumulates in the lesion, resulting in excessive scar tissue. Despite their similarities, keloids and hypertrophic scars have some clinical, pathological, and evolutive differences (<a href="./references#CD011642-bbs2-0068" title="SeifertO , MrowietzU . Keloid scarring: bench and bedside. Archives of Dermatologic Research2009;301(4):259-72.">Seifert 2009</a>). </p> <p>Both genetic predisposition and skin injury play major roles in the development of keloid and hypertrophic scars (<a href="./references#CD011642-bbs2-0045" title="AlsterTS , TanziEL . Hypertrophic scars and keloids. Etiology and management. American Journal of Clinical Dermatology2003;4(4):235-43.">Alster 2003</a>). While keloids may occur at any age, they usually occur in individuals between 10 and 30 years of age (<a href="./references#CD011642-bbs2-0047" title="BermanB , BieleyHC . Adjunct therapies to surgical management of keloids. Dermatologic Surgery1996;22(2):126-30.">Berman 1996</a>). They affect between 4.5% and 16% of black and Hispanic populations, with an incidence of up to 16% in black Africans (<a href="./references#CD011642-bbs2-0045" title="AlsterTS , TanziEL . Hypertrophic scars and keloids. Etiology and management. American Journal of Clinical Dermatology2003;4(4):235-43.">Alster 2003</a>). They occur less frequently in populations with lighter skin. The incidence of hypertrophic scars is probably higher than that of keloid scars (<a href="./references#CD011642-bbs2-0059" title="KöseO , WaseemA . Keloids and hypertrophic scars: are they two different sides of the same coin?Dermatologic Surgery2008;34(3):336-46.">Köse 2008</a>), ranging from 5% to 37% in white people (<a href="./references#CD011642-bbs2-0062" title="Li-TsangCW , LauJC , ChanCC . Prevalence of hypertrophic scar formation and its characteristics among Chinese population. Burns2005;31(5):610-6.">Li‐Tsang 2005</a>), but precise data are lacking. The prevalence of hypertrophic scars ranges from 15% to 63% in white people (<a href="./references#CD011642-bbs2-0062" title="Li-TsangCW , LauJC , ChanCC . Prevalence of hypertrophic scar formation and its characteristics among Chinese population. Burns2005;31(5):610-6.">Li‐Tsang 2005</a>). Both keloid and hypertrophic scars tend to recur after treatment (<a href="./references#CD011642-bbs2-0050" title="CassutoDA , ScrimaliL , SiragóP . Treatment of hypertrophic scars and keloids with an LBO laser (532 nm) and silicone gel sheeting. Journal of Cosmetic and Laser Therapy2010;12(1):32-7.">Cassuto 2010</a>). </p> <p>Clinically, keloids appear as raised scars, exceeding the boundaries of the original injury (<a href="./references#CD011642-bbs2-0064" title="MutalikS . Treatment of keloid and hypertrophic scars. Indian Journal of Dermatology, Venereology, and Leprology2005;71(1):3-8.">Mutalik 2005</a>). They can arise within a few months of the initial injury and often show gradual and undefined growth. They can be of different sizes and patterns and are frequently associated with itching and burning. Keloid scars do not regress spontaneously and usually affect the chest, shoulders, back, posterior neck and ear lobes, but rarely the palms and soles (<a href="./references#CD011642-bbs2-0068" title="SeifertO , MrowietzU . Keloid scarring: bench and bedside. Archives of Dermatologic Research2009;301(4):259-72.">Seifert 2009</a>). In contrast, hypertrophic scars do not exceed the limits of the original skin injury, and are rarely wider than 1 cm. They usually occur around four weeks after the original injury, grow strongly for a few months, and then tend to regress spontaneously within one year (<a href="./references#CD011642-bbs2-0068" title="SeifertO , MrowietzU . Keloid scarring: bench and bedside. Archives of Dermatologic Research2009;301(4):259-72.">Seifert 2009</a>). </p> <p>Due to the recurrent aspect of the lesions, their slowly progressive nature, and the lack of a gold standard therapy, the treatment of hypertrophic scars and keloids represents a significant challenge (<a href="./references#CD011642-bbs2-0050" title="CassutoDA , ScrimaliL , SiragóP . Treatment of hypertrophic scars and keloids with an LBO laser (532 nm) and silicone gel sheeting. Journal of Cosmetic and Laser Therapy2010;12(1):32-7.">Cassuto 2010</a>). Frequently, the treatment of both types of scars is performed by associating two or more techniques (<a href="./references#CD011642-bbs2-0049" title="BouzariN , DavisSC , NouriK . Laser treatment of keloids and hypertrophic scars. International Journal of Dermatology2007;46(1):80-8.">Bouzari 2007</a>, <a href="./references#CD011642-bbs2-0055" title="GuptaS , SharmaVK . Standard guidelines of care: keloids and hypertrophic scars. Indian Journal of Dermatology, Venereology, and Leprology2011;77(1):94-100.">Gupta 2011</a>), looking for a synergistic and or complementary action, or both at different levels of the healing process, with variable results reported in the literature. The main therapies used in the treatment of hypertrophic and keloid scars include medicinal treatments, compressive treatment, surgical treatments, treatment with radiation, and treatment with light sources. </p> <p>Among the medicinal treatments, corticosteroids are considered as first‐line drugs in the treatment of hypertrophic and keloid scars, and are most often used in intralesional applications (<a href="./references#CD011642-bbs2-0055" title="GuptaS , SharmaVK . Standard guidelines of care: keloids and hypertrophic scars. Indian Journal of Dermatology, Venereology, and Leprology2011;77(1):94-100.">Gupta 2011</a>). Other medicinal treatments are the use of intralesional bleomycin (<a href="./references#CD011642-bbs2-0045" title="AlsterTS , TanziEL . Hypertrophic scars and keloids. Etiology and management. American Journal of Clinical Dermatology2003;4(4):235-43.">Alster 2003</a>) and intralesional 5‐ Fluorouracil (<a href="./references#CD011642-bbs2-0064" title="MutalikS . Treatment of keloid and hypertrophic scars. Indian Journal of Dermatology, Venereology, and Leprology2005;71(1):3-8.">Mutalik 2005</a>). Silicone is used in its varied forms, including gel, cream, spray or flexible gel sheeting (<a href="./references#CD011642-bbs2-0045" title="AlsterTS , TanziEL . Hypertrophic scars and keloids. Etiology and management. American Journal of Clinical Dermatology2003;4(4):235-43.">Alster 2003</a>). Regarding surgical treatments, cryosurgery can be useful as it causes tissue ischaemia (which is a reduction in blood flow) and necrosis of scar tissue (<a href="./references#CD011642-bbs2-0045" title="AlsterTS , TanziEL . Hypertrophic scars and keloids. Etiology and management. American Journal of Clinical Dermatology2003;4(4):235-43.">Alster 2003</a>; <a href="./references#CD011642-bbs2-0047" title="BermanB , BieleyHC . Adjunct therapies to surgical management of keloids. Dermatologic Surgery1996;22(2):126-30.">Berman 1996</a>). Surgeries to remove scar volume, by removal of its core, or of the entire scar can also be performed (<a href="./references#CD011642-bbs2-0055" title="GuptaS , SharmaVK . Standard guidelines of care: keloids and hypertrophic scars. Indian Journal of Dermatology, Venereology, and Leprology2011;77(1):94-100.">Gupta 2011</a>). Other treatments include light sources such as Intense Pulsed Light (IPL), which aims to promote vascular ischaemia, interfering with collagen production (<a href="./references#CD011642-bbs2-0053" title="ErolOO , GurlekA , AgaogluG , TopcuogluE , OzH . Treatment of hypertrophic scars and keloids using intense pulsed light (IPL). Aesthetic Plastic Surgery2008;32:902-9.">Erol 2008</a>), and laser therapy. Different laser devices are used, aiming to improve the appearance of hypertrophic and keloid scars by direct destruction of the tissue (fractional or conventional ablative lasers), with consequent reduction in scar volume; coagulation of scar tissue (non‐ablative lasers, fractioned or not), with consequent remodeling of the local collagen and scar improvement; or even by destruction of the scar microvascularisation, leading to ischaemia and consequent reduction in scar volume (<a href="./references#CD011642-bbs2-0045" title="AlsterTS , TanziEL . Hypertrophic scars and keloids. Etiology and management. American Journal of Clinical Dermatology2003;4(4):235-43.">Alster 2003</a>; <a href="./references#CD011642-bbs2-0047" title="BermanB , BieleyHC . Adjunct therapies to surgical management of keloids. Dermatologic Surgery1996;22(2):126-30.">Berman 1996</a>). </p> </section> <section id="CD011642-sec-0011"> <h3 class="title" id="CD011642-sec-0011">Description of the intervention</h3> <p>Different laser systems have been used in the treatment of hypertrophic and keloid scars over the last 30 years (<a href="./references#CD011642-bbs2-0049" title="BouzariN , DavisSC , NouriK . Laser treatment of keloids and hypertrophic scars. International Journal of Dermatology2007;46(1):80-8.">Bouzari 2007</a>; <a href="./references#CD011642-bbs2-0055" title="GuptaS , SharmaVK . Standard guidelines of care: keloids and hypertrophic scars. Indian Journal of Dermatology, Venereology, and Leprology2011;77(1):94-100.">Gupta 2011</a>). The mechanism of lasers follows the principle of 'selective photothermolysis' (<a href="./references#CD011642-bbs2-0046" title="AndersonRR , ParrishJA . Selective phototermolysis: precise microsurgery by selective absorption of pulsed radiation. Science1983;220:524-7.">Anderson 1983</a>). According to this principle, a light with a specific wavelength emitted by a laser device acts on a specific target, which responds to this wavelength. This target is called "chromophore". </p> <p>Different skin structures respond to different wavelengths, so it is necessary to find a laser device that emits a laser beam with a wavelength equal or similar to that of the structure that needs to be reached. This laser beam will 'search' for the structure within the skin that has the same or similar wavelength (the "chromophore"), and then destroy it selectively ("selective photothermolysis"). </p> <p>The patient's skin type (skin type I: pale white skin, blue or green eyes, blond or red hair; type II: fair skin, blue eyes; type III: darker white skin; type IV: light brown skin; type V: brown skin; type VI: dark brown or black skin), the energy released by the device in a certain area (also called fluence), the spot size of the laser light and the speed with which this beam reaches the target, are all factors that influence the results obtained with laser therapy. </p> <p>A laser can be classified as ablative or non‐ablative according to its effect on tissue. Ablative lasers remove part or all of the tissues on which they are applied. They act on the water present in these tissues, causing them to vaporise. Examples of ablative laser devices include carbon dioxide (CO<sub>2</sub>), argon, and 2940 nm erbium‐doped yttrium aluminium garnet (Er:YAG) laser. Non‐ablative lasers act on different structures, such as the melanin pigment or intracellular haemoglobin, leading to necrosis (death) of these structures, without, however, removing them. An example of a non‐ablative laser device is the pulsed‐dye laser (PDL) (<a href="./references#CD011642-bbs2-0026" title="ManuskiattiW , WanitphakdeedechaR , FitzpatrickRE . Effect of pulse width of a 595-nm flashlamp-pumped pulsed dye laser on the treatment response of keloidal and hypertrophic sternotomy scars. Dermatologic Surgery2007;33(2):152-61. ">Manuskiatti 2007</a>). </p> </section> <section id="CD011642-sec-0012"> <h3 class="title" id="CD011642-sec-0012">How the intervention might work</h3> <p>The exact mechanism of action by which laser therapy could improve hypertrophic and keloid scars severity is still unknown. Laser devices such as CO<sub>2</sub> (<a href="./references#CD011642-bbs2-0055" title="GuptaS , SharmaVK . Standard guidelines of care: keloids and hypertrophic scars. Indian Journal of Dermatology, Venereology, and Leprology2011;77(1):94-100.">Gupta 2011</a>; <a href="./references#CD011642-bbs2-0057" title="KantorGR , WheelandRG , BailinPL , WalkerNP , RatzJL . Treatment of earlobe keloids with carbon dioxide laser excision: a report of 16 cases. Journal of Dermatologic Surgery and Oncology1985;11(11):1063-7.">Kantor 1985</a>), argon, and 2940 nm Er:YAG (<a href="./references#CD011642-bbs2-0064" title="MutalikS . Treatment of keloid and hypertrophic scars. Indian Journal of Dermatology, Venereology, and Leprology2005;71(1):3-8.">Mutalik 2005</a>) can cause scar removal through the interaction of the laser energy with the water present in the treated skin, leading to reduction in the lesion volume. Non‐ablative lasers (e.g. 585 nm PDL,1064 nm Q‐switched neodymium‐doped yttrium aluminium garnet (Nd:YAG) laser with low fluence, 532 nm frequency‐doubled Nd:YAG, and 1064 nm Nd:YAG) can cause destruction (coagulation/necrosis) of the capillaries, through the absorption of laser light energy by blood inside the veins (i.e. intravascular haemoglobin; <a href="./references#CD011642-bbs2-0002" title="AsilianA , DaroughehA , ShariatiF . New combination of triamcinolone, 5-fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars. Dermatologic Surgery2006;32(7):907-15. ">Asilian 2006</a>). The destruction of blood vessels decreases blood flow (hypoperfusion) to the treated area, with a consequent decrease in local tissue oxygenation (hypoxia). Changes occur in the tissues as a result of the hypoxia, with the production of new collagen, heating of collagen fibres, dissociation of disulphide bonds (which keep collagen fibres together), and collagen fibre realignment (<a href="./references#CD011642-bbs2-0052" title="ChoSB , LeeJH , LeeSH , LeeSJ , BangD , OhSH . Efﬁcacy and safety of 1064-nm Q-switched Nd:YAG laser with low ﬂuence for keloids and hypertrophic scars. Journal of the European Academy of Dermatology and Venereology2010;24(9):1070-4.">Cho 2010</a>; <a href="./references#CD011642-bbs2-0064" title="MutalikS . Treatment of keloid and hypertrophic scars. Indian Journal of Dermatology, Venereology, and Leprology2005;71(1):3-8.">Mutalik 2005</a>). In this way, laser therapy reorganises collagen deposition in the hypertrophic and keloid scars and improves their clinical aspect and symptoms (<a href="./references#CD011642-bbs2-0058" title="KarsaiS , RoosS , HammesS , RaulinC . Pulsed dye laser: what's new in non-vascular lesions?Journal of the European Academy of Dermatology and Venereology2007;21(7):877-90.">Karsai 2007</a>). The number of laser treatment sessions and the intervals between each session may vary according to the scar and laser device used. Every patient is individually examined and treated by his/her doctor, according to the characteristics of the scar in question. </p> </section> <section id="CD011642-sec-0013"> <h3 class="title" id="CD011642-sec-0013">Why it is important to do this review</h3> <p>Hypertrophic and keloid scars result from abnormal wound healing and have cosmetic implications. They occur in women and men of all ethnicities, often between the ages of 10 and 30 years, and can have a negative impact on a person's physical functioning and quality of life (<a href="./references#CD011642-bbs2-0048" title="BockO , Schmid-OttG , MalewskiP , MrowietzU . Quality of life of patients with keloid and hypertrophic scarring. Archives of Dermatological Research2006;297(10):433-81.">Bock 2006</a>). There are many different treatments for hypertrophic and keloid scars, but there is no gold standard therapy. Laser therapy is an option currently used in the treatment and prevention of keloids and hypertrophic scars, which underlines the need for a systematic review of the most reliable studies. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011642-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011642-sec-0014"></div> <p>To assess the effects of laser therapy for treating hypertrophic and keloid scars.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011642-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011642-sec-0015"></div> <section id="CD011642-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011642-sec-0017"> <h4 class="title">Types of studies</h4> <p>We considered all randomised controlled trials (RCTs) comparing laser therapy with no intervention or another intervention for treating hypertrophic or keloid scars (or both). We did not include cluster‐randomised and cross‐over studies. </p> </section> <section id="CD011642-sec-0018"> <h4 class="title">Types of participants</h4> <p>People with hypertrophic or keloid scars (or both), who had been diagnosed by a health professional, with no restrictions regarding age, sex, or ethnicity. </p> </section> <section id="CD011642-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We considered trials in which laser therapy was used to treat hypertrophic or keloid scars (or both), with any kind of laser device, using any fluency, course duration, number of sessions, and follow‐up time, compared either with no intervention or any other type of therapy. </p> </section> <section id="CD011642-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD011642-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011642-list-0001"> <li> <p>Severity of keloid or hypertrophic scars (or both) measured by health professional and/or participant using a specific scale (as defined by the authors). </p> </li> <li> <p>Incidence and severity of treatment‐related adverse effects.</p> </li> </ul> </p> </section> <section id="CD011642-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011642-list-0002"> <li> <p>Scar size, colour, height, length, width, pliability, skin surface texture, pruritus and pain (non‐treatment related). </p> </li> <li> <p>Cosmesis/aesthetic scar appearance (defined by patient opinion and/or health professional observations). </p> </li> <li> <p>Patient tolerance (measured by reported side effects and adverse reactions).</p> </li> <li> <p>Preference for different modes of treatment measured by patient choice after receiving at least two different types of treatment. </p> </li> <li> <p>Adherence (measured by health professional and/or patient report).</p> </li> <li> <p>Patient's quality of life measured by a validated scale (36‐Item Short Form Health Survey (SF‐36), EuroQol (EQ‐5D58); (<a href="./references#CD011642-bbs2-0051" title="ChingS , ThomaA , McCabeRE , AntonyMM . Measuring outcomes in aesthetic surgery: a comprehensive review of the literature. Plastic and Reconstructive Surgery2003;111(1):469-80.">Ching 2003</a>). </p> </li> <li> <p>Recurrence of the condition.</p> </li> </ul> </p> </section> </section> </section> <section id="CD011642-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>We aimed to identify all relevant RCTs regardless of language or publication status (published, unpublished, in press, or in progress). </p> <section id="CD011642-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases to identify reports of relevant clinical trials: </p> <p> <ul id="CD011642-list-0003"> <li> <p>Cochrane Wounds Specialised Register (searched 23 March 2021);</p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library via the Cochrane Register of Studies (searched 23 March 2021); </p> </li> <li> <p>MEDLINE Ovid including In‐Process &amp; Other Non‐Indexed Citations (1946 to 23 March 2021); </p> </li> <li> <p>Embase Ovid<b>(</b>1974 to 23 March 2021); </p> </li> <li> <p>CINAHL Plus EBSCO (Cumulative Index to Nursing and Allied Health Literature (1937 to 23 March 2021); </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information database) via VHL (Virtual Health Library; 1982 to 23 March 2021). </p> </li> </ul> </p> <p>The search strategies for the Cochrane Wounds Specialised Register, CENTRAL, MEDLINE Ovid, Embase Ovid and CINAHL Plus EBSCO can be found in <a href="./appendices#CD011642-sec-0127">Appendix 1</a>. In MEDLINE Ovid, we combined the subject‐specific strategy with the sensitivity‐ and precision‐maximising version of the Cochrane Highly Sensitive Search Strategy for identifying randomised trials (2008 revision) (<a href="./references#CD011642-bbs2-0060" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , Metzendorf M-I, et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Lefebvre 2021</a>). We combined the Embase Ovid search with the Ovid Embase filter developed by Cochrane UK  (<a href="./references#CD011642-bbs2-0060" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , Metzendorf M-I, et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Lefebvre 2021</a>).  We combined the CINAHL Plus EBSCO search with the trial filter developed by <a href="./references#CD011642-bbs2-0054" title="GlanvilleJ , DooleyG , WisniewskiS , FoxleeR , Noel-StorrA . Development of a search filter to identify reports of controlled clinical trials within CINAHL Plus. Health Information and Libraries Journal2019;36(1):73-90.">Glanville 2019</a>. There were no restrictions with respect to language, date of publication, or study setting. </p> <p>We also searched the following clinical trials registries:</p> <p> <ul id="CD011642-list-0004"> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>; searched 23 March 2021); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="https://www.who.int/clinical-trials-registry-platform" target="_blank">www.who.int/clinical-trials-registry-platform</a>; searched 23 March  2021). </p> </li> </ul> </p> </section> <section id="CD011642-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We aimed to identify other potentially eligible trials or ancillary publications by searching the reference lists of retrieved included trials, as well as relevant systematic reviews, meta‐analyses, and health technology assessment reports. We contacted specialists in the field, authors of the included studies, and laser device manufacturers for any possible unpublished data. We did not perform a separate search for adverse effects of interventions used, we only considered treatment‐related adverse effects described in included studies. </p> </section> </section> <section id="CD011642-sec-0026"> <h3 class="title" id="CD011642-sec-0026">Data collection and analysis</h3> <p>Data collection and analysis were carried out according to methods stated in the published protocol (<a href="./references#CD011642-bbs2-0070" title="LeszczynskiR , Da SilvaCA , KuczynskiU , Da SilvaEM . Laser therapy for treating hypertrophic and keloid scars. Cochrane Database of Systematic Reviews2015, Issue 4. Art. No: CD011642. [DOI: 10.1002/14651858.CD011642]">Leszczynski 2015</a>), based on the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011642-bbs2-0056" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>). </p> <section id="CD011642-sec-0027"> <h4 class="title">Selection of studies</h4> <p>After merging the search results and removing duplicate records, we examined titles and abstracts to select the relevant reports. At least two review authors (RL, ACPNP or CAPS) independently screened the studies identified by the literature search. We retrieved and examined the full text of selected studies for compliance with eligibility criteria and in the case of any disagreements (at this or at any other stage as listed below), a third review author (EMKS) was consulted. Reasons for exclusion of studies after full text retrieval are recorded in the '<a href="./references#CD011642-sec-0163" title="">Characteristics of excluded studies</a>' table. We included a Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) flow chart to document the screening process, <a href="#CD011642-fig-0001">Figure 1</a> (<a href="./references#CD011642-bbs2-0063" title="MoherD , LiberatiA , TetzlaffJM , AltmanDG , PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Open Medicine2009;3(3):123-30.">Moher 2009</a>). </p> <div class="figure" id="CD011642-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011642-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD011642-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>At least two review authors (RL, ACPNP or CAPS) extracted data independently and collected data on a data extraction form. We resolved discrepancies in the results by discussion. We collected the following information. </p> <p> <ul id="CD011642-list-0005"> <li> <p><b>Study features:</b> </p> </li> <li> <p>publication details (e.g. year, country, authors);</p> </li> <li> <p>study design;</p> </li> <li> <p>population data (e.g. age, ethnicity, baseline aspects of keloid and hypertrophic scars, such as severity, duration, symptoms, history of prior trauma or infection at the scar sites, and history concerning treatments and responses); </p> </li> <li> <p>details of interventions (e.g. number of laser treatment sessions, regimen, fluence, scheme, adjunctive therapies, increasing or decreasing fluence, who delivered the intervention, the location of the intervention); </p> </li> <li> <p>size of the scars;</p> </li> <li> <p>cause of the scars;</p> </li> <li> <p>treatment duration;</p> </li> <li> <p>number of participants randomised into each treatment group;</p> </li> <li> <p>number of participants in each group who were cured or failed treatment;</p> </li> <li> <p>numbers of participants lost to follow‐up;</p> </li> <li> <p>duration of follow‐up;</p> </li> <li> <p>source of funding for the trial;</p> </li> <li> <p>care setting.</p> </li> <li> <p><b>Outcomes and results:</b> </p> </li> <li> <p>types of outcome measures;</p> </li> <li> <p>timing of outcomes;</p> </li> <li> <p>results;</p> </li> <li> <p>treatment‐related adverse effects.</p> </li> </ul> </p> <p>Follow‐up data were extracted on the basis that long‐term follow‐up occurs 12 months or more from the beginning of the treatment; intermediate‐term follow‐up occurs between three months and 12 months from the beginning of the treatment; and short‐term follow‐up occurs less than three months from the beginning of the treatment. These criteria were established by the authors of this review, since there is no consensus about the follow‐up in the literature. </p> <p>Where studies had multiple publications, the main study report was used as the reference, with additional details being supplemented from secondary papers. </p> </section> <section id="CD011642-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>At least two review authors (RL, ACPNP or CAPS) independently assessed each included study using the Cochrane tool for assessing risk of bias (<a href="./references#CD011642-bbs2-0056" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>). This tool addresses six specific domains, namely sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other issues (see <a href="./appendices#CD011642-sec-0128">Appendix 2</a> for details of the criteria on which the judgements were based). We completed a risk of bias table for each eligible study. We discussed any disagreements among all review authors to achieve a consensus. We presented assessment of risk of bias using a risk of bias summary figure (see <a href="#CD011642-fig-0002">Figure 2</a>), which presents all the judgements in a cross‐tabulation of study by entry. This display of internal validity indicates the weight the reader can give the results of each study. </p> <div class="figure" id="CD011642-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011642-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> </section> <section id="CD011642-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>The measures of treatment effect were calculated whenever data were available. We calculated risk ratios (RRs) and 95% confidence intervals (CIs) for dichotomous variables. We also calculated the mean difference (MD) and 95% CIs for continuous outcomes. </p> </section> <section id="CD011642-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>When multiple scars of the body received the same intervention, with a separate outcome judgement made for each body part, and the number of body parts was used as the denominator in the analysis, we planned to analyse the data similarly to the situation in cluster‐randomised trials (<a href="./references#CD011642-bbs2-0056" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>). We anticipated a possible unit‐of analysis issue if individual participants with multiple scars were randomised, the allocated treatment was used on multiple scars per participant (or perhaps only for some participants), and then data were presented and analysed by scar not person. This is a type of clustered data, such that the participant is the 'cluster', and presents a unit of analysis error which inflates precision. If there had been studies that contained some or all clustered data, we would have reported this alongside information on whether data had been (incorrectly) treated as independent. We would have recorded this as part of the risk of bias assessment. We would not have undertaken further calculation to adjust for clustering. However, no studies of this type were included. </p> </section> <section id="CD011642-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>Where there were missing or unavailable data, we contacted the study authors to request additional information. Because the study authors failed to respond, we reported dropout rates in the '<a href="./references#CD011642-sec-0162" title="">Characteristics of included studies</a>' tables of the review, and used intention‐to‐treat analysis. All participants were analysed according to their randomisation allocation. Although we planned to perform sensitivity analysis, excluding participants with missing data, to assess the strength of the results (<a href="./references#CD011642-bbs2-0056" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>), due to the lack of information in the included RCTs, this was not possible. </p> </section> <section id="CD011642-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We considered clinical and methodological heterogeneity and quantified heterogeneity among the pooled estimates using the I<sup>2</sup> measure calculated by Review Manager software (<a href="./references#CD011642-bbs2-0065" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5.4 (RevMan 5). Version 5.4. Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">RevMan 2020</a>). This illustrates the percentage of the variability in the effect estimates resulting from heterogeneity rather than sampling error. Whilst the I<sup>2</sup> measure was used to quantify heterogeneity, a holistic assessment of heterogeneity more broadly taking into account study, intervention, population and outcome features was used to guide synthesis decisions. </p> </section> <section id="CD011642-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to assess reporting biases or small study effects by drawing a funnel plot (trial effect versus trial size), assuming a sufficient number of studies (more than 10 for each outcome) were included in the review. As we did not have this number of studies, a funnel plot was not created. </p> </section> <section id="CD011642-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We considered clinical and methodological heterogeneity. We planned to pool data when studies appeared appropriately similar in terms of type of scar, intervention type, duration of follow‐up, and outcome type. Within comparisons, we pooled paired data separately (e.g. from split‐scar designs) from data from parallel‐group trials where both study types were available. (<a href="./references#CD011642-bbs2-0061" title="LesaffreE , PhilstromB , NeedlemanI , WorthingtonH . The design and analysis of split-mouth studies: what statisticians and clinicians should know. Statistics in Medicine2009;28(28):3470-80.">Lesaffre 2009</a>). Where data synthesis was inappropriate, we provide a narrative overview. </p> <p>We presented data using forest plots where possible. For dichotomous outcomes we presented the summary estimate as an RR with 95% CI. Where continuous outcomes were measured in the same way across studies, we present pooled mean differences (MD) with 95% CI. We planned to pool standardised mean difference (SMD) estimates where studies measured the same outcome using different methods; however, no outcomes were measured using different methods. We included studies where multiple treatment groups relevant to the review were compared with only one control group, and present the data separately for these comparisons. </p> </section> <section id="CD011642-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We intended to perform subgroup analyses to consider the following:</p> <p> <ul id="CD011642-list-0006"> <li> <p>types of laser devices;</p> </li> <li> <p>different fluences and schemes;</p> </li> <li> <p>duration of treatment.</p> </li> </ul> </p> <p>If we had found substantial heterogeneity and sufficient data, we planned to investigate the possible causes by exploring the impact of the condition of the individuals and the interventions (e.g. participant characteristics such as skin type, and addition of adjuvant therapies) using subgroup analyses. However, these analyses were not possible because of insufficient data. </p> </section> <section id="CD011642-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>If there had been an adequate number of studies, we would have performed sensitivity analyses based on separation of studies according to risk of bias. This would have been performed by excluding the studies most susceptible to bias on the basis of our risk of bias assessment, namely those with inadequate randomisation sequence generation, allocation concealment, high levels of post‐randomisation losses or exclusions, and unclear or unblinded outcome assessment. </p> </section> <section id="CD011642-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We present the main results of the review in summary of findings tables. These tables present key information concerning the certainty of the evidence, the magnitude of the effects of the interventions examined, and the sum of the available data for the main outcomes (<a href="./references#CD011642-bbs2-0066" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Schünemann 2021a</a>). The summary of findings tables also include an overall grading of the evidence related to each of the main outcomes using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach. The GRADE approach defines the certainty of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the true quantity of specific interest. We evaluated the certainty of evidence considering within‐trial risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias (<a href="./references#CD011642-bbs2-0067" title="SchünemannHJ , VistGE , HigginsJP , SantessoN , DeeksJJ , GlasziouP , et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021.  Available from www.training.cochrane.org/handbook.">Schünemann 2021b</a>). We present the following outcomes in the summary of findings tables: </p> <p> <ul id="CD011642-list-0007"> <li> <p>severity of keloid or hypertrophic scars;</p> </li> <li> <p>incidence and severity of treatment‐related adverse effects.</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011642-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011642-sec-0039"></div> <section id="CD011642-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD011642-sec-0041"> <h4 class="title">Results of the search</h4> <p>We searched the databases previously described (up to 23 March 2021) and this search retrieved 5746 citations. After assessing the abstracts for inclusion criteria, 44 citations were assessed in full. Of these, 17 studies were excluded with justification, 11 studies are ongoing, one study is awaiting classification and 15 randomised controlled trials (RCTs) were included in this systematic review, <a href="#CD011642-fig-0001">Figure 1</a>. </p> </section> <section id="CD011642-sec-0042"> <h4 class="title">Included studies</h4> <p>We included 15 RCTs in the review (<a href="./references#CD011642-bbs2-0001" title="AlsharnoubiJ , ShoukryKE , FawzyMW , MohamedO . Evaluation of scars in children after treatment with low-level laser. Lasers in Medical Science2018;33(9):1991-5. ">Alsharnoubi 2018</a>; <a href="./references#CD011642-bbs2-0002" title="AsilianA , DaroughehA , ShariatiF . New combination of triamcinolone, 5-fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars. Dermatologic Surgery2006;32(7):907-15. ">Asilian 2006</a>; <a href="./references#CD011642-bbs2-0003" title="AzzamOA , BassiounyDA , El-HawaryMS , El MaadawiZM , SobhiRM , El-MesidyMS . Treatment of hypertrophic scars and keloids by fractional carbon dioxide laser: a clinical, histological, and immunohistochemical study. Lasers in Medical Science2016;31(1):9-18. ">Azzam 2016</a>; <a href="./references#CD011642-bbs2-0004" title="BeheraB , KumariR , ThappaDM , MalathiM . Therapeutic efficacy of intralesional steroid with carbon dioxide laser versus with cryotherapy in treatment of keloids: a randomized controlled trial. Dermatologic Surgery2016;42(10):1188-98. ">Behera 2016</a>; <a href="./references#CD011642-bbs2-0005" title="Blome-EberwienS , GogalC , WeissMJ , BoorseD , PagellaP . Prospective evaluation of fractional CO2 laser treatment of mature burn scars. Journal of Burn Care &amp; Research2016;37(6):379-87. ">Blome‐Eberwein 2016</a>; <a href="./references#CD011642-bbs2-0006" title="ChenX , LiuJ , JameelAA , ValeskaM , ZhangJ , XuY , et al. Combined effects of long-pulsed neodymium-yttrium-aluminum-garnet laser, diprospan and 5-fluorouracil in the treatment of keloid scars. Experimental and Therapeutic Medicine2017;13:3607-12. ">Chen 2017</a>; <a href="./references#CD011642-bbs2-0007" title="DaoudAA , GianatasioC , RudnickA , MichaelM , WaibelJ . Efficacy of combined Intense Pulsed Light (IPL) with fractional CO2 laser ablation in the treatment of large hypertrophic scars: a prospective, randomized control trial. Lasers in Surgery and Medicine2019;51(8):1-8. ">Daoud 2019</a>; <a href="./references#CD011642-bbs2-0008" title="KhattabFM , NasrM , KhashabaSA , BessarH . Combination of pulsed dye laser and verapamil in comparison with verapamil alone in the treatment of keloid. Journal of Dermatological Treatment2019;31(2):186-90. ">Khattab 2019</a>; <a href="./references#CD011642-bbs2-0009" title="LinJY , WargerWC , IziksonL , AndersonRR , TannousZ . A prospective, randomized controlled trial on the efficacy of fractional photothermolysis on scar remodeling. Lasers in Surgery and Medicine2011;43:265-72. ">Lin 2011</a>; <a href="./references#CD011642-bbs2-0010" title="ManuskiattiW , FitzpatrickRE , GoldmanMP . Energy density and numbers of treatment affect response of keloidal and hypertrophic sternotomy scars to the 585-nm flashlamp-pumped pulsed-dye laser. Journal of the American Academy of Dermatology2001;45(4):557-65. ">Manuskiatti 2001</a>; <a href="./references#CD011642-bbs2-0011" title="ManuskiattiW , FitzpatrickRE . Treatment response of keloidal and hypertrophic sternotomy scars. Comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Archives of Dermatology2002;138(9):1149-55. ">Manuskiatti 2002</a>; <a href="./references#CD011642-bbs2-0012" title="OmranifardM , RastiM . Comparing the effects of conventional method, pulse dye laser and erbium laser for the treatment of hypertrophic scars in Iranian patients. Journal of Research in Medical Sciences2007;12(6):277-81. ">Omranifard 2007</a>; <a href="./references#CD011642-bbs2-0013" title="SrivastavaS , KumariH , SinghA . Comparison of fractional CO2 laser, verapamil, and triamcinolone for the treatment of keloid. Advances in Wound Care2019;8(1):7-13. ">Srivastava 2019</a>; <a href="./references#CD011642-bbs2-0014" title="VerhaegheE , OngenaeK , BostoenJ , LambertJ . Nonablative fractional laser resurfacing for the treatment of hypertrophic scars: a randomized controlled trial. Dermatologic Surgery2013;39(3 Pt 1):426-34. ">Verhaeghe 2013</a>; <a href="./references#CD011642-bbs2-0015" title="WittenbergGP , FabianBG , BogomilskyJL , SchultzLR , RudneEJ , ChaffinsML , et al. Prospective, single-blind, randomized, controlled study to assess the efficacy of the 585-nm flashlamp-pumped pulsed-dye laser and silicone gel sheeting in hypertrophic scar treatment. Archives of Dermatology1999;135(9):1049-55. ">Wittenberg 1999</a>), with a total of 604 participants. The included studies evaluated different types of lasers with various types of control interventions, including no intervention and different injectable drugs (see <a href="./references#CD011642-sec-0162" title="">Characteristics of included studies</a>). </p> <p><b>Care setting</b> </p> <p>Six studies were conducted in the USA (<a href="./references#CD011642-bbs2-0005" title="Blome-EberwienS , GogalC , WeissMJ , BoorseD , PagellaP . Prospective evaluation of fractional CO2 laser treatment of mature burn scars. Journal of Burn Care &amp; Research2016;37(6):379-87. ">Blome‐Eberwein 2016</a>; <a href="./references#CD011642-bbs2-0007" title="DaoudAA , GianatasioC , RudnickA , MichaelM , WaibelJ . Efficacy of combined Intense Pulsed Light (IPL) with fractional CO2 laser ablation in the treatment of large hypertrophic scars: a prospective, randomized control trial. Lasers in Surgery and Medicine2019;51(8):1-8. ">Daoud 2019</a>; <a href="./references#CD011642-bbs2-0009" title="LinJY , WargerWC , IziksonL , AndersonRR , TannousZ . A prospective, randomized controlled trial on the efficacy of fractional photothermolysis on scar remodeling. Lasers in Surgery and Medicine2011;43:265-72. ">Lin 2011</a>; <a href="./references#CD011642-bbs2-0010" title="ManuskiattiW , FitzpatrickRE , GoldmanMP . Energy density and numbers of treatment affect response of keloidal and hypertrophic sternotomy scars to the 585-nm flashlamp-pumped pulsed-dye laser. Journal of the American Academy of Dermatology2001;45(4):557-65. ">Manuskiatti 2001</a>; <a href="./references#CD011642-bbs2-0011" title="ManuskiattiW , FitzpatrickRE . Treatment response of keloidal and hypertrophic sternotomy scars. Comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Archives of Dermatology2002;138(9):1149-55. ">Manuskiatti 2002</a>; <a href="./references#CD011642-bbs2-0015" title="WittenbergGP , FabianBG , BogomilskyJL , SchultzLR , RudneEJ , ChaffinsML , et al. Prospective, single-blind, randomized, controlled study to assess the efficacy of the 585-nm flashlamp-pumped pulsed-dye laser and silicone gel sheeting in hypertrophic scar treatment. Archives of Dermatology1999;135(9):1049-55. ">Wittenberg 1999</a>), two in Iran (<a href="./references#CD011642-bbs2-0002" title="AsilianA , DaroughehA , ShariatiF . New combination of triamcinolone, 5-fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars. Dermatologic Surgery2006;32(7):907-15. ">Asilian 2006</a>; <a href="./references#CD011642-bbs2-0012" title="OmranifardM , RastiM . Comparing the effects of conventional method, pulse dye laser and erbium laser for the treatment of hypertrophic scars in Iranian patients. Journal of Research in Medical Sciences2007;12(6):277-81. ">Omranifard 2007</a>), one in Belgium (<a href="./references#CD011642-bbs2-0014" title="VerhaegheE , OngenaeK , BostoenJ , LambertJ . Nonablative fractional laser resurfacing for the treatment of hypertrophic scars: a randomized controlled trial. Dermatologic Surgery2013;39(3 Pt 1):426-34. ">Verhaeghe 2013</a>), three in Egypt (<a href="./references#CD011642-bbs2-0001" title="AlsharnoubiJ , ShoukryKE , FawzyMW , MohamedO . Evaluation of scars in children after treatment with low-level laser. Lasers in Medical Science2018;33(9):1991-5. ">Alsharnoubi 2018</a>; <a href="./references#CD011642-bbs2-0003" title="AzzamOA , BassiounyDA , El-HawaryMS , El MaadawiZM , SobhiRM , El-MesidyMS . Treatment of hypertrophic scars and keloids by fractional carbon dioxide laser: a clinical, histological, and immunohistochemical study. Lasers in Medical Science2016;31(1):9-18. ">Azzam 2016</a>; <a href="./references#CD011642-bbs2-0008" title="KhattabFM , NasrM , KhashabaSA , BessarH . Combination of pulsed dye laser and verapamil in comparison with verapamil alone in the treatment of keloid. Journal of Dermatological Treatment2019;31(2):186-90. ">Khattab 2019</a>), two in India (<a href="./references#CD011642-bbs2-0004" title="BeheraB , KumariR , ThappaDM , MalathiM . Therapeutic efficacy of intralesional steroid with carbon dioxide laser versus with cryotherapy in treatment of keloids: a randomized controlled trial. Dermatologic Surgery2016;42(10):1188-98. ">Behera 2016</a>; <a href="./references#CD011642-bbs2-0013" title="SrivastavaS , KumariH , SinghA . Comparison of fractional CO2 laser, verapamil, and triamcinolone for the treatment of keloid. Advances in Wound Care2019;8(1):7-13. ">Srivastava 2019</a>), and one in China (<a href="./references#CD011642-bbs2-0006" title="ChenX , LiuJ , JameelAA , ValeskaM , ZhangJ , XuY , et al. Combined effects of long-pulsed neodymium-yttrium-aluminum-garnet laser, diprospan and 5-fluorouracil in the treatment of keloid scars. Experimental and Therapeutic Medicine2017;13:3607-12. ">Chen 2017</a>). </p> <p>Four studies were conducted in private clinics (<a href="./references#CD011642-bbs2-0002" title="AsilianA , DaroughehA , ShariatiF . New combination of triamcinolone, 5-fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars. Dermatologic Surgery2006;32(7):907-15. ">Asilian 2006</a>; <a href="./references#CD011642-bbs2-0010" title="ManuskiattiW , FitzpatrickRE , GoldmanMP . Energy density and numbers of treatment affect response of keloidal and hypertrophic sternotomy scars to the 585-nm flashlamp-pumped pulsed-dye laser. Journal of the American Academy of Dermatology2001;45(4):557-65. ">Manuskiatti 2001</a>; <a href="./references#CD011642-bbs2-0011" title="ManuskiattiW , FitzpatrickRE . Treatment response of keloidal and hypertrophic sternotomy scars. Comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Archives of Dermatology2002;138(9):1149-55. ">Manuskiatti 2002</a>; <a href="./references#CD011642-bbs2-0012" title="OmranifardM , RastiM . Comparing the effects of conventional method, pulse dye laser and erbium laser for the treatment of hypertrophic scars in Iranian patients. Journal of Research in Medical Sciences2007;12(6):277-81. ">Omranifard 2007</a>), six in hospitals (<a href="./references#CD011642-bbs2-0001" title="AlsharnoubiJ , ShoukryKE , FawzyMW , MohamedO . Evaluation of scars in children after treatment with low-level laser. Lasers in Medical Science2018;33(9):1991-5. ">Alsharnoubi 2018</a>; <a href="./references#CD011642-bbs2-0004" title="BeheraB , KumariR , ThappaDM , MalathiM . Therapeutic efficacy of intralesional steroid with carbon dioxide laser versus with cryotherapy in treatment of keloids: a randomized controlled trial. Dermatologic Surgery2016;42(10):1188-98. ">Behera 2016</a>; <a href="./references#CD011642-bbs2-0006" title="ChenX , LiuJ , JameelAA , ValeskaM , ZhangJ , XuY , et al. Combined effects of long-pulsed neodymium-yttrium-aluminum-garnet laser, diprospan and 5-fluorouracil in the treatment of keloid scars. Experimental and Therapeutic Medicine2017;13:3607-12. ">Chen 2017</a>; <a href="./references#CD011642-bbs2-0009" title="LinJY , WargerWC , IziksonL , AndersonRR , TannousZ . A prospective, randomized controlled trial on the efficacy of fractional photothermolysis on scar remodeling. Lasers in Surgery and Medicine2011;43:265-72. ">Lin 2011</a>; <a href="./references#CD011642-bbs2-0013" title="SrivastavaS , KumariH , SinghA . Comparison of fractional CO2 laser, verapamil, and triamcinolone for the treatment of keloid. Advances in Wound Care2019;8(1):7-13. ">Srivastava 2019</a>; <a href="./references#CD011642-bbs2-0014" title="VerhaegheE , OngenaeK , BostoenJ , LambertJ . Nonablative fractional laser resurfacing for the treatment of hypertrophic scars: a randomized controlled trial. Dermatologic Surgery2013;39(3 Pt 1):426-34. ">Verhaeghe 2013</a>), two in outpatient clinics of University departments or University Hospitals (<a href="./references#CD011642-bbs2-0003" title="AzzamOA , BassiounyDA , El-HawaryMS , El MaadawiZM , SobhiRM , El-MesidyMS . Treatment of hypertrophic scars and keloids by fractional carbon dioxide laser: a clinical, histological, and immunohistochemical study. Lasers in Medical Science2016;31(1):9-18. ">Azzam 2016</a>; <a href="./references#CD011642-bbs2-0008" title="KhattabFM , NasrM , KhashabaSA , BessarH . Combination of pulsed dye laser and verapamil in comparison with verapamil alone in the treatment of keloid. Journal of Dermatological Treatment2019;31(2):186-90. ">Khattab 2019</a>), one in an outpatient burn centre (<a href="./references#CD011642-bbs2-0005" title="Blome-EberwienS , GogalC , WeissMJ , BoorseD , PagellaP . Prospective evaluation of fractional CO2 laser treatment of mature burn scars. Journal of Burn Care &amp; Research2016;37(6):379-87. ">Blome‐Eberwein 2016</a>), and two studies did not specify care settings (<a href="./references#CD011642-bbs2-0007" title="DaoudAA , GianatasioC , RudnickA , MichaelM , WaibelJ . Efficacy of combined Intense Pulsed Light (IPL) with fractional CO2 laser ablation in the treatment of large hypertrophic scars: a prospective, randomized control trial. Lasers in Surgery and Medicine2019;51(8):1-8. ">Daoud 2019</a>; <a href="./references#CD011642-bbs2-0015" title="WittenbergGP , FabianBG , BogomilskyJL , SchultzLR , RudneEJ , ChaffinsML , et al. Prospective, single-blind, randomized, controlled study to assess the efficacy of the 585-nm flashlamp-pumped pulsed-dye laser and silicone gel sheeting in hypertrophic scar treatment. Archives of Dermatology1999;135(9):1049-55. ">Wittenberg 1999</a>). </p> <p><b>Design</b> </p> <p>All of the 15 included studies were single‐centre RCTs, published between 1999 and 2019. The length of participant follow‐up of the studies ranged from 12 weeks to 12 months. </p> <p>Five studies (<a href="./references#CD011642-bbs2-0001" title="AlsharnoubiJ , ShoukryKE , FawzyMW , MohamedO . Evaluation of scars in children after treatment with low-level laser. Lasers in Medical Science2018;33(9):1991-5. ">Alsharnoubi 2018</a>; <a href="./references#CD011642-bbs2-0004" title="BeheraB , KumariR , ThappaDM , MalathiM . Therapeutic efficacy of intralesional steroid with carbon dioxide laser versus with cryotherapy in treatment of keloids: a randomized controlled trial. Dermatologic Surgery2016;42(10):1188-98. ">Behera 2016</a>; <a href="./references#CD011642-bbs2-0005" title="Blome-EberwienS , GogalC , WeissMJ , BoorseD , PagellaP . Prospective evaluation of fractional CO2 laser treatment of mature burn scars. Journal of Burn Care &amp; Research2016;37(6):379-87. ">Blome‐Eberwein 2016</a>; <a href="./references#CD011642-bbs2-0008" title="KhattabFM , NasrM , KhashabaSA , BessarH . Combination of pulsed dye laser and verapamil in comparison with verapamil alone in the treatment of keloid. Journal of Dermatological Treatment2019;31(2):186-90. ">Khattab 2019</a>; <a href="./references#CD011642-bbs2-0014" title="VerhaegheE , OngenaeK , BostoenJ , LambertJ . Nonablative fractional laser resurfacing for the treatment of hypertrophic scars: a randomized controlled trial. Dermatologic Surgery2013;39(3 Pt 1):426-34. ">Verhaeghe 2013</a>) compared two trial arms. Six studies (<a href="./references#CD011642-bbs2-0002" title="AsilianA , DaroughehA , ShariatiF . New combination of triamcinolone, 5-fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars. Dermatologic Surgery2006;32(7):907-15. ">Asilian 2006</a>; <a href="./references#CD011642-bbs2-0006" title="ChenX , LiuJ , JameelAA , ValeskaM , ZhangJ , XuY , et al. Combined effects of long-pulsed neodymium-yttrium-aluminum-garnet laser, diprospan and 5-fluorouracil in the treatment of keloid scars. Experimental and Therapeutic Medicine2017;13:3607-12. ">Chen 2017</a>; <a href="./references#CD011642-bbs2-0007" title="DaoudAA , GianatasioC , RudnickA , MichaelM , WaibelJ . Efficacy of combined Intense Pulsed Light (IPL) with fractional CO2 laser ablation in the treatment of large hypertrophic scars: a prospective, randomized control trial. Lasers in Surgery and Medicine2019;51(8):1-8. ">Daoud 2019</a>; <a href="./references#CD011642-bbs2-0012" title="OmranifardM , RastiM . Comparing the effects of conventional method, pulse dye laser and erbium laser for the treatment of hypertrophic scars in Iranian patients. Journal of Research in Medical Sciences2007;12(6):277-81. ">Omranifard 2007</a>; <a href="./references#CD011642-bbs2-0015" title="WittenbergGP , FabianBG , BogomilskyJL , SchultzLR , RudneEJ , ChaffinsML , et al. Prospective, single-blind, randomized, controlled study to assess the efficacy of the 585-nm flashlamp-pumped pulsed-dye laser and silicone gel sheeting in hypertrophic scar treatment. Archives of Dermatology1999;135(9):1049-55. ">Wittenberg 1999</a>; <a href="./references#CD011642-bbs2-0013" title="SrivastavaS , KumariH , SinghA . Comparison of fractional CO2 laser, verapamil, and triamcinolone for the treatment of keloid. Advances in Wound Care2019;8(1):7-13. ">Srivastava 2019</a>) assessed three trial arms each. Three studies (<a href="./references#CD011642-bbs2-0003" title="AzzamOA , BassiounyDA , El-HawaryMS , El MaadawiZM , SobhiRM , El-MesidyMS . Treatment of hypertrophic scars and keloids by fractional carbon dioxide laser: a clinical, histological, and immunohistochemical study. Lasers in Medical Science2016;31(1):9-18. ">Azzam 2016</a>; <a href="./references#CD011642-bbs2-0009" title="LinJY , WargerWC , IziksonL , AndersonRR , TannousZ . A prospective, randomized controlled trial on the efficacy of fractional photothermolysis on scar remodeling. Lasers in Surgery and Medicine2011;43:265-72. ">Lin 2011</a>; <a href="./references#CD011642-bbs2-0010" title="ManuskiattiW , FitzpatrickRE , GoldmanMP . Energy density and numbers of treatment affect response of keloidal and hypertrophic sternotomy scars to the 585-nm flashlamp-pumped pulsed-dye laser. Journal of the American Academy of Dermatology2001;45(4):557-65. ">Manuskiatti 2001</a>) evaluated four trial arms each, and one study (<a href="./references#CD011642-bbs2-0011" title="ManuskiattiW , FitzpatrickRE . Treatment response of keloidal and hypertrophic sternotomy scars. Comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Archives of Dermatology2002;138(9):1149-55. ">Manuskiatti 2002</a>) assessed five trial arms. </p> <p>Among the included studies, six were parallel group (<a href="./references#CD011642-bbs2-0002" title="AsilianA , DaroughehA , ShariatiF . New combination of triamcinolone, 5-fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars. Dermatologic Surgery2006;32(7):907-15. ">Asilian 2006</a>; <a href="./references#CD011642-bbs2-0004" title="BeheraB , KumariR , ThappaDM , MalathiM . Therapeutic efficacy of intralesional steroid with carbon dioxide laser versus with cryotherapy in treatment of keloids: a randomized controlled trial. Dermatologic Surgery2016;42(10):1188-98. ">Behera 2016</a>; <a href="./references#CD011642-bbs2-0006" title="ChenX , LiuJ , JameelAA , ValeskaM , ZhangJ , XuY , et al. Combined effects of long-pulsed neodymium-yttrium-aluminum-garnet laser, diprospan and 5-fluorouracil in the treatment of keloid scars. Experimental and Therapeutic Medicine2017;13:3607-12. ">Chen 2017</a>; <a href="./references#CD011642-bbs2-0008" title="KhattabFM , NasrM , KhashabaSA , BessarH . Combination of pulsed dye laser and verapamil in comparison with verapamil alone in the treatment of keloid. Journal of Dermatological Treatment2019;31(2):186-90. ">Khattab 2019</a>; <a href="./references#CD011642-bbs2-0012" title="OmranifardM , RastiM . Comparing the effects of conventional method, pulse dye laser and erbium laser for the treatment of hypertrophic scars in Iranian patients. Journal of Research in Medical Sciences2007;12(6):277-81. ">Omranifard 2007</a>; <a href="./references#CD011642-bbs2-0013" title="SrivastavaS , KumariH , SinghA . Comparison of fractional CO2 laser, verapamil, and triamcinolone for the treatment of keloid. Advances in Wound Care2019;8(1):7-13. ">Srivastava 2019</a>), and nine were split‐scar design (<a href="./references#CD011642-bbs2-0001" title="AlsharnoubiJ , ShoukryKE , FawzyMW , MohamedO . Evaluation of scars in children after treatment with low-level laser. Lasers in Medical Science2018;33(9):1991-5. ">Alsharnoubi 2018</a>; <a href="./references#CD011642-bbs2-0003" title="AzzamOA , BassiounyDA , El-HawaryMS , El MaadawiZM , SobhiRM , El-MesidyMS . Treatment of hypertrophic scars and keloids by fractional carbon dioxide laser: a clinical, histological, and immunohistochemical study. Lasers in Medical Science2016;31(1):9-18. ">Azzam 2016</a>; <a href="./references#CD011642-bbs2-0005" title="Blome-EberwienS , GogalC , WeissMJ , BoorseD , PagellaP . Prospective evaluation of fractional CO2 laser treatment of mature burn scars. Journal of Burn Care &amp; Research2016;37(6):379-87. ">Blome‐Eberwein 2016</a>; <a href="./references#CD011642-bbs2-0007" title="DaoudAA , GianatasioC , RudnickA , MichaelM , WaibelJ . Efficacy of combined Intense Pulsed Light (IPL) with fractional CO2 laser ablation in the treatment of large hypertrophic scars: a prospective, randomized control trial. Lasers in Surgery and Medicine2019;51(8):1-8. ">Daoud 2019</a>; <a href="./references#CD011642-bbs2-0009" title="LinJY , WargerWC , IziksonL , AndersonRR , TannousZ . A prospective, randomized controlled trial on the efficacy of fractional photothermolysis on scar remodeling. Lasers in Surgery and Medicine2011;43:265-72. ">Lin 2011</a>; <a href="./references#CD011642-bbs2-0010" title="ManuskiattiW , FitzpatrickRE , GoldmanMP . Energy density and numbers of treatment affect response of keloidal and hypertrophic sternotomy scars to the 585-nm flashlamp-pumped pulsed-dye laser. Journal of the American Academy of Dermatology2001;45(4):557-65. ">Manuskiatti 2001</a>; <a href="./references#CD011642-bbs2-0011" title="ManuskiattiW , FitzpatrickRE . Treatment response of keloidal and hypertrophic sternotomy scars. Comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Archives of Dermatology2002;138(9):1149-55. ">Manuskiatti 2002</a>; <a href="./references#CD011642-bbs2-0014" title="VerhaegheE , OngenaeK , BostoenJ , LambertJ . Nonablative fractional laser resurfacing for the treatment of hypertrophic scars: a randomized controlled trial. Dermatologic Surgery2013;39(3 Pt 1):426-34. ">Verhaeghe 2013</a>; <a href="./references#CD011642-bbs2-0015" title="WittenbergGP , FabianBG , BogomilskyJL , SchultzLR , RudneEJ , ChaffinsML , et al. Prospective, single-blind, randomized, controlled study to assess the efficacy of the 585-nm flashlamp-pumped pulsed-dye laser and silicone gel sheeting in hypertrophic scar treatment. Archives of Dermatology1999;135(9):1049-55. ">Wittenberg 1999</a>). </p> <p><b>Sample sizes</b> </p> <p>The number of participants included in each RCT ranged from 10 (<a href="./references#CD011642-bbs2-0009" title="LinJY , WargerWC , IziksonL , AndersonRR , TannousZ . A prospective, randomized controlled trial on the efficacy of fractional photothermolysis on scar remodeling. Lasers in Surgery and Medicine2011;43:265-72. ">Lin 2011</a>; <a href="./references#CD011642-bbs2-0010" title="ManuskiattiW , FitzpatrickRE , GoldmanMP . Energy density and numbers of treatment affect response of keloidal and hypertrophic sternotomy scars to the 585-nm flashlamp-pumped pulsed-dye laser. Journal of the American Academy of Dermatology2001;45(4):557-65. ">Manuskiatti 2001</a>; <a href="./references#CD011642-bbs2-0011" title="ManuskiattiW , FitzpatrickRE . Treatment response of keloidal and hypertrophic sternotomy scars. Comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Archives of Dermatology2002;138(9):1149-55. ">Manuskiatti 2002</a>) to 120 (<a href="./references#CD011642-bbs2-0012" title="OmranifardM , RastiM . Comparing the effects of conventional method, pulse dye laser and erbium laser for the treatment of hypertrophic scars in Iranian patients. Journal of Research in Medical Sciences2007;12(6):277-81. ">Omranifard 2007</a>), with a total of 604 participants included across the review and a mean of 40.27 participants per trial. A total of 906 scar segments (unit of analysis) were assessed. </p> <p><b>Participants</b> </p> <p>Participants included children and adults (age range from 2 to 81 years) of both sexes, skin types I‐VI, presenting hypertrophic and/or keloid scars. Almost all studies specified inclusion and exclusion criteria, except three (<a href="./references#CD011642-bbs2-0005" title="Blome-EberwienS , GogalC , WeissMJ , BoorseD , PagellaP . Prospective evaluation of fractional CO2 laser treatment of mature burn scars. Journal of Burn Care &amp; Research2016;37(6):379-87. ">Blome‐Eberwein 2016</a>; <a href="./references#CD011642-bbs2-0007" title="DaoudAA , GianatasioC , RudnickA , MichaelM , WaibelJ . Efficacy of combined Intense Pulsed Light (IPL) with fractional CO2 laser ablation in the treatment of large hypertrophic scars: a prospective, randomized control trial. Lasers in Surgery and Medicine2019;51(8):1-8. ">Daoud 2019</a> <a href="./references#CD011642-bbs2-0011" title="ManuskiattiW , FitzpatrickRE . Treatment response of keloidal and hypertrophic sternotomy scars. Comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Archives of Dermatology2002;138(9):1149-55. ">Manuskiatti 2002</a>), which reported only inclusion criteria. Some of the exclusion criteria were pregnancy, lactation, scars with previous treatment, and participants with a history of isotretinoin use within the six months prior to laser treatment. Three trials only included participants with hypertrophic scars (<a href="./references#CD011642-bbs2-0009" title="LinJY , WargerWC , IziksonL , AndersonRR , TannousZ . A prospective, randomized controlled trial on the efficacy of fractional photothermolysis on scar remodeling. Lasers in Surgery and Medicine2011;43:265-72. ">Lin 2011</a>; <a href="./references#CD011642-bbs2-0014" title="VerhaegheE , OngenaeK , BostoenJ , LambertJ . Nonablative fractional laser resurfacing for the treatment of hypertrophic scars: a randomized controlled trial. Dermatologic Surgery2013;39(3 Pt 1):426-34. ">Verhaeghe 2013</a>; <a href="./references#CD011642-bbs2-0015" title="WittenbergGP , FabianBG , BogomilskyJL , SchultzLR , RudneEJ , ChaffinsML , et al. Prospective, single-blind, randomized, controlled study to assess the efficacy of the 585-nm flashlamp-pumped pulsed-dye laser and silicone gel sheeting in hypertrophic scar treatment. Archives of Dermatology1999;135(9):1049-55. ">Wittenberg 1999</a>). </p> <p><b>Interventions</b> </p> <p>In this review, we included trials comparing laser therapy for treating hypertrophic and/or keloid scars with other therapies (including no treatment). Different kinds of laser devices were evaluated, as well as different laser treatment regimens. The number of laser sessions varied from one (<a href="./references#CD011642-bbs2-0004" title="BeheraB , KumariR , ThappaDM , MalathiM . Therapeutic efficacy of intralesional steroid with carbon dioxide laser versus with cryotherapy in treatment of keloids: a randomized controlled trial. Dermatologic Surgery2016;42(10):1188-98. ">Behera 2016</a>) to 24 (<a href="./references#CD011642-bbs2-0001" title="AlsharnoubiJ , ShoukryKE , FawzyMW , MohamedO . Evaluation of scars in children after treatment with low-level laser. Lasers in Medical Science2018;33(9):1991-5. ">Alsharnoubi 2018</a>), with a mean of 6.13 sessions, and the frequency of administration varied from twice a week (<a href="./references#CD011642-bbs2-0001" title="AlsharnoubiJ , ShoukryKE , FawzyMW , MohamedO . Evaluation of scars in children after treatment with low-level laser. Lasers in Medical Science2018;33(9):1991-5. ">Alsharnoubi 2018</a>) to one session every eight weeks (<a href="./references#CD011642-bbs2-0015" title="WittenbergGP , FabianBG , BogomilskyJL , SchultzLR , RudneEJ , ChaffinsML , et al. Prospective, single-blind, randomized, controlled study to assess the efficacy of the 585-nm flashlamp-pumped pulsed-dye laser and silicone gel sheeting in hypertrophic scar treatment. Archives of Dermatology1999;135(9):1049-55. ">Wittenberg 1999</a>). Different kinds of laser treatments were compared with no treatment (<a href="#CD011642-tbl-0004">Table 1</a>), with other treatments (<a href="#CD011642-tbl-0005">Table 2</a>) or were combined with other kinds of laser treatments and compared with other treatments (<a href="#CD011642-tbl-0006">Table 3</a>). Only two authors reported who had performed the laser sessions (in <a href="./references#CD011642-bbs2-0005" title="Blome-EberwienS , GogalC , WeissMJ , BoorseD , PagellaP . Prospective evaluation of fractional CO2 laser treatment of mature burn scars. Journal of Burn Care &amp; Research2016;37(6):379-87. ">Blome‐Eberwein 2016</a> and <a href="./references#CD011642-bbs2-0014" title="VerhaegheE , OngenaeK , BostoenJ , LambertJ . Nonablative fractional laser resurfacing for the treatment of hypertrophic scars: a randomized controlled trial. Dermatologic Surgery2013;39(3 Pt 1):426-34. ">Verhaeghe 2013</a> where  laser sessions were performed by health professionals). </p> <div class="table" id="CD011642-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Laser versus no treatment outcome details</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comparison</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trials (participants)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Definition of outcome in trial/measurement details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>585‐nm PDL versus no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 RCTs (Manuskiatti 2001; 10 participants; 40 segments and Manuskiatti 2002, 10 participants; 20 segments) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Manuskiatti 2001 and Manuskiatti 2002: categories of 25% increments of improvement in scar severity after 32 weeks (graded by the patient) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants with an improvement of 50% or higher in the scar severity</p> <p> </p> <p>Manuskiatti 2001:</p> <p>Laser: 23/30<br/>Control: 4/30 </p> <p> </p> <p>Manuskiatti 2002:</p> <p>Laser: 8/10<br/>Control: 4/10 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>585‐nm PDL versus no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 RCTs (Manuskiatti 2001; 10 participants; 40 segments, Manuskiatti 2002, 10 participants; 20 segments, and Wittenberg 1999; 20 participants; 40 segments) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Manuskiatti 2001: immediate treatment reactions, including purpuric discolorations and erosion secondary to blistering, and adverse sequelae during 32 weeks. </p> <p> </p> <p>Manuskiatti 2002: immediate treatment reactions included mild to moderate pain during treatment, burning sensation, spots of purpura, erosion secondary to blistering. Treatment‐related adverse sequelae including hypopigmentation, telangiectasia, and skin atrophy during 32 weeks. </p> <p> </p> <p>Wittenberg 1999: no definition was provided. Duration: 40 weeks.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Manuskiatti 2001 and 2002: in all participants treated with the PDL the area became purpuric and a small number of participants with skin phototype VI reported erosions.<br/>Manuskiatti 2002: mild to moderate<br/>discomfort or pain related to treatment was in 90% (9/10) of the participants during laser pulsing. </p> <p> </p> <p>Wittenberg 1999: one (1/20) participant dropped out due to pain during laser treatment.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>585‐nm PDL versus no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar size, colour, height, length, width, pliability, skin surface texture, pruritus and pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 RCTs (Manuskiatti 2001; 10 participants; 30 segments and Manuskiatti 2002: 10 participants; 20 segments; Wittenberg 1999; 20 participants; 40 segments) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Manuskiatti 2001 and 2002: scar height evaluated using a dial calliper, erythema using a hand‐held colorimeter after 32 weeks. </p> <p> </p> <p>Wittenberg 1999: blood flow (erythema), elasticity and volume, burning, pruritus, and pain not related to treatment after 40 weeks. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Manuskiatti 2001, 2002: scar height improvement in laser treated areas when compared with control (P &lt; 0.05, and P = 0.005, respectively) (data presented only in graphs) </p> <p> </p> <p>Wittenberg 1999: No statistically significant differences between groups were detected for erythema (P = 0.26), elasticity (P = 0.76), volume (P = 0.13), burning (P = 0.75), pruritus (P = 0.99), and pain not related to treatment (P = 0.41) (results presented only in graphs). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAFL versus no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 RCTS (Verhaeghe 2013; 22 participants, 44 segments; Lin 2011; 20 participants; 20 scars) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verhaeghe 2013:<br/>HPGA and PGA using a VAS ranging from 0 to 100 mm (0 = normal skin and 100 = worst possible scar) ‐ smallest clinically important minimum relevant difference was 20 </p> <p>POSAS: containing vascularisation, pigmentation, thickness, relief, pliability, and surface area (observer part) and pain not related to treatment, itching, colour, stiffness, thickness, and relief (patient part) (range 6 to 60) after 3 months. </p> <p> </p> <p>Lin 2011: categories of 25% increments of improvement in scar severity (graded by the participants and 2 blinded observers) after 3 months. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verhaeghe 2013 (36 segments analysed):</p> <p>Number of participants who got better according to HPGA and PGA.<br/>HPGA:<br/>Laser: 10/18<br/>Control: 5/18<br/>PGA:<br/>Laser: 10/18 </p> <p>Control: 1/18</p> <p>POSAS: Patient part (P = .047)</p> <p>Observer part: not significant (details not provided)</p> <p> </p> <p>Lin 2011:</p> <p>HDTA laser: not significant</p> <p>LDTA: P = 0.001 (data presented only in graphs)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAFL versus no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 RCTS (Verhaeghe 2013; 22 participants, 44 segments; Lin 2011; 20 participants; 20 scars) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verhaeghe 2013: treatment‐related adverse effects included erythema, edema, burning sensation, crusts, purpura, vesicles, hyperpigmentation. Duration: 3 months </p> <p> </p> <p>Lin 2011: side effects, including worsening (erythema, pigmentation, or texture), discolouration, exfoliation, swelling, scabbing, and pain related to treatment, rated on a quartile scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe) during the 3 month‐period. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verhaege 2013:</p> <p>Percentage of participants reporting treatment‐related adverse effects 4 days after treatment (out of 18 analysed):<br/>NAFL treatment: </p> <p>Erythema: 70%</p> <p>Edema: 20%</p> <p>Burning sensation: 18%</p> <p>Crusts: 15%</p> <p>Purpura: 7% purpura</p> <p>Vesicles: 3%</p> <p>After 3 months: Hyperpigmentation: 1 participant</p> <p>*In a small group of participants, the treated part improved less than the untreated part. </p> <p>Median pain (related to treatment) score (IQR) on a VAS (0 = no pain and 100 = worst possible pain) was:<br/>Session 1: 37.0 (26.0–53.5) Session 2: 41.0 (26.7–60.7) </p> <p>Session 3: 53.0 (22.5–71.0) Session 4: 48.0 (23.5–78.5)</p> <p> </p> <p>Lin 2011:</p> <p>Number of participants reporting scar worsening</p> <p>HDTA: 3/10</p> <p> </p> <p>Higher risk of erythema, exfoliation, and pain related to treatment with HDTA compared with LDTA (P = 0.05, P = 0.02, P = 0.01, respectively) (data on side effects were presented only in graphs). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAFL versus no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar size, colour, height, length, width, pliability, skin surface texture, pruritus and pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 RCTS (Verhaeghe 2013; 22 participants, 44 segments; Lin 2011; 20 participants; 20 scars) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verhaeghe 2013: redness, pigmentation, and skin texture after 3 months</p> <p> </p> <p>Lin 2011: erythema, pigmentation, texture after 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verhaeghe 2013:</p> <p>No significant difference in redness, pigmentation, and skin texture (details not provided) </p> <p> </p> <p>Lin 2011: Mean + SD</p> <p>Erythema:<br/>HDTA: 1.33 + 1.26 </p> <p>Control: 0.89 + 0.95</p> <p>LDTA: 1.06 + 1.26<br/>Control: 0.94 + 1.20 </p> <p>Pigmentation:</p> <p>HDTA: 1.06 + 0.95</p> <p>Control: 0.94 + 0.82</p> <p>LDTA: 0.79 + 0.76</p> <p>Control: 0.71 + 0.76</p> <p>Texture:</p> <p>HDTA: 2 + 0.76</p> <p>Control: 1.78 + 0.89</p> <p>LDTA: 2.19 + 0.95<br/>Control: 1.63 + 0.95 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fractional CO<sub>2</sub> Laser versus no treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 RCTS (Azzam 2016: 30 participants; 60 segments, Blome‐Eberwein 2016: 36 participants; 80 scars, Daoud 2019: 23 participants; 46 segments) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azzam 2016: patient satisfaction, as follows:</p> <p>excellent = more than 75 %, good = 50 to 75%, moderate = 25 to 50 % and poor = less than 25 % improvement after 3 months </p> <p> </p> <p>Azzam 2016 and Blome‐Eberwein 2016 used the VSS, including pliability, height, colour, and vascularity </p> <p> </p> <p>Blome‐Eberwein 2016 and Daoud 2019: POSAS</p> <p>including: vascularisation, pigmentation, thickness,</p> <p>relief, pliability, and surface area (observer), itching, colour, and pain not related to treatment </p> <p>stiffness, thickness, and relief (patient)</p> <p>(range 6 to 60) after up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azzam 2016: Number of participants that reported each satisfaction</p> <p>Keloid scar participants</p> <p>Excellent: 6/12</p> <p>Good: 3/12</p> <p>Moderate: 3/12</p> <p>Hypertrophic scar patients<br/>Excellent: 2/7 </p> <p>Good: 1/7</p> <p>Moderate: 2/7</p> <p>Poor: 2/7</p> <p> </p> <p>Azzam 2016:<br/>VSS (Mean + SD) </p> <p>Keloid scar patients</p> <p>Laser: 5.7 + 2.2</p> <p>Control: 7.6 + 1.0</p> <p>Hypertrophic scar patients</p> <p>Laser: 4.6 + 2.5</p> <p>Control: 7.6 + 2.9</p> <p> </p> <p>Blome‐Erbewein 2016</p> <p>VSS (Mean + SD)</p> <p>Hypertrophic scar patients</p> <p>Laser: 6.5 + 2.39</p> <p>Control: 6.41 + 2.31</p> <p> </p> <p>Blome‐Eberwein 2016</p> <p>POSAS</p> <p>Pre‐treatment<br/>Laser: 32.64 ± 12.41<br/>Control: 29.91 ± 13.03 </p> <p>Post‐treatment</p> <p>Laser: 28.51 ± 12.85</p> <p>Control: 24.38 ± 11.41</p> <p> </p> <p>Daoud 2019<br/>POSAS </p> <p>Significant improvements in all categories except for colour (P &lt; 0.001) (results presented in graphs) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fractional CO<sub>2</sub> Laser versus no treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Daoud 2019 23 participants; 46 scar segments)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The authors mention that no treatment‐related adverse effects were reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fractional CO<sub>2</sub> Laser versus no treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar size, colour, height, length, width, pliability, skin surface texture, pruritus and pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 RCTS (Azzam 2016: 30 participants; 60 segments;,Blome‐Eberwein 2016: 36 participants; 80 scars) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azzam 2016: pruritus and pain not related to treatment after 3 months</p> <p> </p> <p>Blome‐Eberwein 2016</p> <p>Scar pliability and height evaluated with suction cup and ultrasound, colour; erythema and pigmentation assessed with Dermaspectrometer), sensation, pruritus, and pain not related to treatment evaluated with POSAS after up to 6 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azzam: number of participants complaining of pruritus and pain</p> <p>Pruritus: 16</p> <p>Pain: 5</p> <p>(details not provided)</p> <p> </p> <p>Blome‐Eberwein 2016: pliability, height, recoil Mean and SD – before and after treatment</p> <p>Scar height</p> <p>Pre‐intervention</p> <p>Laser: 3.15 ± 0.37</p> <p>Control: 2.658 ± 0.344</p> <p>Post‐treatment:</p> <p>Laser: 2.34 ± 0.313</p> <p>Control: 2.46 ± 0.342</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>HDTA:</b> high‐density treatment arm; <b>HPGA:</b> Health Professional Global Assessment; <b>IQR:</b> interquartile range; <b>LDTA:</b> low‐density treatment arm; <b>PGA:</b> patient global assessment; <b>POSAS:</b> Patient and Observer Scar Assessment Scale; (In POSAS, highest values indicate worse scar or sensation); <b>SD:</b> standard deviation; <b>VAS:</b> visual analogue scale; <b>VSS:</b> Vancouver Scar Scale. </p> </div> </div> <div class="table" id="CD011642-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Laser versus other treatments outcome details</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comparison</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trials (participants)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Definition of outcome in trial/measurement details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>585‐nm PDL versus TAC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 RCTs (Omranifard 2007: 80 participants; 80 scars and Manuskiatti 2002: 10 participants; 20 segments) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Omranifard 2007: Patient Satisfaction assessed by VBS, including pigmentation, vascularity, pliability and height (photographs were taken). Self‐assessment: number of participants who considered their scars better or much better after up to 12 months Manuskiatti 2002: categories of 25% increments of improvement in scar severity after 32 weeks (graded by the participant) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Omranifard 2007:</p> <p>VBS (Mean + SD)</p> <p>Post‐treatment</p> <p>PDL: 4.2 + 1.6</p> <p>TAC: 6.7 + 1.6</p> <p>Self‐assessment</p> <p>PDL: 70%</p> <p>TAC: 30%</p> <p>Manuskiatti 2002:</p> <p>Number of participants with a 50% improvement or higher</p> <p>PDL: 8/10</p> <p>TAC: 10/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>585‐nm PDL versus TAC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 RCTs (Omranifard 2007: 80 participants; 80 scars and Manuskiatti 2002: 10 participants; 20 segments) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Omranifard 2007: complications, such as textural or discolouration (hypo‐ or hyperpigmentation) during up to 12 months Manuskiatti 2002: Immediate treat reactions included mild to moderate pain during treatment, burning sensation, spots of purpura, erosion secondary to blistering. Treatment‐related adverse sequelae including hypopigmentation, telangiectasia, and skin atrophy during 32 weeks. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Omranifard 2007: no complication was observed</p> <p>Manuskiatti 2002:</p> <p>Sequelae:</p> <p>PDL: 0/10<br/>TAC: 5/10 (Hypopigmentation 2, Telangiectasia 2, skin atrophy 1)<br/>Mild to moderate pain related to treatment:<br/>PDL: 9/10 </p> <p>Control: 10/10 (further details not provided)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>585‐nm PDL versus TAC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 RCTs (Omranifard 2007: 80 participants; 80 scars and Manuskiatti 2002: 10 participants; 20 segments) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar size, colour, height, length, width, pliability, skin surface texture, pruritus and pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Omranifard 2007: vascularity, using a transparent tool for blanching the scar. Scar height scores: calliper by measuring the maximum vertical elevation of the scar above the normal skin after up to 12 months Manuskiatti 2002: scar height evaluated using a dial calliper, erythema using a hand‐held colorimeter after 32 weeks. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Omranifard 2007:</p> <p>Vascularity (Mean)</p> <p>Pre‐treatment PDL: 2.3</p> <p>TAC: 2.3</p> <p>Post‐treatment</p> <p>PDL: 1.1</p> <p>TAC: 1.95</p> <p>Height (Mean)</p> <p>Pre‐treatment</p> <p>PDL: 2.16</p> <p>TAC: 2.18</p> <p>Post‐treatment</p> <p>PDL: 1.32</p> <p>TAC: 1.93</p> <p>Manuskiatti 2002: No significant difference between groups in height (results presented only in graphs) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>585‐nm PDL versus 5‐FU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Manuskiatti 2002: 10 participants; 20 segments)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Manuskiatti 2002: categories of 25% increments of improvement in scar severity after 32 weeks (graded by the participant). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Manuskiatti 2002:</p> <p>Number of participants with a 50% improvement or higher</p> <p>PDL: 8/10<br/>5‐FU: 10/10 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>585‐nm PDL versus 5‐FU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Manuskiatti 2002: 10 participants; 20 segments)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Manuskiatti 2002: immediate treatment reactions included mild to moderate pain during treatment and spots of purpura during 32 weeks. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Manuskiatti 2002:<br/>Mild to moderate pain during the injection:<br/>PDL: 9/10<br/>5‐FU: 10/10<br/>  </p> <p>Purpura:<br/>PDL: 10/10 </p> <p>5‐FU: 2/10</p> <p> </p> <p>No permanent sequelae were reported in the areas submitted to laser therapy or 5‐FU.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>585‐nm PDL versus 5‐FU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Manuskiatti 2002: 10 participants; 20 segments)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Manuskiatti2002: scar height evaluated using a dial calliper, erythema using a hand‐held colorimeter after 32 weeks. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant difference between groups in height (results presented only in graphs)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>585‐nm PDL versus TAC plus 5‐FU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Manuskiatti 2002: 10 participants; 20 segments)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Manuskiatti 2002: categories of 25% increments of improvement in scar severity after 32 weeks (graded by the participant). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Manuskiatti 2002:</p> <p>Number of participants with a 50% improvement or higher</p> <p>PDL: 8/10</p> <p>TAC plus 5‐FU: 9/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>585‐nm PDL versus TAC plus 5‐FU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Manuskiatti 2002: 10 participants; 20 segments)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Manuskiatti 2002: immediate treatment reactions included mild to moderate pain during treatment and spots of purpura during 32 weeks. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Manuskiatti 2002:<br/>Mild to moderate pain during the injection:<br/>PDL: 9/10<br/>5‐FU: 10/10<br/>  </p> <p>Purpura:<br/>PDL: 10/10 </p> <p>5‐FU: 3/10</p> <p> </p> <p>No permanent sequelae were reported in the areas submitted to laser therapy or 5‐FU.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>585‐nm PDL versus TAC plus 5‐FU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Manuskiatti 2002: 10 participants; 20 segments)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Manuskiatti2002: scar height evaluated using a dial calliper, erythema using a hand‐held colorimeter after 32 weeks. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild to moderate pain not related to treatment</p> <p>PDL: 9/10</p> <p>TAC plus 5‐FU: 10/10</p> <p>No significant difference between groups in height (results presented only in graphs).</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>585‐nm PDL versus Silicone Gel Sheeting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Wittenberg 1999; 20 participants; 40 segments)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wittenberg 1999: No definition is provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wittenberg 1999: one participant dropped out due to pain during laser treatment. One participant did not use SGS because of skin irritation. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Erbium laser versus TAC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Omranifard 2007: 80 participants; 80 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Omranifard 2007: Patient Satisfaction assessed by VBS, including pigmentation, vascularity, pliability and height. (photographs were taken) Self‐assessment: improvement of the scars severity after up to 12 months. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Omranifard 2007:</p> <p>VBS (Mean + SD)</p> <p>Post‐treatment</p> <p>Erbium: 4.6 + 1.9</p> <p>TAC: 6.7 + 1.6</p> <p>Self‐assessment (number of participants who considered their scars better or much better) </p> <p>Erbium: 65%</p> <p>TAC: 30%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Erbium laser versus TAC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Omranifard 2007: 80 participants; 80 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Omranifard 2007: complications, such as textural or discoloration (hypo‐ or hyperpigmentation) during up to 12 months. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Omranifard 2007: no complication was observed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Erbium laser versus TAC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Omranifard 2007: 80 participants; 80 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Omranifard 2007: vascularity, using a transparent tool for blanching the scar. Scar height scores: calliper by measuring the maximum vertical elevation of the scar above the normal skin after up to 12 months. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Omranifard 2007:</p> <p>Vascularity (Mean)</p> <p>pre‐treatment</p> <p>Erbium: 2.4</p> <p>TAC: 2.3</p> <p>Post‐treatment</p> <p>Erbium: 1.15</p> <p>TAC: 1.95</p> <p>Height (Mean)</p> <p>Pre‐treatment</p> <p>Erbium: 2.18</p> <p>TAC: 2.18</p> <p>Post‐treatment</p> <p>Erbium: 1.39</p> <p>TAC: 1.93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fractional CO<sub>2</sub> Laser versus TAC </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Srivastava 2019; 40 participants; 40 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Srivastava 2019: VSS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Srivastava 2019 Results of full scale were not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fractional CO<sub>2</sub> Laser versus TAC </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Srivastava 2019; 40 participants; 40 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Srivastava 2019: pain at injection site, telangiectasia, skin atrophy and charring were evaluated and reported (when they occurred) during 24 weeks. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Srivastava 2019:</p> <p>Number of participants reporting treatment‐related adverse effects</p> <p>Pain at injection site</p> <p>FCO2: 2/20</p> <p>TAC: 8/20</p> <p>Telangiectasia</p> <p>FCO2: 0/20</p> <p>TAC: 2/20</p> <p>Skin atrophy</p> <p>FCO2: 0/20</p> <p>TAC: 1/20</p> <p>Charring</p> <p>FCO2: 3/20</p> <p>TAC: 0/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fractional CO<sub>2</sub> Laser versus TAC </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Srivastava 2019; 40 participants; 40 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Srivastava 2019: height measured with callipers; vascularity by visual inspection; pliability by palpation; pigmentation after blanching (using a piece of clear plastic sheet till scar flattening occurred) and comparing it with the surrounding skin, pruritus, and pain not related to treatment after 24 weeks. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Srivastava 2019:</p> <p>Height (Mean + SD)</p> <p>Pre‐treatment</p> <p>FCO2: 1.95 + 0.76</p> <p>TAC: 1.75 + 0.64</p> <p>Post‐treatment<br/>FCO2: 0.25 + 0.44 </p> <p>TAC: 0 + 0</p> <p>Vascularity</p> <p>Pre‐treatment</p> <p>FCO2: 2.05 + 0.69</p> <p>TAC: 1.65 + 0.49</p> <p>Post‐treatment<br/>FCO2: 0.45 + 0.51 </p> <p>TAC: 0 + 0</p> <p>Pliability</p> <p>Pre‐treatment</p> <p>FCO2: 1.85 + 0.67</p> <p>TAC: 1.9 + 0.64</p> <p>Post‐treatment<br/>FCO2: 0.9 + 0.31 </p> <p>TAC: 0 + 0</p> <p>Pigmentation</p> <p>Pre‐treatment</p> <p>FCO2: 1.60 + 0.50</p> <p>TAC: 1.7 + 0.47</p> <p>Post‐treatment<br/>FCO2: 0.8 + 0.41 </p> <p>TAC: 0.8 + 0.41</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fractional CO<sub>2</sub> Laser versus Verapamil </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Srivastava 2019; 40 participants 40 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Srivastava 2019: VSS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Srivastava 2019: Results of full scale were not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fractional CO<sub>2</sub> Laser versus Verapamil </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Srivastava 2019; 40 participants 40 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Srivastava 2019: pain at injection site, telangiectasia, skin atrophy and charring were evaluated and reported (when they occurred) during 24 weeks. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Srivastava 2019:</p> <p>Number of participants reporting treatment‐related adverse effects</p> <p>Pain at injection site</p> <p>FCO2: 2/20</p> <p>Verapamil: 0/20</p> <p>Telangiectasia</p> <p>FCO2: 0/20</p> <p>Verapamil: 0/20</p> <p>Skin atrophy</p> <p>FCO2: 0/20</p> <p>Verapamil: 0/20</p> <p>Charring</p> <p>FCO2: 3/20</p> <p>Verapamil: 0/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fractional CO<sub>2</sub> Laser versus Verapamil </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Srivastava 2019; 40 participants 40 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Srivastava 2019: height measured with callipers; vascularity by visual inspection; pliability by palpation; pigmentation after blanching (using a piece of clear plastic sheet till scar flattening occurred) and comparing it with the surrounding skin, pruritus, and pain not related to treatment after 24 weeks. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Srivastava 2019:</p> <p>Height (Mean + SD)</p> <p>Pre‐treatment</p> <p>FCO2: 1.95 + 0.76</p> <p>Verapamil: 2.05 + 0.6</p> <p>Post‐treatment<br/>FCO2: 0.25 + 0.44 </p> <p>Verapamil: 0.05 + 0.22</p> <p>Vascularity</p> <p>Pre‐treatment</p> <p>FCO2: 2.05 + 0.69</p> <p>Verapamil: 1.95 + 0.69</p> <p>Post‐treatment<br/>FCO2: 0.45 + 0.51 </p> <p>Verapamil: 0.1 + 0.31</p> <p>Pliability</p> <p>Pre‐treatment</p> <p>FCO2: 1.85 + 0.67</p> <p>Verapamil: 2.1 + 0.64</p> <p>Post‐treatment</p> <p>FCO2: 0.9 + 0.31</p> <p>Verapamil: 0 + 0</p> <p>Pigmentation</p> <p>Pre‐treatment</p> <p>FCO2: 1.60 + 0.50</p> <p>Verapamil: 1.65 + 0.49</p> <p>Post‐treatment<br/>FCO2: 0.8 + 0.41 </p> <p>Verapamil: 0.55 + 0.51</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>5‐FU:</b> Fluorouracil; <b>PDL:</b> Pulsed‐Dye Laser; <b>TAC:</b> Triamcinolone acetonide;<b>VSS:</b> Vancouver Scar scale. </p> </div> </div> <div class="table" id="CD011642-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Laser plus other treatments versus other treatments outcome details</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comparison</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. of Trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Definition of outcome in trial/measurement details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>585‐nm PDL plus TAC plus 5 FU versus TAC plus 5‐FU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Asilian 2006; 43 participants; 43 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asilian 2006: patient and Observer: no improvement; poor = up to 25% improvement; fair = 26% to 50% improvement; good = 51% to 75% improvement; (for the observer assessment photographs were taken) after 12 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asilian 2006:</p> <p>Number of participants and observers reporting good to excellent improvement OA</p> <p>585‐nm PDL plus TAC plus 5 FU: 14/20</p> <p>TAC plus 5‐FU: 8/20</p> <p>PSA</p> <p>585‐nm PDL plus TAC plus 5 FU: 15/20</p> <p>TAC plus 5‐FU: 11/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>585‐nm PDL plus TAC plus 5 FU versus TAC plus 5‐FU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Asilian 2006; 43 participants; 43 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asilian 2006: treatment‐related adverse effects including the presence of purpuric areas by observer interviews during 12 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asilian 2006:</p> <p>In the TAC plus 5‐FU plus PDL group the lesions became purpuric which lasted from 7 to 10 days </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>585‐nm PDL plus TAC plus 5 FU versus TAC plus 5‐FU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Asilian 2006; 43 participants; 43 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asilian 2006: scar length and width using a dial calliper, height using a calliper, erythema, pliability, and pruritus: graded by the observer on a 5‐point scale: 0 = no; 1 = mild; 2 = moderate; 3 = severe; and 4 = very severe. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asilian 2006:</p> <p>Erythema</p> <p>Pre‐treatment</p> <p>PDL plus TAC plus 5‐FU: 3.2</p> <p>TAC plus 5‐FU: 3.3</p> <p>Post‐treatment</p> <p>TAC plus 5‐FU plus PDL: 1.2</p> <p>TAC plus 5‐FU: 1.9</p> <p>Reduction in height (average lesion)</p> <p>TAC plus 5‐FU: 77%</p> <p>PDL plus TAC plus 5‐FU: 79%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CO<sub>2</sub> Laser plus TAC versus Cryosurgery plus TAC </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Behera 2016: 60 participants; 101 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Behera 2016: patient and observer on a 5‐point scale as, poor = up to 25% improvement; fair = 26% to 50% improvement; good = 51% to 75% improvement; and excellent = 76% to 100% improvement (for the observer assessment photographs were taken) VSS after up to 12 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Behera 2016:</p> <p>Number (%) of participants with an improvement of 50% or higher in the scar:</p> <p>PSA:</p> <p>CO<sub>2</sub> Laser plus TAC: 27 (75%); </p> <p>Cryosurgery plus TAC: 21 (77.78%)</p> <p>OA:</p> <p>CO<sub>2</sub> Laser plus TAC: 22 (61.12%); </p> <p>Cryosurgery plus TAC: 23 (85.18%)</p> <p>VSS: CO<sub>2</sub> Laser plus TAC: 19 (52.78%); </p> <p>Cryosurgery plus TAC: 17 (62.96%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CO<sub>2</sub> Laser plus TAC versus Cryosurgery plus TAC </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Behera 2016: 60 participants; 101 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Behera 2016: no definition was provided (after up to 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Behera 2016:</p> <p>CO<sub>2</sub> Laser plus TAC: 6 (16.66%) </p> <p>Cryosurgery plus TAC: 0 (0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CO<sub>2</sub> Laser plus TAC versus Cryosurgery plus TAC </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Behera 2016: 60 participants; 101 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Behera 2016: no definition was provided (during up to 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Behera 2016:</p> <p>Number (%) of participants with atrophy CO<sub>2</sub> Laser plus TAC: 17 (47.23%); Cryosurgery plus TAC: 15 (55.56%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CO<sub>2</sub> Laser plus TAC versus Cryosurgery plus TAC </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Behera 2016: 60 participants; 101 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Behera 2016: height: using a dial calliper, volume, pruritus, and pain not related to treatment after up to 12 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Behera 2016:<br/>Height (mean percentage reduction + SD): </p> <p>CO<sub>2</sub> Laser plus TAC: 49.31 + 50.42; </p> <p>Cryosurgery plus TAC: 65.46 + 35.63</p> <p>Volume (Mean percentage reduction + SD):</p> <p>CO<sub>2</sub> Laser plus TAC: 54.81 + 47.96; </p> <p>Cryosurgery plus TAC: 72.69 + 37.75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nd:YAG laser plus Intralesional corticosteroid plus 5‐FU versus Intralesional corticosteroid plus 5‐FU </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Chen 2017: 46 participants; 46 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chen 2017: patient and observer on a 5‐point scale as, poor = up to 25% improvement; fair = 26% to 50% improvement; good = 51% to 75% improvement; and excellent = 76% to 100% improvement (for the observer assessment photographs were taken) after 3 months. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chen 2017:</p> <p>OA:</p> <p>Number (%) of participants with an improvement of 51% or higher in the scar:</p> <p>Nd:YAG laser plus Intralesional corticosteroid plus 5‐FU: 16 (69.57%);</p> <p>Intralesional corticosteroid plus 5‐FU: 11 (47.83%)</p> <p>PSA: Nd:YAG laser plus Intralesional corticosteroid plus 5‐FU: 18 (78.26%);</p> <p>Intralesional corticosteroid plus 5‐FU: 13 (56.52%%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nd:YAG laser plus Intralesional corticosteroid plus 5‐FU versus Intralesional corticosteroid plus 5‐FU </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Chen 46 participants; 46 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chen 2017: no definition was provided (during 3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chen 2017:</p> <p>Almost all injections were painful.</p> <p>Nd:YAG plus Intralesional corticosteroid plus 5‑FU: the site treated by Nd:YAG became purpuric, which lasted for 7 to 10 days. </p> <p>No adverse textural or pigmentary alterations, and no ulcers or erosions were observed in either groups. No further information was provided regarding adverse events in the trial. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nd:YAG laser plus Intralesional corticosteroid plus 5‐FU versus Intralesional corticosteroid plus 5‐FU </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Chen 46 participants; 46 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chen 2017: erythema, pliability, and pruritus were graded by the observer on a 5‐point scale: 0 = no erythema; 1 = mild erythema; 2 = moderate erythema; 3 = severe erythema; and 4 = very severe erythema after 3 months. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chen 2017:</p> <p>Erythema (P &lt; 0.05), pliability (P &lt; 0.05), and pruritus (P &lt; 0.05) were significantly lower in the laser group (data provided only in graphs). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>He‐Ne laser plus Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream versus Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Alsharnoubi 2018: 15 participants; 30 segments)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alsharnoubi 2018: VSS, including skin thickness, pigmentation, and vascularity after 3 months. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alsharnoubi 2018:</p> <p>VSS: median values</p> <p>Pre‐treatment: 9 (value of the whole scar)</p> <p>Post treatment He‐Ne laser plus Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream: 4; </p> <p>Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream: 6;</p> <p>Height score:</p> <p>Pre‐treatment: 2 (value of the whole scar)</p> <p>Post treatment He‐Ne laser plus Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream: 1; </p> <p>Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream: 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>He‐Ne laser plus Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream versus Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Alsharnoubi 2018: 15 participants; 30 scar segments)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Definition was not provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No treatment‐related adverse effects were reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>He‐Ne laser plus Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream versus Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Alsharnoubi 2018: 15 participants; 30 scar segments)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alsharnoubi 2018: scar thickness using an ultrasound imaging system, perfusion (erythema) using a Laser Doppler perfusion imager. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alsharnoubi 2018:</p> <p>Skin thickness (mean ± SD)</p> <p>Pre‐treatment: 0.52 ± 0.17 mm (whole scar)</p> <p>Post treatment He‐Ne laser plus Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream: 0.34 ± 0.09 mm; </p> <p>Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream: 0.43 ± 0.13 mm </p> <p>Perfusion</p> <p>Pre‐treatment: 1.27 ± 0.54 V (whole scar)</p> <p>Post treatment He‐Ne laser plus Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream: 0.8 ± 0.23 V; </p> <p>Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream: 0.77 ± 0.24 V Pigmentation </p> <p>Pre‐treatment: 2 (whole scar)</p> <p>Post Treatment He‐Ne laser plus Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream: 0; </p> <p>Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream: 2;</p> <p>Vascularity</p> <p>Pre‐treatment: 2 (whole scar)</p> <p>Post Treatment</p> <p>He‐Ne laser plus Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream: 1 </p> <p>Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream: 1 (data presented in graphs) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PDL plus intralesional verapamil versus intralesional verapamil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Khattab 2019; 40 participants; 50 keloid scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khattab 2019: VSS, keloid height measured with callipers; pliability by palpation; vascularity by visual inspection, and pigmentation scored after blanching and comparing it with the surrounding skin after 24 weeks. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khattab 2019:</p> <p>Height (Mean + SD)</p> <p>PDL plus verapamil: 0.21 ± 0.56;</p> <p>Verapamil: 3.10±1.85</p> <p>Pliabilty: PDL plus verapamil: 0.20±0.41;</p> <p>Verapamil: 2.07±0.26</p> <p>Vascularity</p> <p>PDL plus verapamil: 0.03 ± 0.70;</p> <p>Verapamil: 0.87±0.74 Pigmentation</p> <p>PDL plus verapamil: 0.13 ± 0.35;</p> <p>Verapamil: 0.27±0.70</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PDL plus intralesional verapamil versus intralesional verapamil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Khattab 2019; 40 participants; 50 keloid scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khattab 2019: treatment‐related adverse effects were regrowth, pain, hyperpigmentation, depigmentation, and purpura during 24 weeks. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khattab 2019:</p> <p>Treatment‐related adverse events:<br/>Regrowth<br/>PDL plus verapamil: 3 (12%)<br/>Verapamil: 2 (8%)<br/>Pain<br/>PDL plus verapamil: 1 (4%);<br/>Verapamil: 0 (0%)<br/>Hyperpigmentation<br/>PDL plus verapamil: 2 (8%)<br/>Verapamil: 0 (0%)<br/>Depigmentation<br/>PDL plus verapamil: 1 (4%)<br/>Verapamil: 1 (4%)<br/>Purpura<br/>PDL plus verapamil: 7 (28%)<br/>Verapamil: 0 (0%)<br/>Total<br/>PDL plus verapamil: 14 (56%)<br/>Verapamil: 3 (12%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PDL plus intralesional verapamil versus intralesional verapamil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Khattab 2019; 40 participants; 50 keloid scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khattab 2019: height, vascularity, pliability, and pigmentation were assessed at 24 weeks. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khattab 2019:<br/>Height<br/>PDL plus verapamil: 0.21 + 0.56;<br/>Verapamil: 3.1 + 1.85<br/>Vascularity<br/>PDL plus verapamil: 0.03 + 0.07; </p> <p>Verapamil: 0.87 + 0.74</p> <p>Pliability</p> <p>PDL plus verapamil: 0.2 + 0.41;</p> <p>Verapamil: 2.07 + 0.26</p> <p>Pigmentation</p> <p>PDL plus verapamil: 0.13 + 0.35;</p> <p>Verapamil: 0.27 + 0.7</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>5‐FU:</b> Fluorouracil; <b>NdYAG:</b> neodymium‐doped yttrium aluminium garnet; <b>PDL:</b> Pulsed‐Dye Laser; <b>SD:</b> standard deviation; <b>TAC:</b> Triamcinolone acetonide;<b>VSS:</b> Vancouver Scar scale. </p> </div> </div> <p><b>Outcomes</b> </p> <p>The primary outcome of severity of keloid or hypertrophic scars (or both), assessed using a range of specific scales across studies, for both participant and health professional‐reported data, and incidence and severity of treatment‐related adverse effects were reported in 12 of the studies evaluated (<a href="./references#CD011642-bbs2-0001" title="AlsharnoubiJ , ShoukryKE , FawzyMW , MohamedO . Evaluation of scars in children after treatment with low-level laser. Lasers in Medical Science2018;33(9):1991-5. ">Alsharnoubi 2018</a>; <a href="./references#CD011642-bbs2-0002" title="AsilianA , DaroughehA , ShariatiF . New combination of triamcinolone, 5-fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars. Dermatologic Surgery2006;32(7):907-15. ">Asilian 2006</a>; <a href="./references#CD011642-bbs2-0004" title="BeheraB , KumariR , ThappaDM , MalathiM . Therapeutic efficacy of intralesional steroid with carbon dioxide laser versus with cryotherapy in treatment of keloids: a randomized controlled trial. Dermatologic Surgery2016;42(10):1188-98. ">Behera 2016</a>; <a href="./references#CD011642-bbs2-0006" title="ChenX , LiuJ , JameelAA , ValeskaM , ZhangJ , XuY , et al. Combined effects of long-pulsed neodymium-yttrium-aluminum-garnet laser, diprospan and 5-fluorouracil in the treatment of keloid scars. Experimental and Therapeutic Medicine2017;13:3607-12. ">Chen 2017</a>; <a href="./references#CD011642-bbs2-0007" title="DaoudAA , GianatasioC , RudnickA , MichaelM , WaibelJ . Efficacy of combined Intense Pulsed Light (IPL) with fractional CO2 laser ablation in the treatment of large hypertrophic scars: a prospective, randomized control trial. Lasers in Surgery and Medicine2019;51(8):1-8. ">Daoud 2019</a>; <a href="./references#CD011642-bbs2-0008" title="KhattabFM , NasrM , KhashabaSA , BessarH . Combination of pulsed dye laser and verapamil in comparison with verapamil alone in the treatment of keloid. Journal of Dermatological Treatment2019;31(2):186-90. ">Khattab 2019</a>; <a href="./references#CD011642-bbs2-0009" title="LinJY , WargerWC , IziksonL , AndersonRR , TannousZ . A prospective, randomized controlled trial on the efficacy of fractional photothermolysis on scar remodeling. Lasers in Surgery and Medicine2011;43:265-72. ">Lin 2011</a>; <a href="./references#CD011642-bbs2-0010" title="ManuskiattiW , FitzpatrickRE , GoldmanMP . Energy density and numbers of treatment affect response of keloidal and hypertrophic sternotomy scars to the 585-nm flashlamp-pumped pulsed-dye laser. Journal of the American Academy of Dermatology2001;45(4):557-65. ">Manuskiatti 2001</a>; <a href="./references#CD011642-bbs2-0011" title="ManuskiattiW , FitzpatrickRE . Treatment response of keloidal and hypertrophic sternotomy scars. Comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Archives of Dermatology2002;138(9):1149-55. ">Manuskiatti 2002</a>; <a href="./references#CD011642-bbs2-0012" title="OmranifardM , RastiM . Comparing the effects of conventional method, pulse dye laser and erbium laser for the treatment of hypertrophic scars in Iranian patients. Journal of Research in Medical Sciences2007;12(6):277-81. ">Omranifard 2007</a>; <a href="./references#CD011642-bbs2-0013" title="SrivastavaS , KumariH , SinghA . Comparison of fractional CO2 laser, verapamil, and triamcinolone for the treatment of keloid. Advances in Wound Care2019;8(1):7-13. ">Srivastava 2019</a>; <a href="./references#CD011642-bbs2-0014" title="VerhaegheE , OngenaeK , BostoenJ , LambertJ . Nonablative fractional laser resurfacing for the treatment of hypertrophic scars: a randomized controlled trial. Dermatologic Surgery2013;39(3 Pt 1):426-34. ">Verhaeghe 2013</a>). <a href="./references#CD011642-bbs2-0003" title="AzzamOA , BassiounyDA , El-HawaryMS , El MaadawiZM , SobhiRM , El-MesidyMS . Treatment of hypertrophic scars and keloids by fractional carbon dioxide laser: a clinical, histological, and immunohistochemical study. Lasers in Medical Science2016;31(1):9-18. ">Azzam 2016</a> ,and <a href="./references#CD011642-bbs2-0005" title="Blome-EberwienS , GogalC , WeissMJ , BoorseD , PagellaP . Prospective evaluation of fractional CO2 laser treatment of mature burn scars. Journal of Burn Care &amp; Research2016;37(6):379-87. ">Blome‐Eberwein 2016</a> did not report treatment‐related adverse effects. <a href="./references#CD011642-bbs2-0015" title="WittenbergGP , FabianBG , BogomilskyJL , SchultzLR , RudneEJ , ChaffinsML , et al. Prospective, single-blind, randomized, controlled study to assess the efficacy of the 585-nm flashlamp-pumped pulsed-dye laser and silicone gel sheeting in hypertrophic scar treatment. Archives of Dermatology1999;135(9):1049-55. ">Wittenberg 1999</a> only reported treatment‐related adverse effects.  </p> <p>Secondary outcomes were reported as follows.</p> <p> <ul id="CD011642-list-0008"> <li> <p><a href="./references#CD011642-bbs2-0001" title="AlsharnoubiJ , ShoukryKE , FawzyMW , MohamedO . Evaluation of scars in children after treatment with low-level laser. Lasers in Medical Science2018;33(9):1991-5. ">Alsharnoubi 2018</a>: skin thickness, pigmentation, and vascularity </p> </li> <li> <p><a href="./references#CD011642-bbs2-0002" title="AsilianA , DaroughehA , ShariatiF . New combination of triamcinolone, 5-fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars. Dermatologic Surgery2006;32(7):907-15. ">Asilian 2006</a>: colour, height, length, width, pliability, and pruritus </p> </li> <li> <p><a href="./references#CD011642-bbs2-0003" title="AzzamOA , BassiounyDA , El-HawaryMS , El MaadawiZM , SobhiRM , El-MesidyMS . Treatment of hypertrophic scars and keloids by fractional carbon dioxide laser: a clinical, histological, and immunohistochemical study. Lasers in Medical Science2016;31(1):9-18. ">Azzam 2016</a>: pruritus and pain </p> </li> <li> <p><a href="./references#CD011642-bbs2-0004" title="BeheraB , KumariR , ThappaDM , MalathiM . Therapeutic efficacy of intralesional steroid with carbon dioxide laser versus with cryotherapy in treatment of keloids: a randomized controlled trial. Dermatologic Surgery2016;42(10):1188-98. ">Behera 2016</a>: height, volume, pruritus and pain </p> </li> <li> <p><a href="./references#CD011642-bbs2-0005" title="Blome-EberwienS , GogalC , WeissMJ , BoorseD , PagellaP . Prospective evaluation of fractional CO2 laser treatment of mature burn scars. Journal of Burn Care &amp; Research2016;37(6):379-87. ">Blome‐Eberwein 2016</a>: colour, height, pliability, sensation, pruritus and pain </p> </li> <li> <p><a href="./references#CD011642-bbs2-0006" title="ChenX , LiuJ , JameelAA , ValeskaM , ZhangJ , XuY , et al. Combined effects of long-pulsed neodymium-yttrium-aluminum-garnet laser, diprospan and 5-fluorouracil in the treatment of keloid scars. Experimental and Therapeutic Medicine2017;13:3607-12. ">Chen 2017</a>: erythema, pliability, and pruritus </p> </li> <li> <p><a href="./references#CD011642-bbs2-0007" title="DaoudAA , GianatasioC , RudnickA , MichaelM , WaibelJ . Efficacy of combined Intense Pulsed Light (IPL) with fractional CO2 laser ablation in the treatment of large hypertrophic scars: a prospective, randomized control trial. Lasers in Surgery and Medicine2019;51(8):1-8. ">Daoud 2019</a>: colour, matte versus shiny, contour, distortion, and texture </p> </li> <li> <p><a href="./references#CD011642-bbs2-0008" title="KhattabFM , NasrM , KhashabaSA , BessarH . Combination of pulsed dye laser and verapamil in comparison with verapamil alone in the treatment of keloid. Journal of Dermatological Treatment2019;31(2):186-90. ">Khattab 2019</a>: overall appearance, dyschromia (discolourisation), the degree of hypertrophy, and texture </p> </li> <li> <p><a href="./references#CD011642-bbs2-0009" title="LinJY , WargerWC , IziksonL , AndersonRR , TannousZ . A prospective, randomized controlled trial on the efficacy of fractional photothermolysis on scar remodeling. Lasers in Surgery and Medicine2011;43:265-72. ">Lin 2011</a>: size, colour, and texture </p> </li> <li> <p><a href="./references#CD011642-bbs2-0010" title="ManuskiattiW , FitzpatrickRE , GoldmanMP . Energy density and numbers of treatment affect response of keloidal and hypertrophic sternotomy scars to the 585-nm flashlamp-pumped pulsed-dye laser. Journal of the American Academy of Dermatology2001;45(4):557-65. ">Manuskiatti 2001</a>: colour, height, pliability, texture, pruritus and pain </p> </li> <li> <p><a href="./references#CD011642-bbs2-0011" title="ManuskiattiW , FitzpatrickRE . Treatment response of keloidal and hypertrophic sternotomy scars. Comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Archives of Dermatology2002;138(9):1149-55. ">Manuskiatti 2002</a>: colour, height, and pliability </p> </li> <li> <p><a href="./references#CD011642-bbs2-0012" title="OmranifardM , RastiM . Comparing the effects of conventional method, pulse dye laser and erbium laser for the treatment of hypertrophic scars in Iranian patients. Journal of Research in Medical Sciences2007;12(6):277-81. ">Omranifard 2007</a>: colour, height, and patient tolerance </p> </li> <li> <p><a href="./references#CD011642-bbs2-0013" title="SrivastavaS , KumariH , SinghA . Comparison of fractional CO2 laser, verapamil, and triamcinolone for the treatment of keloid. Advances in Wound Care2019;8(1):7-13. ">Srivastava 2019</a>: height, pigmentation, vascularity, and pliability </p> </li> <li> <p><a href="./references#CD011642-bbs2-0014" title="VerhaegheE , OngenaeK , BostoenJ , LambertJ . Nonablative fractional laser resurfacing for the treatment of hypertrophic scars: a randomized controlled trial. Dermatologic Surgery2013;39(3 Pt 1):426-34. ">Verhaeghe 2013</a>: pain, itching, colour, stiffness, thickness, relief, vascularity, pigmentation, pliability, and surface area </p> </li> <li> <p><a href="./references#CD011642-bbs2-0015" title="WittenbergGP , FabianBG , BogomilskyJL , SchultzLR , RudneEJ , ChaffinsML , et al. Prospective, single-blind, randomized, controlled study to assess the efficacy of the 585-nm flashlamp-pumped pulsed-dye laser and silicone gel sheeting in hypertrophic scar treatment. Archives of Dermatology1999;135(9):1049-55. ">Wittenberg 1999</a>: size, pliability, colour, pruritus and pain. </p> </li> </ul> </p> <p>Callipers, colorimeters, ultrasound, cutometer, spectrometer, molds, and forms were used to evaluate these parameters. </p> </section> <section id="CD011642-sec-0043"> <h4 class="title">Excluded studies</h4> <p>Of the 44 full‐text articles evaluated, 17 were excluded and the reasons for their exclusion are described in <a href="./references#CD011642-sec-0163" title="">Characteristics of excluded studies</a>.   </p> <p>One study is awaiting classification (<a href="./references#CD011642-bbs2-0033" title="MaariC . Randomized, controlled, within-patient, single-blinded pilot study to evaluate the efficacy of the ablative fractional CO2 laser in the treatment of hypertrophic scars in adult burn patients. Journal of the American Academy of Dermatology2017;76(6 (Suppl 1)):AB212. [DOI: 10.1016/j.jaad.2017.04.1113]">Maari 2017</a>) and 11 are ongoing studies see <a href="./references#CD011642-sec-0165" title="">Characteristics of ongoing studies</a>. </p> </section> </section> <section id="CD011642-sec-0044"> <h3 class="title">Risk of bias in included studies</h3> <p>We evaluated and presented the risk of bias of each RCT as part of the <a href="./references#CD011642-sec-0162" title="">Characteristics of included studies</a> tables. <a href="#CD011642-fig-0002">Figure 2</a> presents the judgments of the review authors on the methodological appraisal as percentages across all included studies. <a href="#CD011642-fig-0003">Figure 3</a> presents the judgements of the review authors on the methodological appraisal of each risk of bias item of the included studies. All studies were assessed as being at high risk of bias for at least one domain. </p> <div class="figure" id="CD011642-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011642-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD011642-sec-0045"> <h4 class="title">Allocation</h4> <p>Seven studies described their sequence generation methods (<a href="./references#CD011642-bbs2-0003" title="AzzamOA , BassiounyDA , El-HawaryMS , El MaadawiZM , SobhiRM , El-MesidyMS . Treatment of hypertrophic scars and keloids by fractional carbon dioxide laser: a clinical, histological, and immunohistochemical study. Lasers in Medical Science2016;31(1):9-18. ">Azzam 2016</a>; <a href="./references#CD011642-bbs2-0004" title="BeheraB , KumariR , ThappaDM , MalathiM . Therapeutic efficacy of intralesional steroid with carbon dioxide laser versus with cryotherapy in treatment of keloids: a randomized controlled trial. Dermatologic Surgery2016;42(10):1188-98. ">Behera 2016</a>; <a href="./references#CD011642-bbs2-0005" title="Blome-EberwienS , GogalC , WeissMJ , BoorseD , PagellaP . Prospective evaluation of fractional CO2 laser treatment of mature burn scars. Journal of Burn Care &amp; Research2016;37(6):379-87. ">Blome‐Eberwein 2016</a>; <a href="./references#CD011642-bbs2-0009" title="LinJY , WargerWC , IziksonL , AndersonRR , TannousZ . A prospective, randomized controlled trial on the efficacy of fractional photothermolysis on scar remodeling. Lasers in Surgery and Medicine2011;43:265-72. ">Lin 2011</a>; <a href="./references#CD011642-bbs2-0013" title="SrivastavaS , KumariH , SinghA . Comparison of fractional CO2 laser, verapamil, and triamcinolone for the treatment of keloid. Advances in Wound Care2019;8(1):7-13. ">Srivastava 2019</a>; <a href="./references#CD011642-bbs2-0014" title="VerhaegheE , OngenaeK , BostoenJ , LambertJ . Nonablative fractional laser resurfacing for the treatment of hypertrophic scars: a randomized controlled trial. Dermatologic Surgery2013;39(3 Pt 1):426-34. ">Verhaeghe 2013</a>; <a href="./references#CD011642-bbs2-0015" title="WittenbergGP , FabianBG , BogomilskyJL , SchultzLR , RudneEJ , ChaffinsML , et al. Prospective, single-blind, randomized, controlled study to assess the efficacy of the 585-nm flashlamp-pumped pulsed-dye laser and silicone gel sheeting in hypertrophic scar treatment. Archives of Dermatology1999;135(9):1049-55. ">Wittenberg 1999</a>) and were rated as low risk of bias. Four RCTs (<a href="./references#CD011642-bbs2-0003" title="AzzamOA , BassiounyDA , El-HawaryMS , El MaadawiZM , SobhiRM , El-MesidyMS . Treatment of hypertrophic scars and keloids by fractional carbon dioxide laser: a clinical, histological, and immunohistochemical study. Lasers in Medical Science2016;31(1):9-18. ">Azzam 2016</a>; <a href="./references#CD011642-bbs2-0004" title="BeheraB , KumariR , ThappaDM , MalathiM . Therapeutic efficacy of intralesional steroid with carbon dioxide laser versus with cryotherapy in treatment of keloids: a randomized controlled trial. Dermatologic Surgery2016;42(10):1188-98. ">Behera 2016</a>; <a href="./references#CD011642-bbs2-0005" title="Blome-EberwienS , GogalC , WeissMJ , BoorseD , PagellaP . Prospective evaluation of fractional CO2 laser treatment of mature burn scars. Journal of Burn Care &amp; Research2016;37(6):379-87. ">Blome‐Eberwein 2016</a>; <a href="./references#CD011642-bbs2-0014" title="VerhaegheE , OngenaeK , BostoenJ , LambertJ . Nonablative fractional laser resurfacing for the treatment of hypertrophic scars: a randomized controlled trial. Dermatologic Surgery2013;39(3 Pt 1):426-34. ">Verhaeghe 2013</a>) also provided an adequate description of allocation concealment and were rated as low risk of bias: meaning they were considered as low risk for bias arising from the randomisation process. </p> </section> <section id="CD011642-sec-0046"> <h4 class="title">Blinding</h4> <p>Since we were comparing a procedure (laser therapy) with other therapies and blinding is difficult from a practical perspective, participants and interventionists were not blinded in any of the RCTs evaluated and they were considered as high risk for performance bias. Twelve trials (<a href="./references#CD011642-bbs2-0001" title="AlsharnoubiJ , ShoukryKE , FawzyMW , MohamedO . Evaluation of scars in children after treatment with low-level laser. Lasers in Medical Science2018;33(9):1991-5. ">Alsharnoubi 2018</a>; <a href="./references#CD011642-bbs2-0002" title="AsilianA , DaroughehA , ShariatiF . New combination of triamcinolone, 5-fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars. Dermatologic Surgery2006;32(7):907-15. ">Asilian 2006</a>; <a href="./references#CD011642-bbs2-0003" title="AzzamOA , BassiounyDA , El-HawaryMS , El MaadawiZM , SobhiRM , El-MesidyMS . Treatment of hypertrophic scars and keloids by fractional carbon dioxide laser: a clinical, histological, and immunohistochemical study. Lasers in Medical Science2016;31(1):9-18. ">Azzam 2016</a>; <a href="./references#CD011642-bbs2-0004" title="BeheraB , KumariR , ThappaDM , MalathiM . Therapeutic efficacy of intralesional steroid with carbon dioxide laser versus with cryotherapy in treatment of keloids: a randomized controlled trial. Dermatologic Surgery2016;42(10):1188-98. ">Behera 2016</a>; <a href="./references#CD011642-bbs2-0005" title="Blome-EberwienS , GogalC , WeissMJ , BoorseD , PagellaP . Prospective evaluation of fractional CO2 laser treatment of mature burn scars. Journal of Burn Care &amp; Research2016;37(6):379-87. ">Blome‐Eberwein 2016</a>; <a href="./references#CD011642-bbs2-0006" title="ChenX , LiuJ , JameelAA , ValeskaM , ZhangJ , XuY , et al. Combined effects of long-pulsed neodymium-yttrium-aluminum-garnet laser, diprospan and 5-fluorouracil in the treatment of keloid scars. Experimental and Therapeutic Medicine2017;13:3607-12. ">Chen 2017</a>; <a href="./references#CD011642-bbs2-0007" title="DaoudAA , GianatasioC , RudnickA , MichaelM , WaibelJ . Efficacy of combined Intense Pulsed Light (IPL) with fractional CO2 laser ablation in the treatment of large hypertrophic scars: a prospective, randomized control trial. Lasers in Surgery and Medicine2019;51(8):1-8. ">Daoud 2019</a>; <a href="./references#CD011642-bbs2-0009" title="LinJY , WargerWC , IziksonL , AndersonRR , TannousZ . A prospective, randomized controlled trial on the efficacy of fractional photothermolysis on scar remodeling. Lasers in Surgery and Medicine2011;43:265-72. ">Lin 2011</a>; <a href="./references#CD011642-bbs2-0012" title="OmranifardM , RastiM . Comparing the effects of conventional method, pulse dye laser and erbium laser for the treatment of hypertrophic scars in Iranian patients. Journal of Research in Medical Sciences2007;12(6):277-81. ">Omranifard 2007</a>; <a href="./references#CD011642-bbs2-0013" title="SrivastavaS , KumariH , SinghA . Comparison of fractional CO2 laser, verapamil, and triamcinolone for the treatment of keloid. Advances in Wound Care2019;8(1):7-13. ">Srivastava 2019</a>; <a href="./references#CD011642-bbs2-0014" title="VerhaegheE , OngenaeK , BostoenJ , LambertJ . Nonablative fractional laser resurfacing for the treatment of hypertrophic scars: a randomized controlled trial. Dermatologic Surgery2013;39(3 Pt 1):426-34. ">Verhaeghe 2013</a>; <a href="./references#CD011642-bbs2-0015" title="WittenbergGP , FabianBG , BogomilskyJL , SchultzLR , RudneEJ , ChaffinsML , et al. Prospective, single-blind, randomized, controlled study to assess the efficacy of the 585-nm flashlamp-pumped pulsed-dye laser and silicone gel sheeting in hypertrophic scar treatment. Archives of Dermatology1999;135(9):1049-55. ">Wittenberg 1999</a>) had blinded observers, so were rated as low risk for detection bias for non‐participant reported outcomes. The remaining three RCTs <a href="./references#CD011642-bbs2-0008" title="KhattabFM , NasrM , KhashabaSA , BessarH . Combination of pulsed dye laser and verapamil in comparison with verapamil alone in the treatment of keloid. Journal of Dermatological Treatment2019;31(2):186-90. ">Khattab 2019</a>; <a href="./references#CD011642-bbs2-0010" title="ManuskiattiW , FitzpatrickRE , GoldmanMP . Energy density and numbers of treatment affect response of keloidal and hypertrophic sternotomy scars to the 585-nm flashlamp-pumped pulsed-dye laser. Journal of the American Academy of Dermatology2001;45(4):557-65. ">Manuskiatti 2001</a>; <a href="./references#CD011642-bbs2-0011" title="ManuskiattiW , FitzpatrickRE . Treatment response of keloidal and hypertrophic sternotomy scars. Comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Archives of Dermatology2002;138(9):1149-55. ">Manuskiatti 2002</a>) did not mention the blinding of the evaluators and were rated as unclear risk of bias. </p> </section> <section id="CD011642-sec-0047"> <h4 class="title">Incomplete outcome data</h4> <p>In four trials (<a href="./references#CD011642-bbs2-0010" title="ManuskiattiW , FitzpatrickRE , GoldmanMP . Energy density and numbers of treatment affect response of keloidal and hypertrophic sternotomy scars to the 585-nm flashlamp-pumped pulsed-dye laser. Journal of the American Academy of Dermatology2001;45(4):557-65. ">Manuskiatti 2001</a>; <a href="./references#CD011642-bbs2-0011" title="ManuskiattiW , FitzpatrickRE . Treatment response of keloidal and hypertrophic sternotomy scars. Comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Archives of Dermatology2002;138(9):1149-55. ">Manuskiatti 2002</a>; <a href="./references#CD011642-bbs2-0012" title="OmranifardM , RastiM . Comparing the effects of conventional method, pulse dye laser and erbium laser for the treatment of hypertrophic scars in Iranian patients. Journal of Research in Medical Sciences2007;12(6):277-81. ">Omranifard 2007</a>; <a href="./references#CD011642-bbs2-0013" title="SrivastavaS , KumariH , SinghA . Comparison of fractional CO2 laser, verapamil, and triamcinolone for the treatment of keloid. Advances in Wound Care2019;8(1):7-13. ">Srivastava 2019</a>), all participants completed the study, and these trials were considered as low risk of bias. Two RCTs (<a href="./references#CD011642-bbs2-0014" title="VerhaegheE , OngenaeK , BostoenJ , LambertJ . Nonablative fractional laser resurfacing for the treatment of hypertrophic scars: a randomized controlled trial. Dermatologic Surgery2013;39(3 Pt 1):426-34. ">Verhaeghe 2013</a>; <a href="./references#CD011642-bbs2-0015" title="WittenbergGP , FabianBG , BogomilskyJL , SchultzLR , RudneEJ , ChaffinsML , et al. Prospective, single-blind, randomized, controlled study to assess the efficacy of the 585-nm flashlamp-pumped pulsed-dye laser and silicone gel sheeting in hypertrophic scar treatment. Archives of Dermatology1999;135(9):1049-55. ">Wittenberg 1999</a>) reported dropouts, but explained the reasons, and were also rated as low risk of bias. Two trials (<a href="./references#CD011642-bbs2-0001" title="AlsharnoubiJ , ShoukryKE , FawzyMW , MohamedO . Evaluation of scars in children after treatment with low-level laser. Lasers in Medical Science2018;33(9):1991-5. ">Alsharnoubi 2018</a>; <a href="./references#CD011642-bbs2-0008" title="KhattabFM , NasrM , KhashabaSA , BessarH . Combination of pulsed dye laser and verapamil in comparison with verapamil alone in the treatment of keloid. Journal of Dermatological Treatment2019;31(2):186-90. ">Khattab 2019</a>) did not provide enough information to judge if there were losses, and these trials were rated as unclear risk of bias. Two trials (<a href="./references#CD011642-bbs2-0005" title="Blome-EberwienS , GogalC , WeissMJ , BoorseD , PagellaP . Prospective evaluation of fractional CO2 laser treatment of mature burn scars. Journal of Burn Care &amp; Research2016;37(6):379-87. ">Blome‐Eberwein 2016</a>; <a href="./references#CD011642-bbs2-0009" title="LinJY , WargerWC , IziksonL , AndersonRR , TannousZ . A prospective, randomized controlled trial on the efficacy of fractional photothermolysis on scar remodeling. Lasers in Surgery and Medicine2011;43:265-72. ">Lin 2011</a>) had substantial losses and although the reasons for the losses were explained, the authors performed as‐treated analyses. Thus, these trials were rated as high risk of bias. Five trials (<a href="./references#CD011642-bbs2-0002" title="AsilianA , DaroughehA , ShariatiF . New combination of triamcinolone, 5-fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars. Dermatologic Surgery2006;32(7):907-15. ">Asilian 2006</a>; <a href="./references#CD011642-bbs2-0003" title="AzzamOA , BassiounyDA , El-HawaryMS , El MaadawiZM , SobhiRM , El-MesidyMS . Treatment of hypertrophic scars and keloids by fractional carbon dioxide laser: a clinical, histological, and immunohistochemical study. Lasers in Medical Science2016;31(1):9-18. ">Azzam 2016</a>; <a href="./references#CD011642-bbs2-0004" title="BeheraB , KumariR , ThappaDM , MalathiM . Therapeutic efficacy of intralesional steroid with carbon dioxide laser versus with cryotherapy in treatment of keloids: a randomized controlled trial. Dermatologic Surgery2016;42(10):1188-98. ">Behera 2016</a>; <a href="./references#CD011642-bbs2-0006" title="ChenX , LiuJ , JameelAA , ValeskaM , ZhangJ , XuY , et al. Combined effects of long-pulsed neodymium-yttrium-aluminum-garnet laser, diprospan and 5-fluorouracil in the treatment of keloid scars. Experimental and Therapeutic Medicine2017;13:3607-12. ">Chen 2017</a>; <a href="./references#CD011642-bbs2-0007" title="DaoudAA , GianatasioC , RudnickA , MichaelM , WaibelJ . Efficacy of combined Intense Pulsed Light (IPL) with fractional CO2 laser ablation in the treatment of large hypertrophic scars: a prospective, randomized control trial. Lasers in Surgery and Medicine2019;51(8):1-8. ">Daoud 2019</a>) had losses and did not provide enough information about the reasons for dropouts, so were considered at high risk of bias. </p> </section> <section id="CD011642-sec-0048"> <h4 class="title">Selective reporting</h4> <p>Four trials (<a href="./references#CD011642-bbs2-0001" title="AlsharnoubiJ , ShoukryKE , FawzyMW , MohamedO . Evaluation of scars in children after treatment with low-level laser. Lasers in Medical Science2018;33(9):1991-5. ">Alsharnoubi 2018</a>; <a href="./references#CD011642-bbs2-0002" title="AsilianA , DaroughehA , ShariatiF . New combination of triamcinolone, 5-fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars. Dermatologic Surgery2006;32(7):907-15. ">Asilian 2006</a>; <a href="./references#CD011642-bbs2-0003" title="AzzamOA , BassiounyDA , El-HawaryMS , El MaadawiZM , SobhiRM , El-MesidyMS . Treatment of hypertrophic scars and keloids by fractional carbon dioxide laser: a clinical, histological, and immunohistochemical study. Lasers in Medical Science2016;31(1):9-18. ">Azzam 2016</a>; <a href="./references#CD011642-bbs2-0012" title="OmranifardM , RastiM . Comparing the effects of conventional method, pulse dye laser and erbium laser for the treatment of hypertrophic scars in Iranian patients. Journal of Research in Medical Sciences2007;12(6):277-81. ">Omranifard 2007</a>) did not describe the data for all parameters analysed, and their protocols were not available, so they were considered as high risk of bias. Eight RCTs (<a href="./references#CD011642-bbs2-0005" title="Blome-EberwienS , GogalC , WeissMJ , BoorseD , PagellaP . Prospective evaluation of fractional CO2 laser treatment of mature burn scars. Journal of Burn Care &amp; Research2016;37(6):379-87. ">Blome‐Eberwein 2016</a>; <a href="./references#CD011642-bbs2-0006" title="ChenX , LiuJ , JameelAA , ValeskaM , ZhangJ , XuY , et al. Combined effects of long-pulsed neodymium-yttrium-aluminum-garnet laser, diprospan and 5-fluorouracil in the treatment of keloid scars. Experimental and Therapeutic Medicine2017;13:3607-12. ">Chen 2017</a>; <a href="./references#CD011642-bbs2-0008" title="KhattabFM , NasrM , KhashabaSA , BessarH . Combination of pulsed dye laser and verapamil in comparison with verapamil alone in the treatment of keloid. Journal of Dermatological Treatment2019;31(2):186-90. ">Khattab 2019</a>; <a href="./references#CD011642-bbs2-0009" title="LinJY , WargerWC , IziksonL , AndersonRR , TannousZ . A prospective, randomized controlled trial on the efficacy of fractional photothermolysis on scar remodeling. Lasers in Surgery and Medicine2011;43:265-72. ">Lin 2011</a>; <a href="./references#CD011642-bbs2-0010" title="ManuskiattiW , FitzpatrickRE , GoldmanMP . Energy density and numbers of treatment affect response of keloidal and hypertrophic sternotomy scars to the 585-nm flashlamp-pumped pulsed-dye laser. Journal of the American Academy of Dermatology2001;45(4):557-65. ">Manuskiatti 2001</a>; <a href="./references#CD011642-bbs2-0011" title="ManuskiattiW , FitzpatrickRE . Treatment response of keloidal and hypertrophic sternotomy scars. Comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Archives of Dermatology2002;138(9):1149-55. ">Manuskiatti 2002</a>; <a href="./references#CD011642-bbs2-0014" title="VerhaegheE , OngenaeK , BostoenJ , LambertJ . Nonablative fractional laser resurfacing for the treatment of hypertrophic scars: a randomized controlled trial. Dermatologic Surgery2013;39(3 Pt 1):426-34. ">Verhaeghe 2013</a>; <a href="./references#CD011642-bbs2-0015" title="WittenbergGP , FabianBG , BogomilskyJL , SchultzLR , RudneEJ , ChaffinsML , et al. Prospective, single-blind, randomized, controlled study to assess the efficacy of the 585-nm flashlamp-pumped pulsed-dye laser and silicone gel sheeting in hypertrophic scar treatment. Archives of Dermatology1999;135(9):1049-55. ">Wittenberg 1999</a>) reported all parameters specified in the methods section or in their protocols, so were rated as low risk of bias. Three trials (<a href="./references#CD011642-bbs2-0004" title="BeheraB , KumariR , ThappaDM , MalathiM . Therapeutic efficacy of intralesional steroid with carbon dioxide laser versus with cryotherapy in treatment of keloids: a randomized controlled trial. Dermatologic Surgery2016;42(10):1188-98. ">Behera 2016</a>; <a href="./references#CD011642-bbs2-0007" title="DaoudAA , GianatasioC , RudnickA , MichaelM , WaibelJ . Efficacy of combined Intense Pulsed Light (IPL) with fractional CO2 laser ablation in the treatment of large hypertrophic scars: a prospective, randomized control trial. Lasers in Surgery and Medicine2019;51(8):1-8. ">Daoud 2019</a>; <a href="./references#CD011642-bbs2-0013" title="SrivastavaS , KumariH , SinghA . Comparison of fractional CO2 laser, verapamil, and triamcinolone for the treatment of keloid. Advances in Wound Care2019;8(1):7-13. ">Srivastava 2019</a>) were considered as unclear risk of bias as the authors described the findings for all parameters analysed, however, they did not explain what kind of tool they used to analyse these parameters and no trial protocol was available. </p> </section> <section id="CD011642-sec-0049"> <h4 class="title">Other potential sources of bias</h4> <p>All split‐scar trials performed paired analyses as required so we did not consider them to be at risk of bias in terms of analytical approach. There were no other potential sources of bias noted in any of the included studies, and all of them were rated as low risk of bias. </p> </section> </section> <section id="CD011642-sec-0050"> <h3 class="title" id="CD011642-sec-0050">Effects of interventions</h3> <p>See: <a href="./full#CD011642-tbl-0001"><b>Summary of findings 1</b> Laser therapy compared with no treatment for treating hypertrophic and keloid scars</a>; <a href="./full#CD011642-tbl-0002"><b>Summary of findings 2</b> Laser therapy compared with other treatments for treating hypertrophic and keloid scars</a>; <a href="./full#CD011642-tbl-0003"><b>Summary of findings 3</b> Laser therapy plus other treatment compared with other treatment for treating hypertrophic and keloid scars</a> </p> <p>The variability of intervention types, controls, follow‐up periods and limited data reported meant we could only pool data for one comparison (and only two outcomes within this). We report below the results of the effects of interventions, with subgroup analyses, considering the latest time points available in the included studies. The secondary outcomes ‐ cosmesis, tolerance, preference for different modes of treatment, adherence, and change in quality of life ‐ were not reported in any of the included studies. </p> <section id="CD011642-sec-0051"> <h4 class="title">1. Laser versus no treatment</h4> <p><a href="./full#CD011642-tbl-0001">summary of findings Table 1</a> </p> <section id="CD011642-sec-0052"> <h5 class="title">585‐nm pulsed‐dye laser (PDL) versus no treatment (3 studies)</h5> <section id="CD011642-sec-0053"> <h6 class="title">Scar severity measured by health professional and/or participant using a specific scale  </h6> <p>We pooled data from <a href="./references#CD011642-bbs2-0010" title="ManuskiattiW , FitzpatrickRE , GoldmanMP . Energy density and numbers of treatment affect response of keloidal and hypertrophic sternotomy scars to the 585-nm flashlamp-pumped pulsed-dye laser. Journal of the American Academy of Dermatology2001;45(4):557-65. ">Manuskiatti 2001</a> and <a href="./references#CD011642-bbs2-0011" title="ManuskiattiW , FitzpatrickRE . Treatment response of keloidal and hypertrophic sternotomy scars. Comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Archives of Dermatology2002;138(9):1149-55. ">Manuskiatti 2002</a>. There may be more hypertrophic and keloid scar improvement (that is scars are less severe) in 585‐nm PDL‐treated scars compared with no treatment after 32 weeks: risk ratio (RR) 1.96 (95% confidence interval (CI): 1.11 to 3.45, two studies, 60 scar segments (based on unblinded patient self‐assessment of improvement of 50% or higher between the laser treated areas and the control areas) (<a href="./references#CD011642-fig-0004" title="">Analysis 1.1</a>). This is low‐certainty evidence, downgraded once for serious imprecision and once for serious risk of bias. </p> </section> <section id="CD011642-sec-0054"> <h6 class="title">Incidence and severity of treatment‐related adverse effects</h6> <p>Three studies reported incidence of adverse effects related to treatment (<a href="./references#CD011642-bbs2-0015" title="WittenbergGP , FabianBG , BogomilskyJL , SchultzLR , RudneEJ , ChaffinsML , et al. Prospective, single-blind, randomized, controlled study to assess the efficacy of the 585-nm flashlamp-pumped pulsed-dye laser and silicone gel sheeting in hypertrophic scar treatment. Archives of Dermatology1999;135(9):1049-55. ">Wittenberg 1999</a>, <a href="./references#CD011642-bbs2-0010" title="ManuskiattiW , FitzpatrickRE , GoldmanMP . Energy density and numbers of treatment affect response of keloidal and hypertrophic sternotomy scars to the 585-nm flashlamp-pumped pulsed-dye laser. Journal of the American Academy of Dermatology2001;45(4):557-65. ">Manuskiatti 2001</a>, <a href="./references#CD011642-bbs2-0011" title="ManuskiattiW , FitzpatrickRE . Treatment response of keloidal and hypertrophic sternotomy scars. Comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Archives of Dermatology2002;138(9):1149-55. ">Manuskiatti 2002</a>) (<a href="#CD011642-tbl-0004">Table 1</a>). It is uncertain whether the 585‐nm PDL impacts on the incidence of treatment‐related adverse effects. This is very low certainty evidence, downgraded twice for very serious imprecision and once for serious risk of bias (<a href="./full#CD011642-tbl-0001">summary of findings Table 1</a>) (<a href="./references#CD011642-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD011642-sec-0055"> <h6 class="title">Scar size, colour, height, length, width, pliability, skin surface texture, pruritus and pain </h6> <p>Three studies which were at high risk of bias evaluated these outcomes (<a href="./references#CD011642-bbs2-0015" title="WittenbergGP , FabianBG , BogomilskyJL , SchultzLR , RudneEJ , ChaffinsML , et al. Prospective, single-blind, randomized, controlled study to assess the efficacy of the 585-nm flashlamp-pumped pulsed-dye laser and silicone gel sheeting in hypertrophic scar treatment. Archives of Dermatology1999;135(9):1049-55. ">Wittenberg 1999</a>, <a href="./references#CD011642-bbs2-0010" title="ManuskiattiW , FitzpatrickRE , GoldmanMP . Energy density and numbers of treatment affect response of keloidal and hypertrophic sternotomy scars to the 585-nm flashlamp-pumped pulsed-dye laser. Journal of the American Academy of Dermatology2001;45(4):557-65. ">Manuskiatti 2001</a> and <a href="./references#CD011642-bbs2-0011" title="ManuskiattiW , FitzpatrickRE . Treatment response of keloidal and hypertrophic sternotomy scars. Comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Archives of Dermatology2002;138(9):1149-55. ">Manuskiatti 2002</a>). </p> <p>In <a href="./references#CD011642-bbs2-0015" title="WittenbergGP , FabianBG , BogomilskyJL , SchultzLR , RudneEJ , ChaffinsML , et al. Prospective, single-blind, randomized, controlled study to assess the efficacy of the 585-nm flashlamp-pumped pulsed-dye laser and silicone gel sheeting in hypertrophic scar treatment. Archives of Dermatology1999;135(9):1049-55. ">Wittenberg 1999</a>, the study authors reported there were no significant differences in blood flow (erythema), elasticity and volume between intervention and control groups at the end of the follow up period. Results were presented graphically and not analysed here further. There was also no reported difference between groups in patients who rated scar burning, pruritus, and pain not related to treatment. </p> <p>In <a href="./references#CD011642-bbs2-0010" title="ManuskiattiW , FitzpatrickRE , GoldmanMP . Energy density and numbers of treatment affect response of keloidal and hypertrophic sternotomy scars to the 585-nm flashlamp-pumped pulsed-dye laser. Journal of the American Academy of Dermatology2001;45(4):557-65. ">Manuskiatti 2001</a> and <a href="./references#CD011642-bbs2-0011" title="ManuskiattiW , FitzpatrickRE . Treatment response of keloidal and hypertrophic sternotomy scars. Comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Archives of Dermatology2002;138(9):1149-55. ">Manuskiatti 2002</a>, the authors reported scar height reduction in laser treated areas when compared with control (P &lt; 0.05, and P = 0.005, respectively). The results were presented graphically, with no data for further analysis. </p> </section> </section> <section id="CD011642-sec-0056"> <h5 class="title">Nonablative fractional laser (NAFL) versus no treatment (2 studies)</h5> <section id="CD011642-sec-0057"> <h6 class="title">Scar severity measured by health professional and/or participant using a specific scale  </h6> <p>From <a href="./references#CD011642-bbs2-0014" title="VerhaegheE , OngenaeK , BostoenJ , LambertJ . Nonablative fractional laser resurfacing for the treatment of hypertrophic scars: a randomized controlled trial. Dermatologic Surgery2013;39(3 Pt 1):426-34. ">Verhaeghe 2013</a> it is unclear whether NAFL impacts on hypertrophic scar severity compared with no treatment when measured using a blinded health professional global assessment at three months, as this is very low‐certainty evidence, downgraded twice due to very serious imprecision and once for serious risk of bias) (<a href="./references#CD011642-fig-0006" title="">Analysis 2.1</a>). </p> <p>In <a href="./references#CD011642-bbs2-0014" title="VerhaegheE , OngenaeK , BostoenJ , LambertJ . Nonablative fractional laser resurfacing for the treatment of hypertrophic scars: a randomized controlled trial. Dermatologic Surgery2013;39(3 Pt 1):426-34. ">Verhaeghe 2013</a>, the authors described an improvement in the patient global assessment (PGA) at one month (reported P = 0.006) and three months (reported P = 0.02) after the final NAFL treatment with no further data available. The certainty of evidence was assessed as very low, downgraded twice due to very serious imprecision and once for serious risk of bias. </p> <p>In <a href="./references#CD011642-bbs2-0014" title="VerhaegheE , OngenaeK , BostoenJ , LambertJ . Nonablative fractional laser resurfacing for the treatment of hypertrophic scars: a randomized controlled trial. Dermatologic Surgery2013;39(3 Pt 1):426-34. ">Verhaeghe 2013</a> the authors reported an improvement in NAFL treated hypertrophic scars compared with no treatment on the participant part of the Patient and Observer Scar Assessment Scale (POSAS) at one month and three months, however the size of the difference was not reported. No data for the observer part of the scale was presented. This is very low‐certainty evidence, downgraded twice due to very serious imprecision and once for serious risk of bias. </p> <p>For patient self‐assessments in <a href="./references#CD011642-bbs2-0009" title="LinJY , WargerWC , IziksonL , AndersonRR , TannousZ . A prospective, randomized controlled trial on the efficacy of fractional photothermolysis on scar remodeling. Lasers in Surgery and Medicine2011;43:265-72. ">Lin 2011</a> we were unable to fully analyse the data, because the results were presented only in graphs and did not allow extraction. </p> </section> <section id="CD011642-sec-0058"> <h6 class="title">Incidence and severity of treatment‐related adverse effects</h6> <p>It is uncertain whether NAFL treatment leads to a higher incidence of treatment‐related adverse effects. This is very low‐certainty evidence, downgraded twice for very serious imprecision and once for serious risk of bias (<a href="./full#CD011642-tbl-0001">summary of findings Table 1</a>) (<a href="./references#CD011642-fig-0007" title="">Analysis 2.2</a>). </p> </section> <section id="CD011642-sec-0059"> <h6 class="title">Scar size, colour, height, length, width, pliability, skin surface texture, pruritus and pain </h6> <p>In a small study  which was at high risk of bias (<a href="./references#CD011642-bbs2-0009" title="LinJY , WargerWC , IziksonL , AndersonRR , TannousZ . A prospective, randomized controlled trial on the efficacy of fractional photothermolysis on scar remodeling. Lasers in Surgery and Medicine2011;43:265-72. ">Lin 2011</a>), two different parameters of NAFL, including a high‐density treatment arm (HDTA) and a low‐density treatment arm (LDTA), were compared with a control intervention for the treatment of hypertrophic scars. In this study, small differences that were imprecise were noted between HDTA treated groups compared with the control group for a range of outcomes: erythema mean difference ((MD) 0.44; 95% CI ‐0.54 to 1.42), pigmentation (MD 0.12; 95% CI ‐0.66 to 0.90]) and texture (MD 0.22; 95% CI ‐0.50 to 0.94). Similarly, small and imprecise differences were also found for LDTA treated groups when compared with the control group: erythema (MD 0.12; 95% CI: ‐0.96 to 1.20), pigmentation (MD 0.08; 95% CI: ‐0.59 to 0.75) and texture (MD 0.56; 95% CI: ‐0.27 to 1.39) (<a href="./references#CD011642-fig-0008" title="">Analysis 2.3</a>). Erythema, pigmentation and texture were assessed based on a four‐point scale (where 0 was no improvement or worsened, and 3 was a marked improvement). </p> <p><a href="./references#CD011642-bbs2-0014" title="VerhaegheE , OngenaeK , BostoenJ , LambertJ . Nonablative fractional laser resurfacing for the treatment of hypertrophic scars: a randomized controlled trial. Dermatologic Surgery2013;39(3 Pt 1):426-34. ">Verhaeghe 2013</a> reported no improvement in redness and pigmentation of skin scars (skin reflectance measurements) treated with NAFL, when compared with control, one and three months after the final treatment. </p> </section> </section> <section id="CD011642-sec-0060"> <h5 class="title">Fractional CO<sub>2</sub> laser versus no treatment (3 studies) </h5> <p><a href="./references#CD011642-bbs2-0003" title="AzzamOA , BassiounyDA , El-HawaryMS , El MaadawiZM , SobhiRM , El-MesidyMS . Treatment of hypertrophic scars and keloids by fractional carbon dioxide laser: a clinical, histological, and immunohistochemical study. Lasers in Medical Science2016;31(1):9-18. ">Azzam 2016</a> compared ablative fractional CO<sub>2</sub> laser for treating hypertrophic and keloid scars with no treatment. <a href="./references#CD011642-bbs2-0005" title="Blome-EberwienS , GogalC , WeissMJ , BoorseD , PagellaP . Prospective evaluation of fractional CO2 laser treatment of mature burn scars. Journal of Burn Care &amp; Research2016;37(6):379-87. ">Blome‐Eberwein 2016</a> and <a href="./references#CD011642-bbs2-0007" title="DaoudAA , GianatasioC , RudnickA , MichaelM , WaibelJ . Efficacy of combined Intense Pulsed Light (IPL) with fractional CO2 laser ablation in the treatment of large hypertrophic scars: a prospective, randomized control trial. Lasers in Surgery and Medicine2019;51(8):1-8. ">Daoud 2019</a> compared ablative fractional CO<sub>2</sub> laser for treating hypertrophic scars with no treatment. </p> <section id="CD011642-sec-0061"> <h6 class="title">Scar severity measured by health professional and/or participant using a specific scale  </h6> <p>It is uncertain whether fractional CO<sub>2</sub> impacts on hypertrophic scar severity compared with no treatment as evaluated with the Vancouver Burn Scar (VBS) scale by blinded observers (<a href="./references#CD011642-bbs2-0003" title="AzzamOA , BassiounyDA , El-HawaryMS , El MaadawiZM , SobhiRM , El-MesidyMS . Treatment of hypertrophic scars and keloids by fractional carbon dioxide laser: a clinical, histological, and immunohistochemical study. Lasers in Medical Science2016;31(1):9-18. ">Azzam 2016</a>; <a href="./references#CD011642-bbs2-0005" title="Blome-EberwienS , GogalC , WeissMJ , BoorseD , PagellaP . Prospective evaluation of fractional CO2 laser treatment of mature burn scars. Journal of Burn Care &amp; Research2016;37(6):379-87. ">Blome‐Eberwein 2016</a>) or impacts on keloid scar severity (<a href="./references#CD011642-bbs2-0003" title="AzzamOA , BassiounyDA , El-HawaryMS , El MaadawiZM , SobhiRM , El-MesidyMS . Treatment of hypertrophic scars and keloids by fractional carbon dioxide laser: a clinical, histological, and immunohistochemical study. Lasers in Medical Science2016;31(1):9-18. ">Azzam 2016</a>) after up to six months. The evidence is of very low certainty, as we downgraded twice for very serious imprecision, and once for serious risk of bias (<a href="./references#CD011642-fig-0009" title="">Analysis 3.1</a>). </p> <p>The evidence is very uncertain about the effect of fractional CO<sub>2</sub> compared with no treatment on scar severity based on the POSAS values (<a href="./references#CD011642-fig-0010" title="">Analysis 3.2</a>). The evidence is of very low certainty, as we downgraded twice for very serious imprecision and once for serious risk of bias (<a href="./full#CD011642-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD011642-sec-0062"> <h6 class="title">Incidence and severity of treatment‐related adverse effects</h6> <p>These data were not assessed in <a href="./references#CD011642-bbs2-0003" title="AzzamOA , BassiounyDA , El-HawaryMS , El MaadawiZM , SobhiRM , El-MesidyMS . Treatment of hypertrophic scars and keloids by fractional carbon dioxide laser: a clinical, histological, and immunohistochemical study. Lasers in Medical Science2016;31(1):9-18. ">Azzam 2016</a> and <a href="./references#CD011642-bbs2-0005" title="Blome-EberwienS , GogalC , WeissMJ , BoorseD , PagellaP . Prospective evaluation of fractional CO2 laser treatment of mature burn scars. Journal of Burn Care &amp; Research2016;37(6):379-87. ">Blome‐Eberwein 2016</a>. In <a href="./references#CD011642-bbs2-0007" title="DaoudAA , GianatasioC , RudnickA , MichaelM , WaibelJ . Efficacy of combined Intense Pulsed Light (IPL) with fractional CO2 laser ablation in the treatment of large hypertrophic scars: a prospective, randomized control trial. Lasers in Surgery and Medicine2019;51(8):1-8. ">Daoud 2019</a>; there were no treatment‐related adverse effects reported. </p> </section> <section id="CD011642-sec-0063"> <h6 class="title">Scar size, colour, height, length, width, pliability, skin surface texture, pruritus and pain </h6> <p>In a study which was at high risk of bias (<a href="./references#CD011642-bbs2-0005" title="Blome-EberwienS , GogalC , WeissMJ , BoorseD , PagellaP . Prospective evaluation of fractional CO2 laser treatment of mature burn scars. Journal of Burn Care &amp; Research2016;37(6):379-87. ">Blome‐Eberwein 2016</a>), pliability, height (in the suction cup), and "recoil" of hypertrophic scars were reported as not improving significantly in the laser group or in the control group. No, or only small, differences that were imprecise were noted between fractional CO<sub>2</sub> laser‐treated groups compared with control group for a range of outcomes: scar height assessed by ultrasound (MD ‐0.12 millimetres (mm); 95% CI ‐0.27 to 0.03); erythema and pigmentation assessed by dermatospectrometry (MD 0.73; 95% CI ‐1.27 to 2.73, and MD ‐1.14; ‐7.16 to 4.88, respectively), and scar‐related pruritus and pain not related to treatment assessed as part of the POSAS (MD 0.41; 95% CI ‐0.66 to 1.48, and MD 0.41; 95% CI ‐0.63 to 1.45, respectively) (<a href="./references#CD011642-fig-0011" title="">Analysis 3.3</a>). </p> <p><a href="./references#CD011642-bbs2-0003" title="AzzamOA , BassiounyDA , El-HawaryMS , El MaadawiZM , SobhiRM , El-MesidyMS . Treatment of hypertrophic scars and keloids by fractional carbon dioxide laser: a clinical, histological, and immunohistochemical study. Lasers in Medical Science2016;31(1):9-18. ">Azzam 2016</a> reported that scar pain not related to treatment decreased in six (54.5%) of the 11 participants (three had keloid and three had hypertrophic scars), and the pruritus disappeared in 11 (68.8%) (seven had keloid and four had hypertrophic scars) of the 16 cases after treatment. Results for this trial were not presented by treatment arm and no further data were available for analysis. </p> </section> </section> </section> <section id="CD011642-sec-0064"> <h4 class="title">2. Laser versus other treatments</h4> <p><a href="./full#CD011642-tbl-0002">summary of findings Table 2</a> </p> <section id="CD011642-sec-0065"> <h5 class="title">585‐nm PDL versus triamcinolone acetonide (TAC) (2 studies)</h5> <section id="CD011642-sec-0066"> <h6 class="title">Scar severity measured by health professional and/or participant using a specific scale </h6> <p>It is uncertain whether PDL impacts on hypertrophic scar severity compared with TAC when measured using blinded observer assessment (<a href="./references#CD011642-bbs2-0012" title="OmranifardM , RastiM . Comparing the effects of conventional method, pulse dye laser and erbium laser for the treatment of hypertrophic scars in Iranian patients. Journal of Research in Medical Sciences2007;12(6):277-81. ">Omranifard 2007</a>) (<a href="./references#CD011642-fig-0012" title="">Analysis 4.1</a>) or on hypertrophic and keloid scar severity compared with TAC when measured using patient self‐assessment (PSA) (<a href="./references#CD011642-bbs2-0011" title="ManuskiattiW , FitzpatrickRE . Treatment response of keloidal and hypertrophic sternotomy scars. Comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Archives of Dermatology2002;138(9):1149-55. ">Manuskiatti 2002</a>, <a href="./references#CD011642-bbs2-0012" title="OmranifardM , RastiM . Comparing the effects of conventional method, pulse dye laser and erbium laser for the treatment of hypertrophic scars in Iranian patients. Journal of Research in Medical Sciences2007;12(6):277-81. ">Omranifard 2007</a>) (<a href="./references#CD011642-fig-0013" title="">Analysis 4.2</a>), as the certainty of evidence was assessed as very low, downgraded twice due to very serious imprecision and once due to serious risk of bias. </p> </section> <section id="CD011642-sec-0067"> <h6 class="title">Incidence and severity of treatment‐related adverse effects</h6> <p>In <a href="./references#CD011642-bbs2-0012" title="OmranifardM , RastiM . Comparing the effects of conventional method, pulse dye laser and erbium laser for the treatment of hypertrophic scars in Iranian patients. Journal of Research in Medical Sciences2007;12(6):277-81. ">Omranifard 2007</a>, no complications were reported. In <a href="./references#CD011642-bbs2-0011" title="ManuskiattiW , FitzpatrickRE . Treatment response of keloidal and hypertrophic sternotomy scars. Comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Archives of Dermatology2002;138(9):1149-55. ">Manuskiatti 2002</a>, it is unclear whether 585‐nm PDL leads to more treatment‐related adverse effects, including sequelae (<a href="./references#CD011642-fig-0014" title="">Analysis 4.3</a>) or treatment‐related pain (<a href="./references#CD011642-fig-0014" title="">Analysis 4.3</a>) than TAC, as the evidence was rated as very low certainty, downgraded twice due to very serious imprecision and once due to serious risk of bias (<a href="./full#CD011642-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD011642-sec-0068"> <h6 class="title">Scar size, colour, height, length, width, pliability, skin surface texture, pruritus and pain </h6> <p>In <a href="./references#CD011642-bbs2-0011" title="ManuskiattiW , FitzpatrickRE . Treatment response of keloidal and hypertrophic sternotomy scars. Comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Archives of Dermatology2002;138(9):1149-55. ">Manuskiatti 2002</a>, the results were presented in graphs, with no data for further analysis. In <a href="./references#CD011642-bbs2-0012" title="OmranifardM , RastiM . Comparing the effects of conventional method, pulse dye laser and erbium laser for the treatment of hypertrophic scars in Iranian patients. Journal of Research in Medical Sciences2007;12(6):277-81. ">Omranifard 2007</a> no measures of variability were provided and no further analysis was possible (<a href="#CD011642-tbl-0005">Table 2</a>) </p> </section> </section> <section id="CD011642-sec-0069"> <h5 class="title">585‐nm PDL versus 5‐Fluorouracil (5‐FU) (1 study)</h5> <section id="CD011642-sec-0070"> <h6 class="title">Scar severity measured by health professional and/or participant using a specific scale  </h6> <p>It is uncertain whether PDL impacts on hypertrophic and keloid scar severity measured using patient self‐assessment compared with 5‐FU (<a href="./references#CD011642-bbs2-0011" title="ManuskiattiW , FitzpatrickRE . Treatment response of keloidal and hypertrophic sternotomy scars. Comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Archives of Dermatology2002;138(9):1149-55. ">Manuskiatti 2002</a>) (<a href="./references#CD011642-fig-0015" title="">Analysis 5.1</a>). The certainty of the evidence is very low, downgraded twice due to very serious imprecision and once due to serious risk of bias. </p> </section> <section id="CD011642-sec-0071"> <h6 class="title">Incidence and severity of treatment‐related adverse effects</h6> <p>It is uncertain whether 585‐nm PDL treatment impacts on the incidence of treatment‐related adverse effects compared with 5‐FU. The certainty of the evidence is very low, downgraded twice due to very serious imprecision and once due to serious risk of bias (<a href="./full#CD011642-tbl-0002">summary of findings Table 2</a>) (<a href="./references#CD011642-fig-0016" title="">Analysis 5.2</a>). </p> </section> <section id="CD011642-sec-0072"> <h6 class="title">Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain </h6> <p>The results were presented only graphically and further data extraction and analyses were not possible. </p> </section> </section> <section id="CD011642-sec-0073"> <h5 class="title">585‐nm PDL versus TAC plus 5‐FU (1 study)</h5> <section id="CD011642-sec-0074"> <h6 class="title">Scar severity measured by health professional and/or participant using a specific scale  </h6> <p>It is uncertain whether PDL impacts on hypertrophic and keloid scar severity compared with TAC plus 5‐FU for the participant assessments. The certainty of the evidence is very low downgraded twice due very serious imprecision and once due to serious risk of bias (<a href="./references#CD011642-fig-0017" title="">Analysis 6.1</a>) (<a href="./references#CD011642-bbs2-0011" title="ManuskiattiW , FitzpatrickRE . Treatment response of keloidal and hypertrophic sternotomy scars. Comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Archives of Dermatology2002;138(9):1149-55. ">Manuskiatti 2002</a>). </p> </section> <section id="CD011642-sec-0075"> <h6 class="title">Incidence and severity of treatment‐related adverse effects</h6> <p>It is uncertain whether 585‐nm PDL treatment impacts on the incidence of treatment‐related adverse effects compared with TAC plus 5‐FU. The certainty of the evidence is very low, downgraded twice due to very serious imprecision and once due to serious risk of bias (<a href="./full#CD011642-tbl-0002">summary of findings Table 2</a>) (<a href="./references#CD011642-fig-0018" title="">Analysis 6.2</a>). </p> </section> <section id="CD011642-sec-0076"> <h6 class="title">Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain </h6> <p>Authors reported the changes in height, erythema and pliability between intervention areas only in graphical formats that did not allow data extraction and further analyses. </p> </section> </section> <section id="CD011642-sec-0077"> <h5 class="title">585‐nm PDL versus silicone gel sheeting (1 study)</h5> <section id="CD011642-sec-0078"> <h6 class="title">Scar severity measured by health professional and/or participant using a specific scale  </h6> <p>This outcome was not reported.</p> </section> <section id="CD011642-sec-0079"> <h6 class="title">Incidence and severity of treatment‐related adverse effects</h6> <p>It is uncertain whether 585‐nm PDL treatment impacts on the incidence of treatment‐related adverse effects compared with silicone gel sheeting. The certainty of the evidence is very low, downgraded twice due to very serious imprecision and once due to serious risk of bias (<a href="./full#CD011642-tbl-0002">summary of findings Table 2</a>) (<a href="./references#CD011642-fig-0019" title="">Analysis 7.1</a>). </p> </section> <section id="CD011642-sec-0080"> <h6 class="title">Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain </h6> <p>In a small study which was at high risk of bias (<a href="./references#CD011642-bbs2-0015" title="WittenbergGP , FabianBG , BogomilskyJL , SchultzLR , RudneEJ , ChaffinsML , et al. Prospective, single-blind, randomized, controlled study to assess the efficacy of the 585-nm flashlamp-pumped pulsed-dye laser and silicone gel sheeting in hypertrophic scar treatment. Archives of Dermatology1999;135(9):1049-55. ">Wittenberg 1999</a>), the study authors reported that 585‐nm PDL treatment did not improve blood flow, volume and pruritus in hypertrophic scars when compared with silicone gel sheeting. There was also no reported difference between groups in patients who rated scar elasticity, burning, and pain not related to treatment. Results were presented graphically and not analysed further here. </p> </section> </section> <section id="CD011642-sec-0081"> <h5 class="title">Erbium laser versus TAC (1 study)</h5> <section id="CD011642-sec-0082"> <h6 class="title">Scar severity measured by health professional and/or participant using a specific scale </h6> <p>It is uncertain whether erbium laser impacts on hypertrophic scar severity compared with TAC treatment assessed with VBS score (<a href="./references#CD011642-fig-0020" title="">Analysis 8.1</a>) and obtained through patient self‐assessment measured by the number of patients considering the scar better or much better (<a href="./references#CD011642-fig-0021" title="">Analysis 8.2</a>) (<a href="./references#CD011642-bbs2-0012" title="OmranifardM , RastiM . Comparing the effects of conventional method, pulse dye laser and erbium laser for the treatment of hypertrophic scars in Iranian patients. Journal of Research in Medical Sciences2007;12(6):277-81. ">Omranifard 2007</a>). The certainty of this evidence was very low, downgraded twice due to very serious imprecision and once due to serious risk of bias. </p> </section> <section id="CD011642-sec-0083"> <h6 class="title">Incidence and severity of treatment‐related adverse effects</h6> <p>The authors reported no complications such as permanent pigmentation change, ulceration or infection in either treatment group. </p> </section> <section id="CD011642-sec-0084"> <h6 class="title">Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain </h6> <p>These outcomes were not reported.</p> </section> </section> <section id="CD011642-sec-0085"> <h5 class="title">Fractional CO<sub>2</sub> Laser versus TAC (1 study) </h5> <section id="CD011642-sec-0086"> <h6 class="title">Scar severity measured by health professional and/or participant using a specific scale  </h6> <p>The authors did not report the means of the full Vancouver Scar Scale (VSS), reporting only separate results of keloid scar height, vascularity, pigmentation, and pliability (<a href="./references#CD011642-bbs2-0013" title="SrivastavaS , KumariH , SinghA . Comparison of fractional CO2 laser, verapamil, and triamcinolone for the treatment of keloid. Advances in Wound Care2019;8(1):7-13. ">Srivastava 2019</a>). </p> </section> <section id="CD011642-sec-0087"> <h6 class="title">Incidence and severity of treatment‐related adverse effects</h6> <p>It is uncertain whether fractional CO<sub>2</sub> laser treatment impacts on treatment‐related adverse effects, including the incidence of pain at injection site, telangiectasia (a condition in which tiny blood vessels cause thread‐like red lines on the skin), skin atrophy, and charring (skin burning so that its surface becomes blackened) compared with TAC (<a href="./references#CD011642-fig-0022" title="">Analysis 9.1</a>). The certainty of evidence was rated as very low. We downgraded the evidence twice for very serious imprecision and once for serious risk of bias (<a href="./full#CD011642-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD011642-sec-0088"> <h6 class="title">Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain </h6> <p>A small study which was at high risk of bias assessed these outcomes (<a href="./references#CD011642-bbs2-0013" title="SrivastavaS , KumariH , SinghA . Comparison of fractional CO2 laser, verapamil, and triamcinolone for the treatment of keloid. Advances in Wound Care2019;8(1):7-13. ">Srivastava 2019</a>). In this study, height was measured with callipers, vascularity was assessed by visual inspection, pliability was assessed by palpation, and pigmentation was scored after blanching and comparing it with the surrounding skin. </p> <p>After 12 weeks of treatment, the results of this study suggested no or only a small difference between treatments in the assessment of height (MD 0.90; 95% CI 0.60 to 1.20), vascularity (MD 0.70; 95% CI 0.37 to 1.03), and pliability (MD 0.40; 95% CI 0.13 to 0.67) (<a href="./references#CD011642-fig-0023" title="">Analysis 9.2</a>). Regarding pigmentation, no further analysis was possible based on reported data. </p> <p>After 24 weeks of treatment, it was not possible to analyse whether there were differences between fractional laser and TAC for scar height, vascularity and pliability based on reported data. Data on keloid scar pigmentation suggested no, or only a small difference, between treatments (MD 0.00; 95% CI ‐0.25 to 0.25; one study, 40 participants, 40 scars) (<a href="./references#CD011642-fig-0024" title="">Analysis 9.3</a>). </p> </section> </section> <section id="CD011642-sec-0089"> <h5 class="title">Fractional CO<sub>2</sub> laser versus intralesional verapamil (1 study) </h5> <section id="CD011642-sec-0090"> <h6 class="title">Scar severity measured by health professional and/or participant using a specific scale  </h6> <p>Although the authors used VSS, they did not report the means of the full scale, reporting only the separate results of keloid scar height, vascularity pigmentation, and pliability (<a href="./references#CD011642-bbs2-0013" title="SrivastavaS , KumariH , SinghA . Comparison of fractional CO2 laser, verapamil, and triamcinolone for the treatment of keloid. Advances in Wound Care2019;8(1):7-13. ">Srivastava 2019</a>). </p> </section> <section id="CD011642-sec-0091"> <h6 class="title">Incidence and severity of treatment‐related adverse effects</h6> <p>It is uncertain whether fractional CO<sub>2</sub> laser treatment impacts on the incidence of treatment‐related adverse effects, including pain at injection site and charring (skin burning so that its surface becomes blackened) compared with intralesional verapamil (<a href="./references#CD011642-fig-0025" title="">Analysis 10.1</a>). No treatment‐related adverse effects occurred in the verapamil group. No events of teleangiectasia or skin atrophy (skin thinning) occurred in either groups. The certainty of evidence is very low, downgraded twice due to very serious imprecision and once due to serious risk of bias (<a href="./full#CD011642-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD011642-sec-0092"> <h6 class="title">Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain </h6> <p>Only one small study which was at high risk of bias assessed these outcomes (<a href="./references#CD011642-bbs2-0013" title="SrivastavaS , KumariH , SinghA . Comparison of fractional CO2 laser, verapamil, and triamcinolone for the treatment of keloid. Advances in Wound Care2019;8(1):7-13. ">Srivastava 2019</a>). In this study, height was measured with callipers, pliability was assessed by palpation, vascularity was assessed by visual inspection, and pigmentation was scored after blanching and comparing it with the surrounding skin. </p> <p>After 12 weeks of treatment, the results of this study suggested no or only a small difference between treatments in the assessment of height (MD 0.30; 95% CI ‐0.00 to 0.60), pigmentation (MD ‐0.40; 95% CI ‐0.68 to ‐0.12), vascularity (MD 0.10; 95% CI ‐0.17 to 0.37), and pliability (MD 0.10; 95% CI ‐0.19 to 0.39) (<a href="./references#CD011642-fig-0026" title="">Analysis 10.2</a>). </p> <p>After 24 weeks of treatment, these results also suggested no, or only a small difference between treatments in the assessment of keloid scar height (MD 0.20; 95% CI ‐0.02 to 0.42), scar pigmentation (MD 0.25; 95% CI ‐0.04 to 0.54), and scar vascularity (MD 0.35; 95% CI 0.09 to 0.61) (<a href="./references#CD011642-fig-0027" title="">Analysis 10.3</a>). No quantitative analysis was possible regarding pliability as SD in the verapamil group was 0. </p> </section> </section> </section> <section id="CD011642-sec-0093"> <h4 class="title">3. Laser plus other treatment versus other treatment</h4> <p><a href="./full#CD011642-tbl-0003">summary of findings Table 3</a> </p> <section id="CD011642-sec-0094"> <h5 class="title">585‐nm PDL plus TAC plus 5 FU versus TAC plus 5‐FU (1 study)</h5> <section id="CD011642-sec-0095"> <h6 class="title">Scar severity measured by health professional and/or participant using a specific scale  </h6> <p>The evidence is uncertain about the effect of 585‐nm PDL plus TAC plus 5 FU compared with TAC plus 5‐FU on hypertrophic and keloid scar severity assessed by a blinded observer assessment, and by patient self‐assessment at 12 weeks (<a href="./references#CD011642-fig-0028" title="">Analysis 11.1</a>) (<a href="./references#CD011642-bbs2-0002" title="AsilianA , DaroughehA , ShariatiF . New combination of triamcinolone, 5-fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars. Dermatologic Surgery2006;32(7):907-15. ">Asilian 2006</a>). The certainty of evidence was rated as very low, downgraded twice for imprecision and once for serious risk of bias. </p> </section> <section id="CD011642-sec-0096"> <h6 class="title">Incidence and severity of treatment‐related adverse effects</h6> <p>At the end of the study, no treatment‐related adverse effects were observed in either group. </p> </section> <section id="CD011642-sec-0097"> <h6 class="title">Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain </h6> <p>A small study which was at high risk of bias, (<a href="./references#CD011642-bbs2-0002" title="AsilianA , DaroughehA , ShariatiF . New combination of triamcinolone, 5-fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars. Dermatologic Surgery2006;32(7):907-15. ">Asilian 2006</a>), assessed these outcomes. At the end of the study, the study authors reported that the erythema score in the TAC plus 5‐FU plus PDL group was lower than in the TAC plus 5‐FU group (reported P&lt; 0.05) (<a href="#CD011642-tbl-0006">Table 3</a>). In this study, erythema was graded by the observer on a 5‐point scale, where 0 was no erythema and 4 was very severe erythema. Results were presented graphically and not analysed further here. </p> </section> </section> <section id="CD011642-sec-0098"> <h5 class="title">CO<sub>2</sub> laser plus TAC versus cryosurgery plus TAC (1 study) </h5> <section id="CD011642-sec-0099"> <h6 class="title">Scar severity measured by health professional and/or participant using a specific scale  </h6> <p>It is unclear whether CO<sub>2</sub> Laser plus TAC impacts on keloid scar severity compared with cryosurgery plus TAC when measured using blinded observer assessment, patient self‐assessment and VBS Assessment Scale, respectively (<a href="./references#CD011642-fig-0029" title="">Analysis 12.1</a>). The certainty of this evidence was rated as very low downgraded twice due to very serious imprecision and once due to serious risk of bias. </p> </section> <section id="CD011642-sec-0100"> <h6 class="title">Incidence and severity of treatment‐related adverse effects</h6> <p>It is also uncertain whether there is a difference between groups in the incidence of treatment‐related adverse effects (<a href="./references#CD011642-fig-0030" title="">Analysis 12.2</a>). The certainty of this evidence was rated as very low, downgraded twice due to very serious imprecision and once due to serious risk of bias. </p> </section> <section id="CD011642-sec-0101"> <h6 class="title">Change in scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain </h6> <p>A small study which was at high risk of bias, (<a href="./references#CD011642-bbs2-0004" title="BeheraB , KumariR , ThappaDM , MalathiM . Therapeutic efficacy of intralesional steroid with carbon dioxide laser versus with cryotherapy in treatment of keloids: a randomized controlled trial. Dermatologic Surgery2016;42(10):1188-98. ">Behera 2016</a>), assessed this outcomes. After 12 months, the results of this study suggested no or only a small difference in scar height (MD ‐ 16.15 mm, 95% CI: ‐38.24 to 5.94, one study, 60 scar segments) or volume (MD ‐17.88, 95% CI: ‐39.72 to 3.96, one study, 60 segments scars) (<a href="./references#CD011642-fig-0031" title="">Analysis 12.3</a>). The authors reported a difference between groups in pain not related to treatment (P = 0.0010) favouring CO<sub>2</sub> laser, but no difference in pruritus score (P = 0.2262). We could not extract or analyse relevant data further. </p> </section> <section id="CD011642-sec-0102"> <h6 class="title">Recurrence of the condition</h6> <p>In <a href="./references#CD011642-bbs2-0004" title="BeheraB , KumariR , ThappaDM , MalathiM . Therapeutic efficacy of intralesional steroid with carbon dioxide laser versus with cryotherapy in treatment of keloids: a randomized controlled trial. Dermatologic Surgery2016;42(10):1188-98. ">Behera 2016</a>, at 12 months, there was a recurrence of 6 keloid scars (16.66%), all of which belonged to the CO<sub>2</sub> laser group (RR: 13.00; 95% CI: 0.76 to 220.96; one study, 60 scar segments) (<a href="./references#CD011642-fig-0032" title="">Analysis 12.4</a>) </p> </section> </section> <section id="CD011642-sec-0103"> <h5 class="title">Neodymium‐doped yttrium aluminium garnet (Nd:YAG) laser plus intralesional corticosteroid (diprospan, including betamethasone disodium phosphate plus betamethasone dipropionate) plus 5‐FU <i>versus</i> intralesional corticosteroid (diprospan, including betamethasone disodium phosphate plus betamethasone dipropionate) plus 5‐FU (1 study) </h5> <section id="CD011642-sec-0104"> <h6 class="title">Scar severity measured by health professional and/or participant using a specific scale  </h6> <p>It is uncertain whether Nd:YAG laser plus intralesional corticosteroid diprospan plus 5‐FU impacts on keloid scar severity compared with Intralesional corticosteroid diprospan plus 5‐FU when measured using the number of patients and blinded observers reporting good to excellent improvement (<a href="./references#CD011642-fig-0033" title="">Analysis 13.1</a>) (<a href="./references#CD011642-bbs2-0006" title="ChenX , LiuJ , JameelAA , ValeskaM , ZhangJ , XuY , et al. Combined effects of long-pulsed neodymium-yttrium-aluminum-garnet laser, diprospan and 5-fluorouracil in the treatment of keloid scars. Experimental and Therapeutic Medicine2017;13:3607-12. ">Chen 2017</a>). This evidence is of very low certainty downgraded twice due to very serious imprecision and once due to serious risk of bias. </p> </section> <section id="CD011642-sec-0105"> <h6 class="title">Incidence and severity of treatment‐related adverse effects</h6> <p>It is also uncertain whether there is a difference between groups in the incidence of treatment‐related adverse effects. Almost all injections were reported by participants as being painful, and the sites treated by Nd:YAG laser became purpuric (which lasted for 7‐10 days). No treatment‐related adverse textural or pigmentary alterations, and no ulcers or erosions were observed in either groups. The certainty of evidence is very low, downgraded twice due to very serious imprecision and once due to serious risk of bias </p> </section> <section id="CD011642-sec-0106"> <h6 class="title">Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain </h6> <p>A small study which was at high risk of bias, (<a href="./references#CD011642-bbs2-0006" title="ChenX , LiuJ , JameelAA , ValeskaM , ZhangJ , XuY , et al. Combined effects of long-pulsed neodymium-yttrium-aluminum-garnet laser, diprospan and 5-fluorouracil in the treatment of keloid scars. Experimental and Therapeutic Medicine2017;13:3607-12. ">Chen 2017</a>), assessed these outcomes. During this study, the observer compared images of the lesions, and rated the erythema, pliability and pruritus of the lesions on a 5‑point scale where 0 was no and 4 was very severe. In the third month, erythema (P &lt; 0.05), pliability (P&lt; 0.05), and pruritus (P &lt; 0.05) were reported by the authors to be significantly lower in the Nd:YAG plus intralesional corticosteroid plus 5‐FU laser group than in the intralesional corticosteroid plus 5‐FU group. These data were provided only in graphs and we could not extract further data to analyse. </p> </section> </section> <section id="CD011642-sec-0107"> <h5 class="title">He‐Ne laser plus decamethyltetrasiloxane, polydimethylsiloxane and cyclopentasiloxane cream versus decamethyltetrasiloxane, polydimethylsiloxane and cyclopentasiloxane cream (1 study) </h5> <section id="CD011642-sec-0108"> <h6 class="title">Scar severity measured by health professional and/or participant using a specific scale  </h6> <p>In <a href="./references#CD011642-bbs2-0001" title="AlsharnoubiJ , ShoukryKE , FawzyMW , MohamedO . Evaluation of scars in children after treatment with low-level laser. Lasers in Medical Science2018;33(9):1991-5. ">Alsharnoubi 2018</a>, the authors reported a significant decrease in the median values of VSS of the intervention area compared with the control areas (P = 0.003). Study authors reported these results only in graphical formats that did not allow data extraction and further analyses. This evidence was rated as very low certainty, downgraded twice due to very serious imprecision and once due to serious risk of bias. </p> </section> <section id="CD011642-sec-0109"> <h6 class="title">Incidence and severity of treatment‐related adverse effects</h6> <p>It is also uncertain whether there is a difference between groups in the incidence of treatment‐related adverse effects. No treatment‐related adverse effects were reported in either groups. </p> </section> <section id="CD011642-sec-0110"> <h6 class="title">Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain </h6> <p>A small study which was at high risk of bias, (<a href="./references#CD011642-bbs2-0001" title="AlsharnoubiJ , ShoukryKE , FawzyMW , MohamedO . Evaluation of scars in children after treatment with low-level laser. Lasers in Medical Science2018;33(9):1991-5. ">Alsharnoubi 2018</a>) assessed these outcomes. The skin thickness after the treatment measured by ultrasonography was slightly smaller in the laser treated hypertrophic scar segments (MD ‐0.09 mm; 95% CI ‐0.17 to ‐0.01; one study; 15 participants; 30 segments) (<a href="./references#CD011642-fig-0034" title="">Analysis 14.1</a>) </p> </section> </section> <section id="CD011642-sec-0111"> <h5 class="title">595 nm PDL plus intralesional verapamil versus intralesional verapamil (1 study)</h5> <section id="CD011642-sec-0112"> <h6 class="title">Scar severity measured by health professional and/or participant using a specific scale  </h6> <p>In <a href="./references#CD011642-bbs2-0008" title="KhattabFM , NasrM , KhashabaSA , BessarH . Combination of pulsed dye laser and verapamil in comparison with verapamil alone in the treatment of keloid. Journal of Dermatological Treatment2019;31(2):186-90. ">Khattab 2019</a>, although the authors used the VSS, they did not report the means of the full scale, reporting only the separate results of keloid scar height, vascularity pigmentation, and pliability. </p> </section> <section id="CD011642-sec-0113"> <h6 class="title">Incidence and severity of treatment‐related adverse effects</h6> <p>It is uncertain whether there is a difference in the incidence of treatment‐related adverse effects (<a href="./references#CD011642-fig-0035" title="">Analysis 15.1</a>). The certainty of evidence was rated as very low, downgraded twice due to very serious imprecision and once due to serious risk of bias (<a href="./full#CD011642-tbl-0003">summary of findings Table 3</a>). </p> </section> <section id="CD011642-sec-0114"> <h6 class="title">Change in scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain </h6> <p>A small study which was at high risk of bias assessed these outcomes (<a href="./references#CD011642-bbs2-0008" title="KhattabFM , NasrM , KhashabaSA , BessarH . Combination of pulsed dye laser and verapamil in comparison with verapamil alone in the treatment of keloid. Journal of Dermatological Treatment2019;31(2):186-90. ">Khattab 2019</a>). After 12 weeks of treatment, measures of keloid scar height (MD ‐2.61; 95% CI ‐3.68 to ‐1.54; one study; 40 participants; 50 scars) and pliability (MD ‐2.06; 95% CI ‐2.46 to ‐1.66; one study; 40 participants; 50 scars) were lower in 595 nm PDL plus verapamil group. However, the results of this study suggested no or only a small difference between groups for vascularity (MD 0.06; 95% CI ‐0.34 to 0.46) and pigmentation (MD ‐0.27; 95% CI ‐0.62 to 0.08) (<a href="./references#CD011642-fig-0036" title="">Analysis 15.2</a>). </p> <p>After 24 weeks of treatment, laser was superior to verapamil in the assessment of height (MD ‐2.89; 95% CI ‐3.65 to ‐2.13; one study; 40 participants; 50 scars), vascularity (MD ‐0.84; 95% CI ‐1.24 to ‐0.44; one study; 40 participants; 50 scars), and pliability (MD ‐1.87 95%CI ‐2.06 to ‐1.68; one study; 40 participants; 50 scars). No statistically significant difference was found between groups for pigmentation (<a href="./references#CD011642-fig-0037" title="">Analysis 15.3</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011642-sec-0115" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011642-sec-0115"></div> <section id="CD011642-sec-0116"> <h3 class="title" id="CD011642-sec-0116">Summary of main results</h3> <p>In this review, we found eight studies (<a href="./references#CD011642-bbs2-0015" title="WittenbergGP , FabianBG , BogomilskyJL , SchultzLR , RudneEJ , ChaffinsML , et al. Prospective, single-blind, randomized, controlled study to assess the efficacy of the 585-nm flashlamp-pumped pulsed-dye laser and silicone gel sheeting in hypertrophic scar treatment. Archives of Dermatology1999;135(9):1049-55. ">Wittenberg 1999</a>, <a href="./references#CD011642-bbs2-0010" title="ManuskiattiW , FitzpatrickRE , GoldmanMP . Energy density and numbers of treatment affect response of keloidal and hypertrophic sternotomy scars to the 585-nm flashlamp-pumped pulsed-dye laser. Journal of the American Academy of Dermatology2001;45(4):557-65. ">Manuskiatti 2001</a>, <a href="./references#CD011642-bbs2-0011" title="ManuskiattiW , FitzpatrickRE . Treatment response of keloidal and hypertrophic sternotomy scars. Comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Archives of Dermatology2002;138(9):1149-55. ">Manuskiatti 2002</a>, <a href="./references#CD011642-bbs2-0009" title="LinJY , WargerWC , IziksonL , AndersonRR , TannousZ . A prospective, randomized controlled trial on the efficacy of fractional photothermolysis on scar remodeling. Lasers in Surgery and Medicine2011;43:265-72. ">Lin 2011</a>, <a href="./references#CD011642-bbs2-0014" title="VerhaegheE , OngenaeK , BostoenJ , LambertJ . Nonablative fractional laser resurfacing for the treatment of hypertrophic scars: a randomized controlled trial. Dermatologic Surgery2013;39(3 Pt 1):426-34. ">Verhaeghe 2013</a>, <a href="./references#CD011642-bbs2-0003" title="AzzamOA , BassiounyDA , El-HawaryMS , El MaadawiZM , SobhiRM , El-MesidyMS . Treatment of hypertrophic scars and keloids by fractional carbon dioxide laser: a clinical, histological, and immunohistochemical study. Lasers in Medical Science2016;31(1):9-18. ">Azzam 2016</a>, <a href="./references#CD011642-bbs2-0005" title="Blome-EberwienS , GogalC , WeissMJ , BoorseD , PagellaP . Prospective evaluation of fractional CO2 laser treatment of mature burn scars. Journal of Burn Care &amp; Research2016;37(6):379-87. ">Blome‐Eberwein 2016</a>, <a href="./references#CD011642-bbs2-0007" title="DaoudAA , GianatasioC , RudnickA , MichaelM , WaibelJ . Efficacy of combined Intense Pulsed Light (IPL) with fractional CO2 laser ablation in the treatment of large hypertrophic scars: a prospective, randomized control trial. Lasers in Surgery and Medicine2019;51(8):1-8. ">Daoud 2019</a>) that compared laser treatments with no treatment. There is low‐certainty evidence from two randomised controlled trials (RCTs) (<a href="./references#CD011642-bbs2-0010" title="ManuskiattiW , FitzpatrickRE , GoldmanMP . Energy density and numbers of treatment affect response of keloidal and hypertrophic sternotomy scars to the 585-nm flashlamp-pumped pulsed-dye laser. Journal of the American Academy of Dermatology2001;45(4):557-65. ">Manuskiatti 2001</a>, <a href="./references#CD011642-bbs2-0011" title="ManuskiattiW , FitzpatrickRE . Treatment response of keloidal and hypertrophic sternotomy scars. Comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Archives of Dermatology2002;138(9):1149-55. ">Manuskiatti 2002</a>) indicating that 585‐nm pulsed‐dye laser (PDL) may reduce keloid and hypertrophic scar severity compared with no treatment, based on unblinded patient self‐assessments of improvement of 50% or more over a 32‐week period of follow‐up. Of note, although these studies suggest that PDL may reduce scar severity compared with no treatment, we have not found any adequate studies showing the minimally clinically important differences in any of the severity rating scales, which makes it difficult for the professionals to transpose these results to clinical practice. The evidence for all other outcomes is uncertain. Adverse effects associated with treatment delivery and secondary outcomes, including erythema, elasticity, volume, and height were assessed by small studies at high risk of bias that either reported imprecise estimates or presented results only graphically, without further data to analyse. </p> <p>Other types of laser therapy, such as non‐ablative fractional laser (NAFL) (<a href="./references#CD011642-bbs2-0009" title="LinJY , WargerWC , IziksonL , AndersonRR , TannousZ . A prospective, randomized controlled trial on the efficacy of fractional photothermolysis on scar remodeling. Lasers in Surgery and Medicine2011;43:265-72. ">Lin 2011</a>, <a href="./references#CD011642-bbs2-0014" title="VerhaegheE , OngenaeK , BostoenJ , LambertJ . Nonablative fractional laser resurfacing for the treatment of hypertrophic scars: a randomized controlled trial. Dermatologic Surgery2013;39(3 Pt 1):426-34. ">Verhaeghe 2013</a>) and fractional CO<sub>2</sub> (<a href="./references#CD011642-bbs2-0003" title="AzzamOA , BassiounyDA , El-HawaryMS , El MaadawiZM , SobhiRM , El-MesidyMS . Treatment of hypertrophic scars and keloids by fractional carbon dioxide laser: a clinical, histological, and immunohistochemical study. Lasers in Medical Science2016;31(1):9-18. ">Azzam 2016</a>, <a href="./references#CD011642-bbs2-0005" title="Blome-EberwienS , GogalC , WeissMJ , BoorseD , PagellaP . Prospective evaluation of fractional CO2 laser treatment of mature burn scars. Journal of Burn Care &amp; Research2016;37(6):379-87. ">Blome‐Eberwein 2016</a>, <a href="./references#CD011642-bbs2-0007" title="DaoudAA , GianatasioC , RudnickA , MichaelM , WaibelJ . Efficacy of combined Intense Pulsed Light (IPL) with fractional CO2 laser ablation in the treatment of large hypertrophic scars: a prospective, randomized control trial. Lasers in Surgery and Medicine2019;51(8):1-8. ">Daoud 2019</a>), were compared with no treatment. However, results regarding the effectiveness of NAFL on the severity of scars are not consistent when assessed by participants compared with assessment by health professionals. Similarly, the results regarding the fractional CO<sub>2</sub> laser are conflicting. While one study on keloid scars showed a possible benefit of using fractional CO<sub>2</sub> as compared with no treatment, the pooled results from two RCTs on hypertrophic scars did not show the same results. Because the studies provide inconsistent results, have a small number of patients, exhibit important methodological limitations, and have poorly reported their data, no conclusion can be drawn from these results. </p> <p>We also found four studies that compared laser treatments with other treatments (<a href="./references#CD011642-bbs2-0015" title="WittenbergGP , FabianBG , BogomilskyJL , SchultzLR , RudneEJ , ChaffinsML , et al. Prospective, single-blind, randomized, controlled study to assess the efficacy of the 585-nm flashlamp-pumped pulsed-dye laser and silicone gel sheeting in hypertrophic scar treatment. Archives of Dermatology1999;135(9):1049-55. ">Wittenberg 1999</a>, <a href="./references#CD011642-bbs2-0011" title="ManuskiattiW , FitzpatrickRE . Treatment response of keloidal and hypertrophic sternotomy scars. Comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Archives of Dermatology2002;138(9):1149-55. ">Manuskiatti 2002</a>, <a href="./references#CD011642-bbs2-0012" title="OmranifardM , RastiM . Comparing the effects of conventional method, pulse dye laser and erbium laser for the treatment of hypertrophic scars in Iranian patients. Journal of Research in Medical Sciences2007;12(6):277-81. ">Omranifard 2007</a>, <a href="./references#CD011642-bbs2-0013" title="SrivastavaS , KumariH , SinghA . Comparison of fractional CO2 laser, verapamil, and triamcinolone for the treatment of keloid. Advances in Wound Care2019;8(1):7-13. ">Srivastava 2019</a>) and five studies that compared laser combined with other treatments versus other treatments (<a href="./references#CD011642-bbs2-0002" title="AsilianA , DaroughehA , ShariatiF . New combination of triamcinolone, 5-fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars. Dermatologic Surgery2006;32(7):907-15. ">Asilian 2006</a>, <a href="./references#CD011642-bbs2-0004" title="BeheraB , KumariR , ThappaDM , MalathiM . Therapeutic efficacy of intralesional steroid with carbon dioxide laser versus with cryotherapy in treatment of keloids: a randomized controlled trial. Dermatologic Surgery2016;42(10):1188-98. ">Behera 2016</a>, <a href="./references#CD011642-bbs2-0006" title="ChenX , LiuJ , JameelAA , ValeskaM , ZhangJ , XuY , et al. Combined effects of long-pulsed neodymium-yttrium-aluminum-garnet laser, diprospan and 5-fluorouracil in the treatment of keloid scars. Experimental and Therapeutic Medicine2017;13:3607-12. ">Chen 2017</a>, <a href="./references#CD011642-bbs2-0001" title="AlsharnoubiJ , ShoukryKE , FawzyMW , MohamedO . Evaluation of scars in children after treatment with low-level laser. Lasers in Medical Science2018;33(9):1991-5. ">Alsharnoubi 2018</a>, <a href="./references#CD011642-bbs2-0008" title="KhattabFM , NasrM , KhashabaSA , BessarH . Combination of pulsed dye laser and verapamil in comparison with verapamil alone in the treatment of keloid. Journal of Dermatological Treatment2019;31(2):186-90. ">Khattab 2019</a>). However, the evidence from these studies is also limited, mainly by the risk of bias and imprecision of effect estimates. As the overall certainty of the available evidence for all these comparisons and all outcomes is very low, it is also unclear whether laser alone or combined with other treatments, in general, results in a difference in the severity of scars when compared with other treatments. </p> </section> <section id="CD011642-sec-0117"> <h3 class="title" id="CD011642-sec-0117">Overall completeness and applicability of evidence</h3> <p>The small number of participants, varying schemes of laser therapy, different types of lasers, and comparisons of different treatment options, made it difficult to compare the results obtained. Currently, several types of lasers are available, such as 585 nm PDL, NAFL, Fractional CO<sub>2</sub> Laser, erbium, neodymium‐doped yttrium aluminium garnet (Nd:YAG), and helium‐neon (He‐Ne) laser. The best available evidence is of low‐certainty from two RCTs (<a href="./references#CD011642-bbs2-0010" title="ManuskiattiW , FitzpatrickRE , GoldmanMP . Energy density and numbers of treatment affect response of keloidal and hypertrophic sternotomy scars to the 585-nm flashlamp-pumped pulsed-dye laser. Journal of the American Academy of Dermatology2001;45(4):557-65. ">Manuskiatti 2001</a>, <a href="./references#CD011642-bbs2-0011" title="ManuskiattiW , FitzpatrickRE . Treatment response of keloidal and hypertrophic sternotomy scars. Comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Archives of Dermatology2002;138(9):1149-55. ">Manuskiatti 2002</a>) on 585‐nm PDL. The results of these studies suggest 585‐nm PDL may reduce keloid and hypertrophic scars severity compared with no treatment. Of note, PDL 585 nm was one of the first developed types of lasers, and availability of the devices in clinical practice may have influenced the amount of research performed with the types of lasers (<a href="./references#CD011642-bbs2-0069" title="VrijmanC , DroogeAM , LimpensJ , BosJD , Van der VeenJP , SpulsPI , et al. Laser and intense pulsed light therapy for the treatment of hypertrophic scars: a systematic review. British Journal of Dermatology2011;165(5):934-42.">Vrijman 2011</a>). </p> <p>As a result of the lack of robust, homogeneous evidence, most of the data were presented as narrative analyses to permit the individual evaluation of the results obtained with each type of laser. Some outcomes which we originally intended to evaluate, such as cosmesis, patient's preferred treatment, adherence, and quality of life, were not addressed in the included studies and the majority of the trials had short follow‐up periods. To help guide clinical practice, we also planned to perform subgroup analyses on different types of laser devices, fluences, schemes, and duration of treatment. However, current available evidence is insufficient to draw any conclusions or support the routine use of any type of laser to treat hypertrophic and keloid scars in clinical practice. </p> </section> <section id="CD011642-sec-0118"> <h3 class="title" id="CD011642-sec-0118">Quality of the evidence</h3> <p>Fifteen RCTs with a total of 604 participants were included. Nevertheless, several limitations in the included studies should be underscored. Although blinding of participants and personnel may be very difficult from a practical perspective, except for one study (<a href="./references#CD011642-bbs2-0014" title="VerhaegheE , OngenaeK , BostoenJ , LambertJ . Nonablative fractional laser resurfacing for the treatment of hypertrophic scars: a randomized controlled trial. Dermatologic Surgery2013;39(3 Pt 1):426-34. ">Verhaeghe 2013</a>), all trials included in this review had other important methodological limitations and a high or unclear risk of bias for at least two domains. Of note, only one trial (<a href="./references#CD011642-bbs2-0004" title="BeheraB , KumariR , ThappaDM , MalathiM . Therapeutic efficacy of intralesional steroid with carbon dioxide laser versus with cryotherapy in treatment of keloids: a randomized controlled trial. Dermatologic Surgery2016;42(10):1188-98. ">Behera 2016</a>) reported the scar recurrence rates during the follow‐up period, which is clinically important outcome, and a prevalent condition. This limitation brings into question the long‐term effects of these interventions. </p> <p>Of note, several of our results were based on split‐scar trials. Although all split‐scar trials used paired analyses and we have not combined the results of split‐scar trials with those from parallel studies, we should interpret these results carefully. We should not rule out the possibility of "spill‐over" of the treatment from one scar segment to the other. </p> <p>Due to small sample sizes, small numbers of studies, unblinded assessments, and attrition bias, the certainty of the evidence comparing laser treatment with no treatment, laser treatment with other treatments, and laser plus other treatment with other treatment, is low to very low. Furthermore, in some cases, data were also insufficiently reported or reported in ways that did not allow extraction and further analysis. Therefore, none of the available trials were of high‐methodological quality and the true efficacy of laser therapy may not be fully clarified until high‐quality trials are published. </p> </section> <section id="CD011642-sec-0119"> <h3 class="title" id="CD011642-sec-0119">Potential biases in the review process</h3> <p>The most important databases, clinical trials, contacts with specialists and other research sources were included in our study searches in order to identify and collect all relevant RCTs, regardless of language or publication status. Moreover, strict collection and evaluation of data was performed by the review authors in order to avoid errors in the conduct of this systematic review. Some data were only available in incomplete formats in graphs and did not allow for extraction. Although we tried to contact the authors, we did not receive a response. We were also unable to assess publication bias due to the insufficient number of included RCTs in each comparison. Nevertheless, we believe this scientifically‐rigorous systematic review exposes literature gaps and provides critical data upon which to base further trials and protocols. </p> </section> <section id="CD011642-sec-0120"> <h3 class="title" id="CD011642-sec-0120">Agreements and disagreements with other studies or reviews</h3> <p>We did not find a systematic review that evaluated laser therapy for treating both hypertrophic and keloid scars, but we found a systematic review assessing the effects of laser and intense pulsed light (IPL) for the treatment of hypertrophic scars (<a href="./references#CD011642-bbs2-0069" title="VrijmanC , DroogeAM , LimpensJ , BosJD , Van der VeenJP , SpulsPI , et al. Laser and intense pulsed light therapy for the treatment of hypertrophic scars: a systematic review. British Journal of Dermatology2011;165(5):934-42.">Vrijman 2011</a>). Differently from this review, <a href="./references#CD011642-bbs2-0069" title="VrijmanC , DroogeAM , LimpensJ , BosJD , Van der VeenJP , SpulsPI , et al. Laser and intense pulsed light therapy for the treatment of hypertrophic scars: a systematic review. British Journal of Dermatology2011;165(5):934-42.">Vrijman 2011</a> evaluated not only RCTs, but also non‐randomised trials, in which only hypertrophic scars were treated with laser or IPL. Our search strategy was also broader than in <a href="./references#CD011642-bbs2-0069" title="VrijmanC , DroogeAM , LimpensJ , BosJD , Van der VeenJP , SpulsPI , et al. Laser and intense pulsed light therapy for the treatment of hypertrophic scars: a systematic review. British Journal of Dermatology2011;165(5):934-42.">Vrijman 2011</a>, and included MEDLINE, Embase and CENTRAL, as well as other databases, such as EBSCO CINAHL, LILACS, Clinicaltrials.gov, the World Health Organization (WHO) International Clinical Trials Registry Platform and European Union (EU) Clinical Trials Register Platform (ICTRP). We excluded trials comparing laser in both arms without control areas and non‐randomised clinical trials, in order to minimise bias. Due to the different parameters used to select the studies and evaluate the data between this systematic review and that published by <a href="./references#CD011642-bbs2-0069" title="VrijmanC , DroogeAM , LimpensJ , BosJD , Van der VeenJP , SpulsPI , et al. Laser and intense pulsed light therapy for the treatment of hypertrophic scars: a systematic review. British Journal of Dermatology2011;165(5):934-42.">Vrijman 2011</a>, the findings could not be compared. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011642-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011642-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/full#CD011642-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011642-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/full#CD011642-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011642-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/full#CD011642-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: 585‐nm Pulsed‐Dye Laser (PDL) versus no treatment, Outcome 1: Severity of scar: Patient self‐assessment (32 weeks)" data-id="CD011642-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: 585‐nm Pulsed‐Dye Laser (PDL) versus no treatment, Outcome 1: Severity of scar: Patient self‐assessment (32 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: 585‐nm Pulsed‐Dye Laser (PDL) versus no treatment, Outcome 2: Incidence and severity of treatment‐related adverse effects (32 weeks)" data-id="CD011642-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: 585‐nm Pulsed‐Dye Laser (PDL) versus no treatment, Outcome 2: Incidence and severity of treatment‐related adverse effects (32 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Non‐ablative Fractional Laser (NAFL) versus no treatment, Outcome 1: Severity of scar: Health Professional Global Assessment (3 months)" data-id="CD011642-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Non‐ablative Fractional Laser (NAFL) versus no treatment, Outcome 1: Severity of scar: Health Professional Global Assessment (3 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Non‐ablative Fractional Laser (NAFL) versus no treatment, Outcome 2: Incidence and severity of treatment‐related adverse effects (3 months)" data-id="CD011642-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Non‐ablative Fractional Laser (NAFL) versus no treatment, Outcome 2: Incidence and severity of treatment‐related adverse effects (3 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Non‐ablative Fractional Laser (NAFL) versus no treatment, Outcome 3: Scar size, colour, height, length, width, pliability, skin surface texture, pruritus and pain (3 months)" data-id="CD011642-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Non‐ablative Fractional Laser (NAFL) versus no treatment, Outcome 3: Scar size, colour, height, length, width, pliability, skin surface texture, pruritus and pain (3 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Fractional carbon dioxide (CO2) versus no treatment, Outcome 1: Severity of scar: Vancouver Burn Scar (VBS) scale (up to 6 months)" data-id="CD011642-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Fractional carbon dioxide (CO<sub>2</sub>) versus no treatment, Outcome 1: Severity of scar: Vancouver Burn Scar (VBS) scale (up to 6 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Fractional carbon dioxide (CO2) versus no treatment, Outcome 2: Severity of scar: Patient and Observer Scar Assessment Scale (POSAS) (at least one month)" data-id="CD011642-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Fractional carbon dioxide (CO<sub>2</sub>) versus no treatment, Outcome 2: Severity of scar: Patient and Observer Scar Assessment Scale (POSAS) (at least one month) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Fractional carbon dioxide (CO2) versus no treatment, Outcome 3: Scar size, colour, height, length, width, pliability, skin surface texture, pruritus and pain (12 to 18 weeks)" data-id="CD011642-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Fractional carbon dioxide (CO<sub>2</sub>) versus no treatment, Outcome 3: Scar size, colour, height, length, width, pliability, skin surface texture, pruritus and pain (12 to 18 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: 585‐nm Pulsed‐Dye Laser (PDL) versus Triamcinolone acetonide (TAC), Outcome 1: Severity of scars: Vancouver Burn Scar (VBS) scale (up to 12 months)" data-id="CD011642-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: 585‐nm Pulsed‐Dye Laser (PDL) versus Triamcinolone acetonide (TAC), Outcome 1: Severity of scars: Vancouver Burn Scar (VBS) scale (up to 12 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: 585‐nm Pulsed‐Dye Laser (PDL) versus Triamcinolone acetonide (TAC), Outcome 2: Severity of scars: Patient self‐assessment (up to 12 months)" data-id="CD011642-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: 585‐nm Pulsed‐Dye Laser (PDL) versus Triamcinolone acetonide (TAC), Outcome 2: Severity of scars: Patient self‐assessment (up to 12 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: 585‐nm Pulsed‐Dye Laser (PDL) versus Triamcinolone acetonide (TAC), Outcome 3: Incidence and severity of treatment‐related adverse effects (up to 12 months)" data-id="CD011642-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: 585‐nm Pulsed‐Dye Laser (PDL) versus Triamcinolone acetonide (TAC), Outcome 3: Incidence and severity of treatment‐related adverse effects (up to 12 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: 585‐nm Pulsed‐Dye Laser (PDL) versus 5‐Fluorouracil (5‐FU), Outcome 1: Severity of scars: Patient self‐assessment (32 weeks)" data-id="CD011642-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: 585‐nm Pulsed‐Dye Laser (PDL) versus 5‐Fluorouracil (5‐FU), Outcome 1: Severity of scars: Patient self‐assessment (32 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: 585‐nm Pulsed‐Dye Laser (PDL) versus 5‐Fluorouracil (5‐FU), Outcome 2: Incidence and severity of treatment‐related adverse effects (32 weeks)" data-id="CD011642-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: 585‐nm Pulsed‐Dye Laser (PDL) versus 5‐Fluorouracil (5‐FU), Outcome 2: Incidence and severity of treatment‐related adverse effects (32 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: 585‐nm Pulsed‐Dye Laser (PDL) versus Triamcinolone acetonide (TAC) plus 5‐Fluorouracil (5‐FU), Outcome 1: Severity of scars: Patient self‐assessment (32 weeks)" data-id="CD011642-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: 585‐nm Pulsed‐Dye Laser (PDL) versus Triamcinolone acetonide (TAC) plus 5‐Fluorouracil (5‐FU), Outcome 1: Severity of scars: Patient self‐assessment (32 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: 585‐nm Pulsed‐Dye Laser (PDL) versus Triamcinolone acetonide (TAC) plus 5‐Fluorouracil (5‐FU), Outcome 2: Incidence and severity of treatment‐related adverse effects (32 weeks)" data-id="CD011642-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: 585‐nm Pulsed‐Dye Laser (PDL) versus Triamcinolone acetonide (TAC) plus 5‐Fluorouracil (5‐FU), Outcome 2: Incidence and severity of treatment‐related adverse effects (32 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: 585‐nm Pulsed‐Dye Laser (PDL) versus Silicone Gel Sheeting, Outcome 1: Incidence and severity of treatment‐related adverse effects (24 weeks)" data-id="CD011642-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: 585‐nm Pulsed‐Dye Laser (PDL) versus Silicone Gel Sheeting, Outcome 1: Incidence and severity of treatment‐related adverse effects (24 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Erbium laser versus Triamcinolone acetonide (TAC), Outcome 1: Severity of scars: Vancouver Burn Scar (VBS) scale (up to 12 months)" data-id="CD011642-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Erbium laser versus Triamcinolone acetonide (TAC), Outcome 1: Severity of scars: Vancouver Burn Scar (VBS) scale (up to 12 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Erbium laser versus Triamcinolone acetonide (TAC), Outcome 2: Severity of scars: Patient self‐assessment (up to 12 months)" data-id="CD011642-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Erbium laser versus Triamcinolone acetonide (TAC), Outcome 2: Severity of scars: Patient self‐assessment (up to 12 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Fractional carbon dioxide (CO2) laser versus intralesional Triamcinolone acetonide (TAC), Outcome 1: Incidence of treatment‐related adverse effects (24 weeks)" data-id="CD011642-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Fractional carbon dioxide (CO<sub>2</sub>) laser versus intralesional Triamcinolone acetonide (TAC), Outcome 1: Incidence of treatment‐related adverse effects (24 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Fractional carbon dioxide (CO2) laser versus intralesional Triamcinolone acetonide (TAC), Outcome 2: Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain (12 weeks)" data-id="CD011642-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: Fractional carbon dioxide (CO<sub>2</sub>) laser versus intralesional Triamcinolone acetonide (TAC), Outcome 2: Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain (12 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-CMP-009.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Fractional carbon dioxide (CO2) laser versus intralesional Triamcinolone acetonide (TAC), Outcome 3: Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain (24 weeks)" data-id="CD011642-fig-0024" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-009.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-CMP-009.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9: Fractional carbon dioxide (CO<sub>2</sub>) laser versus intralesional Triamcinolone acetonide (TAC), Outcome 3: Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain (24 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-009.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Fractional carbon dioxide (CO2) laser versus Intralesional Verapamil, Outcome 1: Incidence of treatment‐related adverse effects (24 weeks)" data-id="CD011642-fig-0025" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: Fractional carbon dioxide (CO<sub>2</sub>) laser versus Intralesional Verapamil, Outcome 1: Incidence of treatment‐related adverse effects (24 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Fractional carbon dioxide (CO2) laser versus Intralesional Verapamil, Outcome 2: Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain (12 weeks)" data-id="CD011642-fig-0026" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: Fractional carbon dioxide (CO<sub>2</sub>) laser versus Intralesional Verapamil, Outcome 2: Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain (12 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-CMP-010.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Fractional carbon dioxide (CO2) laser versus Intralesional Verapamil, Outcome 3: Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain (24 weeks)" data-id="CD011642-fig-0027" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-010.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-CMP-010.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10: Fractional carbon dioxide (CO<sub>2</sub>) laser versus Intralesional Verapamil, Outcome 3: Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain (24 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-010.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: 585‐nm Pulsed‐Dye Laser (PDL) plus Triamcinolone acetonide (TAC) plus 5‐Fluorouracil (5‐FU) versus TAC plus 5‐FU, Outcome 1: Severity of scars (12 weeks)" data-id="CD011642-fig-0028" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: 585‐nm Pulsed‐Dye Laser (PDL) plus Triamcinolone acetonide (TAC) plus 5‐Fluorouracil (5‐FU) versus TAC plus 5‐FU, Outcome 1: Severity of scars (12 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-CMP-012.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Carbon dioxide (CO2) Laser plus Triamcinolone acetonide (TAC) versus Cryosurgery plus TAC, Outcome 1: Severity of scars (12 months)" data-id="CD011642-fig-0029" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-012.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-CMP-012.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12: Carbon dioxide (CO2) Laser plus Triamcinolone acetonide (TAC) versus Cryosurgery plus TAC, Outcome 1: Severity of scars (12 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-012.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-CMP-012.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Carbon dioxide (CO2) Laser plus Triamcinolone acetonide (TAC) versus Cryosurgery plus TAC, Outcome 2: Incidence and severity of treatment‐related adverse effects (12 months)" data-id="CD011642-fig-0030" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-012.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-CMP-012.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12: Carbon dioxide (CO2) Laser plus Triamcinolone acetonide (TAC) versus Cryosurgery plus TAC, Outcome 2: Incidence and severity of treatment‐related adverse effects (12 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-012.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-CMP-012.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Carbon dioxide (CO2) Laser plus Triamcinolone acetonide (TAC) versus Cryosurgery plus TAC, Outcome 3: Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain(12 months)" data-id="CD011642-fig-0031" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-012.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-CMP-012.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12: Carbon dioxide (CO2) Laser plus Triamcinolone acetonide (TAC) versus Cryosurgery plus TAC, Outcome 3: Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain(12 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-012.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-CMP-012.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Carbon dioxide (CO2) Laser plus Triamcinolone acetonide (TAC) versus Cryosurgery plus TAC, Outcome 4: Recurrence of the condition (12 months)" data-id="CD011642-fig-0032" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-012.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-CMP-012.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.4</div> <div class="figure-caption"> <p>Comparison 12: Carbon dioxide (CO2) Laser plus Triamcinolone acetonide (TAC) versus Cryosurgery plus TAC, Outcome 4: Recurrence of the condition (12 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-012.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-CMP-013.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Neodymium‐doped yttrium aluminum garnet (Nd:YAG) laser plus intralesional corticosteroid diprospan plus 5‐Fluorouracil (5‐FU) versus Intralesional corticosteroid diprospan plus 5‐FU, Outcome 1: Severity of scars (3 months)" data-id="CD011642-fig-0033" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-013.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-CMP-013.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13: Neodymium‐doped yttrium aluminum garnet (Nd:YAG) laser plus intralesional corticosteroid diprospan plus 5‐Fluorouracil (5‐FU) versus Intralesional corticosteroid diprospan plus 5‐FU, Outcome 1: Severity of scars (3 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-013.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-CMP-014.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Helium–neon (He‐Ne) laser plus Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream versus Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream, Outcome 1: Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain (12 weeks)" data-id="CD011642-fig-0034" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-014.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-CMP-014.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14: Helium–neon (He‐Ne) laser plus Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream versus Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream, Outcome 1: Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain (12 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-014.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-CMP-015.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: 595‐nm Pulsed‐Dye Laser (PDL) plus intralesional verapamil versus intralesional verapamil, Outcome 1: Incidence of treatment‐related adverse effects (24 weeks)" data-id="CD011642-fig-0035" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-015.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-CMP-015.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15: 595‐nm Pulsed‐Dye Laser (PDL) plus intralesional verapamil versus intralesional verapamil, Outcome 1: Incidence of treatment‐related adverse effects (24 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-015.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-CMP-015.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: 595‐nm Pulsed‐Dye Laser (PDL) plus intralesional verapamil versus intralesional verapamil, Outcome 2: Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain (change from baseline) (12 weeks)" data-id="CD011642-fig-0036" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-015.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-CMP-015.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.2</div> <div class="figure-caption"> <p>Comparison 15: 595‐nm Pulsed‐Dye Laser (PDL) plus intralesional verapamil versus intralesional verapamil, Outcome 2: Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain (change from baseline) (12 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-015.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011642-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/urn:x-wiley:14651858:media:CD011642:CD011642-CMP-015.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: 595‐nm Pulsed‐Dye Laser (PDL) plus intralesional verapamil versus intralesional verapamil, Outcome 3: Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain (change from baseline) (24 weeks)" data-id="CD011642-fig-0037" src="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-015.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_t/tCD011642-CMP-015.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.3</div> <div class="figure-caption"> <p>Comparison 15: 595‐nm Pulsed‐Dye Laser (PDL) plus intralesional verapamil versus intralesional verapamil, Outcome 3: Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain (change from baseline) (24 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/media/CDSR/CD011642/image_n/nCD011642-CMP-015.03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011642-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Laser therapy compared with no treatment for treating hypertrophic and keloid scars</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Laser therapy</b> <b>compared with no treatment for treating hypertrophic and keloid scars</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with hypertrophic and keloid scars<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> laser therapy (various types ‐ 585‐nm Pulsed‐Dye Laser (PDL), Non‐Ablative Fractional Laser (NAFL), Fractional CO<sub>2</sub>)<br/><b>Comparison:</b> no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of scar segment<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with no treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Laser therapy</b> </p> </th> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Scar severity ‐ 585‐nm Pulsed‐Dye Laser (PDL) versus no treatment ‐ patient self‐assessment of scar improvement of 50% or higher ‐ hypertrophic and keloid scars ‐ follow‐up: 32 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.96<br/>(1.11 to 3.45) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>60<br/>(2 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<sup>1,2</sup><br/>Low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> <p>There may be more hypertrophic and keloid scar improvement (that is scars are less severe) in 585‐nm PDL‐treated scars compared with no treatment after 32 weeks. </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>400 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>784 per 1000<br/>  </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ 585‐nm PDL versus no treatment ‐ mild to moderate discomfort or pain related to treatment ‐ hypertrophic and keloid scars ‐follow‐up: 32 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Two split‐scar trials (n = 60) reported this outcome. In these studies, participants reported mild to moderate discomfort or pain in 10 out of 30 (10/30) (33%) PDL treated areas versus 0 out of 30 (0/30) (0%) no treatment areas (RR 8.62; 1.10 to 67.39). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>2,3</sup><br/>Very low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p> It is uncertain whether there is any difference in the incidence and severity of treatment‐related adverse effects in 585‐nm PDL‐treated hypertrophic and keloid scars compared with no treatment after 32 weeks. </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ 585‐nm PDL versus no treatment ‐ purpura ‐ hypertrophic and keloid scars ‐ follow‐up: 32 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Two split‐scar trials (n = 60) reported this outcome. In these studies, purpura was observed in 40 out of 40 (40/40) (100%) PDL treated areas versus 0 out of 20 (0/20) (0%) no treatment areas (RR 21.32; 3.14 to 144.86). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>2,3</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Scar severity ‐ Non‐Ablative Fractional Laser (NAFL) versus no treatment ‐ health professional global assessment measured on a visual analogue scale (VAS) ranging from 0 to 100 mm (0 = as normal skin and 100 = worst possible scar) ‐ hypertrophic scars ‐ follow‐up: 3 months </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 2.00</p> <p>(0.85 to 4.69)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>36</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>3,4 </sup><br/>Very low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>It is uncertain whether there is any difference in the scar severity in NAFL‐treated hypertrophic scars compared with no treatment after 3 months. </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>278 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>556 per 1000</p> <p> </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity ‐ NAFL versus no treatment ‐ patient global assessment measured on a VAS ranging from 0 to 100 mm (0 = as normal skin and 100 = worst possible scar) ‐ hypertrophic scars ‐ follow‐up: 3 months </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One split‐scar trial (n = 36) reported this outcome. In this study, the authors reported an improvement in scar severity in NAFL treated hypertrophic scars compared with no treatment on the patient global assessment at 1 month (reported P = 0.006) and 3 months (reported P = 0.02). </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>5,6</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity ‐ NAFL versus no treatment ‐ Patient and Observer Scar Assessment Scale (POSAS) (higher scores = worse scar appearance) ‐ hypertrophic scars ‐ follow‐up: up to 3 months </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One split‐scar trial (n = 36) reported this outcome. In this study, the authors reported an improvement in scar severity in NAFL treated hypertrophic scars compared with no treatment on the participant part of the scale at 1 month and 3 months. The size of the difference was not reported and no data for the observer part of the scale was presented. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>5,6</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ NAFL versus no treatment ‐ scar worsening ‐ hypertrophic scars ‐ follow‐up: 3 months </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One split‐scar trial (n = 20) reported this outcome. In this study, 3 out of 10 (3/10) (30%) NAFL treated areas versus 0 out of 10 (0/10) (0%) no treatment areas were considered by the patients to have worsened (RR 7.00; 0.41 to 120.16). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>3,7</sup><br/>Very low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>It is uncertain whether there is any difference in the incidence and severity of treatment‐related adverse effects in NAFL‐treated hypertrophic scars compared with no treatment after 3 months. </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ NAFL versus no treatment ‐ hyperpigmentation ‐ hypertrophic scars ‐ follow‐up: 3 months </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One split‐scar trial (n = 36) reported this outcome. In this study, hyperpigmentation was observed in 1 out of 18 (1/18) (6%) NAFL treated areas versus 0 out of 18 (0/18) (0%) no treatment areas (RR 3.00; 0.13 to 69.09). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>3,5 </sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Scar severity ‐ Fractional Carbon Dioxide (CO<sub>2</sub>) Laser versus no treatment ‐ Vancouver Burn Scar (VBS) scale (higher scores = worse scar appearance) ‐ hypertrophic scars ‐ follow‐up: up to 3 months </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>104</p> <p>(2 studies)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>6,8</sup><br/>Very low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>It is uncertain whether there is any difference in the scar severity in Fractional CO<sub>2</sub>‐treated hypertrophic and keloid scars compared with no treatment after up to 3 months, and in Fractional CO<sub>2</sub>‐treated hypertrophic scars compared with no treatment after at least 1 month. </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Baseline mean in the no treatment group was 7.6</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD 1.30 lower<br/>(4.32 lower to 1.71 higher) </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Scar severity ‐ Fractional CO<sub>2</sub> Laser versus no treatment ‐ VBS (higher scores = worse scar appearance) ‐ keloid scars ‐ follow‐up: 3 months </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>24</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>6,9</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Baseline mean in the no treatment group was 7.6</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD 1.90 lower<br/>(3.02 lower to 0.78 lower) </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Scar severity ‐ Fractional CO<sub>2</sub> Laser versus no treatment ‐ POSAS scale (higher scores = worse scar appearance) ‐ hypertrophic scars ‐ follow‐up: at least 1 month </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>80</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>6,10</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Baseline mean in the no treatment group was 29.9</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD 4.13 higher (1.24 lower to 9.50 higher)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% confidence interval) is based on the mean risk in the comparison group and the relative effect of the intervention (and its 95% CI). </p> <p>ƚThe assumed risk in the comparison group is based on the event rate observed in the control arms of included trials. Where no events occurred, the risk was not calculated. </p> <p> </p> <p>VAS: visual analogue scale ‐ ranging from 0 to 100 mm (0 = normal skin and 100 = worst possible scar); </p> <p>Patient self‐assessment ‐ based on a 4‐point scale (1 = 0 to 25% improvement, 2 = 25 to 50% improvement, 3 = 50 to 75% improvement, and 4 = 75% or greater improvement); </p> <p>POSAS: Patient and Observer Scar Assessment Scale ‐ the lowest score (6) reflects normal skin, and the highest score (60) reflects the worst imaginable scar; </p> <p>VBS: Vancouver Burn Scar Assessment Scale ‐ severity of scar was determined by numeric value from a minimum of 0 to 13 as the most severe form. </p> <p><b>CI:</b> Confidence Interval; <b>CO<sub>2</sub>:</b> carbon dioxide;<b>LDTA:</b> (Low‐Density Treatment Arm of NAFL), <b>HDTA:</b> (High‐Density Treatment Arm of NAFL); <b>MD:</b> Mean Difference; <b>NAFL:</b> Non‐Ablative Fractional Laser ;<b>PDL:</b> Pulsed‐Dye Laser; <b>RR:</b> Risk Ratio; <b>VBS:</b> Vancouver Burn Scar Assessment Scale. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded 1 level for serious imprecision due to small number of events. </p> <p><sup>2</sup> Downgraded 1 level for serious risk of bias (lack of blinding of participants and assessors (patient‐reported outcome), and unclear sequence generation and allocation concealment). </p> <p><sup>3</sup> Downgraded 2 levels for very serious imprecision due to small number of events and large confidence interval. </p> <p><sup>4</sup> Downgraded 1 level for serious risk of bias (lack of blinding of participants). </p> <p><sup>5</sup> Downgraded 1 level for serious risk of bias (lack of blinding of participants and assessors (patient‐reported outcome)). </p> <p><sup>6</sup> Downgraded 2 levels for very serious imprecision due to small sample size and large confidence interval. </p> <p><sup>7</sup> Downgraded 1 level for serious risk of bias (lack of blinding of participants and assessors (patient‐reported outcome), incomplete outcome data, and unclear allocation concealment). </p> <p><sup>8</sup> Downgraded 1 level for serious risk of bias (selective reporting in one study, and lack of blinding of participants and incomplete outcome data in 2 studies). </p> <p><sup>9</sup> Downgraded 1 level for serious risk of bias (lack of blinding of participants, incomplete outcome data and selective reporting). </p> <p><sup>10</sup> Downgraded 1 level for serious risk of bias (lack of blinding of participants and assessors (patient‐reported outcome) and incomplete outcome data). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Laser therapy compared with no treatment for treating hypertrophic and keloid scars</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/full#CD011642-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011642-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Laser therapy compared with other treatments for treating hypertrophic and keloid scars</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Laser therapy compared with other treatments for treating hypertrophic and keloid scars</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with hypertrophic and keloid scars<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> laser therapy (various types ‐ 585‐nm Pulsed‐Dye Laser (PDL), Erbium Laser, Fractional Carbon Dioxide (CO<sub>2</sub>) Laser)<br/><b>Comparison:</b> other treatments (various types ‐ triamcinolone acetonide (TAC), 5‐Fluorouracil (5‐FU), verapamil) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of scar segments<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with other treatments</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Laser therapy</b> </p> </th> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Scar severity ‐ 585‐nm Pulsed‐Dye Laser (PDL) versus Triamcinolone acetonide (TAC) ‐ Vancouver Burn Scar (VBS) (Higher score = worse scar appearance) ‐ hypertrophic scars ‐ follow‐up: up to 12 months </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>80<br/>(1 study) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>1,2</sup><br/>Very low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>It is uncertain whether there is any difference in the scar severity in PDL‐treated hypertrophic and keloid scars compared with TAC after up to 12 months. </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Baseline mean in the other treatment group was 6.7</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.5 lower<br/>(3.2 lower to 1.8 lower) </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity ‐ 585‐nm PDL versus TAC ‐ patient self‐assessment of scar improvement of 50% or higher, or patients considering the scar better or much better ‐ hypertrophic and keloid scars ‐ follow‐up: up to 12 months </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One split‐scar trial (n = 20) and one parallel trial (n = 80) reported this outcome. In the split scar trial, 8 out of 10 (8/10) (80%) PDL treated areas versus 10 out of 10 (10/10) (100%) TAC treated areas were considered to have improved 50% or more by participants (RR 0.81; 0.57 to 1.14), and in the parallel trial, 28 out of 40 participants (28/40) (70%) treated with PDL and 12 out of 40 participants (12/40) (30%) treated with TAC considered their scars better or much better (RR 2.33; 1.39 to 3.91). </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>3,4</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ 585‐nm PDL versus TAC: sequelae ‐ hypertrophic and keloid scars ‐ follow‐up: 32 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.09<br/>(0.01 to 1.45) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>20<br/>(1 study) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>3,5</sup><br/>Very low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>It is uncertain whether there is any difference in the incidence and severity of treatment‐related adverse effects in PDL‐treated hypertrophic and keloid scars compared with TAC after 32 weeks.   </p> <p> </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>500 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>45 per 1000<br/>  </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ 585‐nm PDL versus TAC ‐ mild to moderate pain related to treatment ‐ hypertrophic and keloid scars ‐ follow‐up: 32 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One split‐scar trial (n = 20) reported this outcome. In this study, participants reported to have felt mild to moderate pain during the intervention in 10 out of 10 (10/10) (100%) TAC treated areas versus in 9 out of 10 (9/10) (90%) PDL treated areas (RR 0.90; 0.69 to 1.18).  </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>3,5</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity ‐ 585‐nm PDL versus 5‐FU ‐ patient self‐assessment of scar improvement of 50% or higher ‐ hypertrophic and keloid scars ‐ follow‐up: 32 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One split‐scar trial (n = 20) reported this outcome. In this study, 8 out of 10 (8/10) (80%) PDL treated areas versus 10 out of 10 (10/10) (100%) 5‐FU treated areas were reported by the participants to have improved 50% or more (RR 0.81; 0.57 to 1.14). </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>3,5</sup><br/>Very low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>It is uncertain whether there is any difference in the scar severity in PDL‐treated hypertrophic and keloid scars compared with 5‐FU after 32 weeks.  </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ 585‐nm PDL versus 5‐FU ‐ mild to moderate pain related to treatment ‐ hypertrophic and keloid scars ‐ follow‐up: 32 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One split‐scar trial (n = 20) reported this outcome. In this study, participants reported to have felt mild to moderate pain during the intervention in 9 out of 10 (9/10) (90%) PDL treated areas versus in 10 out of 10 (10/10) (100%) 5‐FU treated areas (RR 0.90; 0.69 to 1.18). </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>3,5</sup><br/>Very low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>It is uncertain whether there is any difference in the incidence and severity of treatment‐related adverse effects in PDL‐treated hypertrophic and keloid scars compared with 5‐FU after 32 weeks. </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ 585‐nm PDL versus 5‐FU ‐ purpura ‐ hypertrophic and keloid scars ‐ follow‐up: 32 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One split‐scar trial (n = 20) reported this outcome. In this study, purpura was observed in 10 out of 10 (10/10) (100%) PDL treated areas versus in 2 out of 10 (2/10) (20%) 5‐FU treated areas (RR 4.20; 1.40 to 12.58). </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>3,5</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Scar severity ‐ 585‐nm PDL versus TAC plus 5‐FU ‐ patient self‐assessment of scar improvement of 50% or higher ‐ hypertrophic and keloid scars ‐ follow‐up: 32 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.89<br/>(0.61 to 1.29) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>20<br/>(1 study) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>3,5</sup><br/>Very low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p> It is uncertain whether there is any difference in the scar severity in PDL‐treated hypertrophic and keloid scars compared with TAC plus 5‐FU after 32 weeks. </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>900 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>801 per 1000</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ 585‐nm PDL versus TAC plus 5‐FU ‐ mild to moderate pain related to treatment ‐ hypertrophic and keloid scars ‐ follow‐up: 32 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One split‐scar trial (n = 20) reported this outcome. In this study, participants reported to have felt mild to moderate pain during the intervention in 9 out of 10 (9/10) (90%) PDL treated areas versus in 10 out of 10 (10/10) (100%) TAC plus 5‐FU treated areas (RR 0.90; 0.69 to 1.18). </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>3,5</sup><br/>Very low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>It is uncertain whether there is any difference in the incidence and severity of treatment‐related adverse effects in PDL‐treated hypertrophic and keloid scars compared with TAC plus 5‐FU after 32 weeks. </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ 585‐nm PDL versus TAC plus 5‐FU ‐ purpura ‐ hypertrophic and keloid scars ‐ follow‐up: 32 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One split‐scar trial (n = 20) reported this outcome. In this study, purpura was observed in 10 out of 10 (10/10) (100%) PDL treated areas versus in 3 out of 10 (3/10) (30%) TAC plus 5‐FU treated areas (RR 3.00; 1.25 to 7.19). </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>3,5</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ 585‐nm PDL versus silicone gel sheeting ‐ pain during laser treatments ‐ hypertrophic scars ‐ follow‐up: 24 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One split‐scar trial (n = 40) reported this outcome. In this study, participants reported to have felt pain during laser treatment in 1 out of 20 (1/20) (5%) PDL treated areas versus in 0 out of 20 (0/20) (0%) silicone gel sheeting treated areas (RR 3.00; 0.13 to 69.52). </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>3,6</sup><br/>Very low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>It is uncertain whether there is any difference in the incidence and severity of treatment‐related adverse effects in PDL‐treated hypertrophic scars compared with silicone gel sheeting after 24 weeks.   </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ 585‐nm PDL versus silicone gel sheeting ‐ skin irritation ‐ hypertrophic scars ‐ follow‐up: 24 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One split‐scar trial (n = 40) reported this outcome. In this study, participants reported to have felt skin irritation related to laser treatment in 0 out of 20 (0/20) (0%) PDL treated areas versus in 1 out of 20 (1/20) (5%) silicone gel sheeting treated areas (RR 0.33; 0.01 to 7.72). </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>3,6</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Scar severity ‐ erbium laser versus TAC ‐ VBS (Higher scores = worse scar appearance) ‐ hypertrophic scars ‐ follow‐up: up to 12 months </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Baseline mean in the other treatment group was 6.7</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.10 lower<br/>(2.87 lower to 1.33 lower) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(1 study) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>1,2</sup><br/>Very low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p> It is uncertain whether there is any difference in the scar severity in erbium‐treated hypertrophic scars compared with TAC after up to 12 months. </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Scar severity ‐ erbium laser versus TAC ‐ patient self‐assessment ‐ patients considering the scar much better ‐ hypertrophic scars ‐ follow‐up: up to 12 months </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.17<br/>(1.28 to 3.66) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>80<br/>(1 study) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<sup>3,7</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>651 per 1000<br/>  </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ fractional carbon dioxide (CO<sub>2</sub>) laser versus TAC ‐ pain at injection site ‐ keloid scars ‐ follow‐up: 24 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.25</p> <p>(0.06 to 1.03)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>40<br/>(1 study) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>3,8</sup><br/>Very low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p>It is uncertain whether there is any difference in the incidence and severity of treatment‐related adverse effects in fractional CO<sub>2</sub>‐treated keloid scars compared with TAC after 24 weeks.  </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>400 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>100 per 1000</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ fractional CO<sub>2</sub> laser versus TAC ‐ telangectasia ‐ keloid scars ‐ follow‐up: 24 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.20</p> <p>(0.01 to 3.92)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>40<br/>(1 study) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>3,8</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>100 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>20 per 1000</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ fractional CO<sub>2</sub> laser versus TAC ‐ skin atrophy ‐ keloid scars ‐ follow‐up: 24 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.33</p> <p>(0.01 to 7.72)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>40<br/>(1 study) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>3,8</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>50 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>17 per 1000</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ fractional CO<sub>2</sub> laser versus TAC ‐ charring ‐ keloid scars ‐ follow‐up: 24 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One parallel trial (n = 40) reported this outcome. In this study, charring was observed in 3 out of 20 (3/20) (15%) participants treated with fractional CO<sub>2</sub> laser and 0 out of 20 (0/20) (0%) participants treated with TAC (RR 7.00; 0.38 to 127.32). </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>3,8</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ fractional CO<sub>2</sub> laser versus verapamil ‐ pain at injection site ‐ keloid scars ‐ follow‐up: 24 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One parallel trial (n = 40) reported this outcome. In this study, pain at injection site was reported by 2 out of 20 (2/20) (10%) participants treated with fractional CO<sub>2</sub> laser group and 0 out of 20 (0/20) (0%) participants treated with verapamil (RR 5.00; 0.26 to 98.00). </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>3,8</sup><br/>Very low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p> It is uncertain whether there is any difference in the incidence and severity of treatment‐related adverse effects in fractional CO<sub>2</sub>‐treated keloid scars compared with verapamil after 24 weeks. </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects ‐ fractional CO<sub>2</sub> laser versus verapamil ‐ charring ‐ keloid scars ‐ follow‐up: 24 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One parallel trial (n = 40) reported this outcome. In this study, charring was observed in 3 out of 20 (3/20) (15%) participants treated with fractional CO<sub>2</sub> laser group and 0 out of 20 (0/20) (0%) participants treated with verapamil group (RR 7.0; 0.38 to 127.32) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>3,8</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% confidence interval) is based on the mean risk in the comparison group and the relative effect of the intervention (and its 95% CI). </p> <p>ƚThe assumed risk in the comparison group is based on the event rate observed in the control arms of included trials. Where no events occurred, the risk was not calculated. </p> <p> </p> <p>Vancouver Burn Scar (VBS) Assessment Scale ‐ severity of scar was determined by numeric value from a minimum of 0 to 13 as the most severe form. </p> <p>Patient self‐assessment ‐ based on a 4‐point scale (1 = 0 to 25% improvement, 2 = 25 to 50% improvement, 3 = 50 to 75% improvement, and 4 = 75% or greater improvement). </p> <p><b>CI:</b> Confidence Interval; <b>CO<sub>2</sub>:</b> carbon dioxide; <b>MD:</b> Mean Difference; <b>PDL:</b> Pulsed‐Dye Laser;<b>RR:</b> Risk Ratio; <b>TAC:</b> Triamcinolone acetonide;<b>5‐FU:</b> 5‐fluorouracil;<b>VBS:</b> Vancouver Burn Scar Assessment Scale;. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded 2 levels for very serious imprecision due to small sample size and large confidence interval. </p> <p><sup>2</sup> Downgraded 1 level due to serious risk of bias (lack of blinding of participants, selective reporting, and unclear sequence generation and allocation concealment). </p> <p><sup>3</sup> Downgraded 2 levels for very serious imprecision due to small number of events and large confidence interval. </p> <p><sup>4</sup> Downgraded 1 level due to serious risk of bias (lack of blinding of participants and assessors (patient‐reported outcome) and unclear sequence generation and allocation concealment in 2 studies, and selective reporting in 1 study). </p> <p><sup>5</sup> Downgraded 1 level due to serious risk of bias (lack of blinding of participants and assessors (patient‐reported outcome) and unclear sequence generation and allocation concealment). </p> <p><sup>6</sup> Downgraded 1 level due to serious risk of bias (lack of blinding of participants and assessors (patient‐reported outcome) and unclear allocation concealment). </p> <p><sup>7</sup> Downgraded 1 level due to serious risk of bias (lack of blinding of participants and assessors (patient‐reported outcome) and selective reporting, and unclear sequence generation and allocation concealment). </p> <p><sup>8</sup> Downgraded 1 level due to serious risk of bias (lack of blinding of participants and assessors (patient‐reported outcome), and unclear allocation concealment and selective reporting). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Laser therapy compared with other treatments for treating hypertrophic and keloid scars</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/full#CD011642-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011642-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Laser therapy plus other treatment compared with other treatment for treating hypertrophic and keloid scars</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Laser therapy plus other treatment compared with other treatment for treating hypertrophic and keloid scars</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with hypertrophic and keloid scars<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> laser therapy (various types ‐ 585‐nm Pulsed‐Dye Laser (PDL), erbium laser, carbon dioxide (CO<sub>2</sub>) laser, Neodymium‐doped yttrium aluminium garnet (Nd:YAG) laser, Helium‐Neon (He‐Ne) laser) plus other treatments (various types ‐ triamcinolone acetonide (TAC), 5‐Fluorouracil (5‐FU), Diprospan, decamethyltetrasiloxane, polydimethylsiloxane and cyclopentasiloxane cream and verapamil)<br/><b>Comparison:</b> other treatments (various types ‐ triamcinolone acetonide (TAC), 5‐Fluorouracil (5‐FU), Diprospan, decamethyltetrasiloxane, polydimethylsiloxane and cyclopentasiloxane cream, cryosurgery and verapamil) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of scar segments<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with other treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Laser therapy plus other treatment</b> </p> </th> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Scar severity ‐ 585‐nm pulsed‐dye laser (PDL) plus triamcinolone acetonide (TAC) plus 5‐Fluorouracil (5‐FU) versus TAC plus 5‐FU ‐ blinded observer assessment of good to excellent scar improvement ‐ hypertrophic and keloid scars ‐ follow‐up: 12 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.75</p> <p>(0.95 to 3.22)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>40<br/>(1 study) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<sup>1,2</sup><br/>Very low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p> It is uncertain whether there is any difference in the scar severity in PDL plus TAC plus 5‐FU‐treated hypertrophic and keloid scars compared with TAC plus 5‐FU after 12 weeks. </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>400 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>700 per 1000<br/>  </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Scar severity ‐ 585‐nm PDL plus TAC plus 5 FU versus TAC plus 5‐FU ‐ patient self‐assessment of good to excellent scar improvement ‐ hypertrophic and keloid scars ‐ follow‐up: 12 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.36</p> <p>(0.85 to 2.18)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>40<br/>(1 study) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<sup>1,3</sup><br/>Very low </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>550 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>748 per 1000<br/>  </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Scar severity ‐ carbon dioxide (CO<sub>2</sub>) laser plus TAC versus cryosurgery plus TAC. Mean percentage reduction ‐ blinded observer assessment ‐ keloid scars ‐ follow‐up: 12 months </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>60</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>4,5</sup><br/>Very low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p> It is uncertain whether there is any difference in the scar severity in CO<sub>2</sub> plus TAC‐treated keloid scars compared with cryosurgery plus TAC after 12 months. </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Baseline mean in the other treatment group was 74.44</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD 16.11 lower<br/>(34.49 lower to 2.27 higher) </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Scar severity ‐ CO<sub>2</sub> laser plus TAC versus cryosurgery plus TAC Mean percentage reduction ‐ patient self‐assessment score (higher scores = worse scar appearance) ‐ keloid scars ‐ follow‐up: 12 months </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>60</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>4,6</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Baseline mean in the other treatment group was 74.26</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD 7.59 lower<br/>(22.83 lower to 7.65 higher) </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Incidence of treatment‐related adverse effects: CO<sub>2</sub> laser plus TAC versus cryosurgery plus TAC ‐ atrophy ‐ keloid scars ‐ follow‐up: 12 months </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.13</p> <p>(0.70 to 1.82)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>60</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>4,6</sup><br/>Very low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p>It is uncertain whether there is any difference in the incidence and severity of treatment‐related adverse effects in CO<sub>2</sub> plus TAC‐treated keloid scars compared with cryosurgery plus TAC after 12 months.   </p> <p> </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>500 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>565 per 1000</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Incidence of treatment‐related adverse effects ‐ CO<sub>2</sub> laser plus TAC versus cryosurgery plus TAC ‐ erythema ‐ keloid scars ‐ follow‐up: 12 months </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.50</p> <p>(0.47 to 4.78)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>60</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>4,6</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>133 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>200 per 1000</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Incidence of treatment‐related adverse effects ‐ CO<sub>2</sub> laser plus TAC versus cryosurgery plus TAC ‐ telangiectasia ‐ keloid scars ‐ follow‐up: 12 months </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.33</p> <p>(0.07 to 1.52)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>60</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>4,6</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>200 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>66 per 1000</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Incidence of treatment‐related adverse effects ‐ CO<sub>2</sub> laser plus TAC versus cryosurgery plus TAC ‐ hypopigmentation ‐ keloid scars ‐ follow‐up: 12 months </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.60</p> <p>(0.16 to 2.29)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>60</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>4,6</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>167 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>100 per 1000</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Scar severity ‐ Neodymium‐doped yttrium aluminium garnet (Nd:YAG) laser plus Diprospan plus 5‐FU versus Diprospan plus 5‐FU ‐ blinded observer assessment of good to excellent scar improvement ‐ keloid scars ‐ follow‐up: 3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.45</p> <p>(0.88 to 2.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>46</p> <p>(1study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>1,7</sup><br/>Very low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p> It is uncertain whether there is any difference in the scar severity in Nd:YAG plus Diprospan plus 5‐FU‐treated keloid scars compared with Diprospan plus 5‐FU after 3 months. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>478 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>693 per 1000</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Scar severity: Nd:YAG laser plus Diprospan plus 5‐FU versus Diprospan plus 5‐FU ‐ patient self‐assessment of scar improvement of 50% or higher ‐ keloid scars ‐ follow‐up: 3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.38</p> <p>(0.91 to 2.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>46</p> <p>(1study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>1,8</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>565 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>780 per 1000</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects: Nd:YAG laser plus Diprospan plus 5‐FU versus Diprospan plus 5‐FU ‐ keloid scars ‐ follow‐up: 3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One parallel trial (n = 46) reported this outcome. In this study, almost all injections were reported by participants as being painful, and the sites treated by Nd:YAG laser became purpuric (which lasted for 7 to 10 days). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>1,8</sup><br/>Very low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>It is uncertain whether there is any difference in the incidence and severity of treatment‐related adverse effects in Nd:YAG plus Diprospan plus 5‐FU‐treated keloid scars compared with Diprospan plus 5‐FU after 3 months. </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity ‐ Helium‐Neon (He‐Ne) laser plus decamethyltetrasiloxane, polydimethylsiloxane and cyclopentasiloxane cream versus decamethyltetrasiloxane, polydimethylsiloxane and cyclopentasiloxane cream ‐ Vancouver Scar scale (VSS) (higher scores = worse scar appearance) ‐ hypertrophic scars ‐ follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One split‐scar trial (n = 30) reported this outcome. In this study, a significant decrease in the median values of VSS of the intervention area compared with the control area (P = 0.003) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>4,9</sup><br/>Very low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> It is uncertain whether there is any difference in the scar severity in He‐Ne plus decamethyltetrasiloxane, polydimethylsiloxane and cyclopentasiloxane cream‐treated hypertrophic scars compared with decamethyltetrasiloxane, polydimethylsiloxane and cyclopentasiloxane cream after 12 weeks. </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ regrowth ‐ keloid scars ‐ follow‐up: 24 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.50</p> <p>(0.27 to 8.22)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>50</p> <p>(1study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>1,10</sup><br/>Very low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="9" valign=""> <p> It is uncertain whether there is any difference in the incidence and severity of treatment‐related adverse effects in PDL plus verapamil‐treated keloid scars compared with verapamil after 24 weeks. </p> <p> </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>80 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>120 per 1000</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ pain related to treatment ‐ keloid scars ‐ follow‐up: 24 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One parallel trial (n = 50) reported this outcome. In this study, pain at injection site was reported by 1 out of 25 (1/25) (4%) participants treated with 595‐nm PDL plus verapamil and by 0 out of 25 (0/15) (0%) participants treated with verapamil (RR 3.00; 0.13 to 70.30) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>1,10</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ hyperpigmentation ‐ keloid scars ‐ follow‐up: 24 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One parallel trial (n = 50) reported this outcome. In this study, hyperpigmentation was observed in 2 out of 25 (2/25) (8%) participants treated with 595‐nm PDL plus verapamil and by 0 out of 25 (0/15) (0%) participants treated with verapamil (RR 5.00; 0.25 to 99.16) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>1,10</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ depigmentation ‐ keloid scars ‐ follow‐up: 24 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.00</p> <p>(0.07 to 15.12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>50</p> <p>(1study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>1,10</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>40 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>40 per 1000</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ purpura ‐ keloid scars ‐ follow‐up: 24 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>One parallel trial (n = 50) reported this outcome. In this study, hyperpigmentation was observed in 7 out of 25 (7/25) (28%) participants treated with 595‐nm PDL plus verapamil and by 0 out of 25 (0/15) (0%) participants treated with verapamil (RR 15.00; 0.90 to 249.30) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>1,10</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ total ‐ keloid scars ‐ follow‐up: 24 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 4.67</p> <p>(1.53 to 14.26)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>50</p> <p>(1study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<sup>1,10</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>120 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>560 per 1000</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% confidence interval) is based on the mean risk in the comparison group and the relative effect of the intervention (and its 95% CI). </p> <p>ƚThe assumed risk in the comparison group is based on the event rate observed in the control arms of included trials. Where no events occurred, the risk was not calculated. </p> <p>‐ Diprospan contains betamethasone disodium phosphate plus betamethasone dipropionate.</p> <p> </p> <p>Patient self‐assessment ‐ based on a 4‐point scale (1 = 0 to 25% improvement, 2 = 25 to 50% improvement, 3 = 50 to 75% improvement, and 4 = 75% or greater improvement); </p> <p>VBS: Vancouver Burn Scar Assessment Scale ‐ severity of scar was determined by numeric value from a minimum of 0 to 13 as the most severe form. </p> <p><b>CI:</b> Confidence Interval; ; <b>CO:<sub>2</sub> </b> carbon dioxide;<b>5‐FU:</b> 5‐fluorouracil; <b>He‐Ne:</b> Helium‐Neon; <b>NdYAG: </b> neodymium‐doped yttrium aluminium garnet; <b>PDL:</b> Pulsed‐Dye Laser; <b>RR:</b> Risk Ratio; <b>TAC:</b> Triamcinolone acetonide. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded 2 levels for very serious imprecision due to small number of events and large confidence interval. </p> <p><sup>2</sup> Downgraded 1 level due to serious risk of bias (lack of blinding of participants, incomplete outcome data and selective reporting, and unclear sequence generation and allocation concealment). </p> <p><sup>3</sup> Downgraded 1 level due to serious risk of bias (lack of blinding of participants and assessors (patient‐reported outcome), incomplete outcome data and selective reporting, and unclear sequence generation and allocation concealment) </p> <p><sup>4</sup> Downgraded 2 levels for very serious imprecision due to small sample size and large confidence interval. </p> <p><sup>5</sup> Downgraded 1 level due to serious risk of bias (lack of blinding of participants and incomplete outcome data, and unclear selective reporting). </p> <p><sup>6</sup> Downgraded 1 level due to serious risk of bias (lack of blinding of participants and assessors (patient‐reported outcome) and incomplete outcome data, and unclear selective reporting). </p> <p><sup>7</sup> Downgraded 1 level due to serious risk of bias (lack of blinding of participants and incomplete outcome data, and unclear sequence generation and allocation concealment). </p> <p><sup>8</sup> Downgraded 1 level due to serious risk of bias (lack of blinding of participants and assessors (patient‐reported outcome) and incomplete outcome data, and unclear sequence generation and allocation concealment). </p> <p><sup>9</sup> Downgraded 1 level due to serious risk of bias (lack of blinding of participants and selective reporting, and unclear sequence generation, allocation concealment and incomplete outcome data). </p> <p><sup>10</sup> Downgraded 1 level due to serious risk of bias (lack of blinding of participants and assessors (patient‐reported outcome), and unclear sequence generation, allocation concealment and incomplete outcome data). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Laser therapy plus other treatment compared with other treatment for treating hypertrophic and keloid scars</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/full#CD011642-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011642-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Laser versus no treatment outcome details</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comparison</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trials (participants)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Definition of outcome in trial/measurement details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>585‐nm PDL versus no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 RCTs (Manuskiatti 2001; 10 participants; 40 segments and Manuskiatti 2002, 10 participants; 20 segments) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Manuskiatti 2001 and Manuskiatti 2002: categories of 25% increments of improvement in scar severity after 32 weeks (graded by the patient) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants with an improvement of 50% or higher in the scar severity</p> <p> </p> <p>Manuskiatti 2001:</p> <p>Laser: 23/30<br/>Control: 4/30 </p> <p> </p> <p>Manuskiatti 2002:</p> <p>Laser: 8/10<br/>Control: 4/10 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>585‐nm PDL versus no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 RCTs (Manuskiatti 2001; 10 participants; 40 segments, Manuskiatti 2002, 10 participants; 20 segments, and Wittenberg 1999; 20 participants; 40 segments) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Manuskiatti 2001: immediate treatment reactions, including purpuric discolorations and erosion secondary to blistering, and adverse sequelae during 32 weeks. </p> <p> </p> <p>Manuskiatti 2002: immediate treatment reactions included mild to moderate pain during treatment, burning sensation, spots of purpura, erosion secondary to blistering. Treatment‐related adverse sequelae including hypopigmentation, telangiectasia, and skin atrophy during 32 weeks. </p> <p> </p> <p>Wittenberg 1999: no definition was provided. Duration: 40 weeks.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Manuskiatti 2001 and 2002: in all participants treated with the PDL the area became purpuric and a small number of participants with skin phototype VI reported erosions.<br/>Manuskiatti 2002: mild to moderate<br/>discomfort or pain related to treatment was in 90% (9/10) of the participants during laser pulsing. </p> <p> </p> <p>Wittenberg 1999: one (1/20) participant dropped out due to pain during laser treatment.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>585‐nm PDL versus no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar size, colour, height, length, width, pliability, skin surface texture, pruritus and pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 RCTs (Manuskiatti 2001; 10 participants; 30 segments and Manuskiatti 2002: 10 participants; 20 segments; Wittenberg 1999; 20 participants; 40 segments) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Manuskiatti 2001 and 2002: scar height evaluated using a dial calliper, erythema using a hand‐held colorimeter after 32 weeks. </p> <p> </p> <p>Wittenberg 1999: blood flow (erythema), elasticity and volume, burning, pruritus, and pain not related to treatment after 40 weeks. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Manuskiatti 2001, 2002: scar height improvement in laser treated areas when compared with control (P &lt; 0.05, and P = 0.005, respectively) (data presented only in graphs) </p> <p> </p> <p>Wittenberg 1999: No statistically significant differences between groups were detected for erythema (P = 0.26), elasticity (P = 0.76), volume (P = 0.13), burning (P = 0.75), pruritus (P = 0.99), and pain not related to treatment (P = 0.41) (results presented only in graphs). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAFL versus no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 RCTS (Verhaeghe 2013; 22 participants, 44 segments; Lin 2011; 20 participants; 20 scars) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verhaeghe 2013:<br/>HPGA and PGA using a VAS ranging from 0 to 100 mm (0 = normal skin and 100 = worst possible scar) ‐ smallest clinically important minimum relevant difference was 20 </p> <p>POSAS: containing vascularisation, pigmentation, thickness, relief, pliability, and surface area (observer part) and pain not related to treatment, itching, colour, stiffness, thickness, and relief (patient part) (range 6 to 60) after 3 months. </p> <p> </p> <p>Lin 2011: categories of 25% increments of improvement in scar severity (graded by the participants and 2 blinded observers) after 3 months. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verhaeghe 2013 (36 segments analysed):</p> <p>Number of participants who got better according to HPGA and PGA.<br/>HPGA:<br/>Laser: 10/18<br/>Control: 5/18<br/>PGA:<br/>Laser: 10/18 </p> <p>Control: 1/18</p> <p>POSAS: Patient part (P = .047)</p> <p>Observer part: not significant (details not provided)</p> <p> </p> <p>Lin 2011:</p> <p>HDTA laser: not significant</p> <p>LDTA: P = 0.001 (data presented only in graphs)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAFL versus no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 RCTS (Verhaeghe 2013; 22 participants, 44 segments; Lin 2011; 20 participants; 20 scars) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verhaeghe 2013: treatment‐related adverse effects included erythema, edema, burning sensation, crusts, purpura, vesicles, hyperpigmentation. Duration: 3 months </p> <p> </p> <p>Lin 2011: side effects, including worsening (erythema, pigmentation, or texture), discolouration, exfoliation, swelling, scabbing, and pain related to treatment, rated on a quartile scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe) during the 3 month‐period. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verhaege 2013:</p> <p>Percentage of participants reporting treatment‐related adverse effects 4 days after treatment (out of 18 analysed):<br/>NAFL treatment: </p> <p>Erythema: 70%</p> <p>Edema: 20%</p> <p>Burning sensation: 18%</p> <p>Crusts: 15%</p> <p>Purpura: 7% purpura</p> <p>Vesicles: 3%</p> <p>After 3 months: Hyperpigmentation: 1 participant</p> <p>*In a small group of participants, the treated part improved less than the untreated part. </p> <p>Median pain (related to treatment) score (IQR) on a VAS (0 = no pain and 100 = worst possible pain) was:<br/>Session 1: 37.0 (26.0–53.5) Session 2: 41.0 (26.7–60.7) </p> <p>Session 3: 53.0 (22.5–71.0) Session 4: 48.0 (23.5–78.5)</p> <p> </p> <p>Lin 2011:</p> <p>Number of participants reporting scar worsening</p> <p>HDTA: 3/10</p> <p> </p> <p>Higher risk of erythema, exfoliation, and pain related to treatment with HDTA compared with LDTA (P = 0.05, P = 0.02, P = 0.01, respectively) (data on side effects were presented only in graphs). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAFL versus no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar size, colour, height, length, width, pliability, skin surface texture, pruritus and pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 RCTS (Verhaeghe 2013; 22 participants, 44 segments; Lin 2011; 20 participants; 20 scars) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verhaeghe 2013: redness, pigmentation, and skin texture after 3 months</p> <p> </p> <p>Lin 2011: erythema, pigmentation, texture after 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verhaeghe 2013:</p> <p>No significant difference in redness, pigmentation, and skin texture (details not provided) </p> <p> </p> <p>Lin 2011: Mean + SD</p> <p>Erythema:<br/>HDTA: 1.33 + 1.26 </p> <p>Control: 0.89 + 0.95</p> <p>LDTA: 1.06 + 1.26<br/>Control: 0.94 + 1.20 </p> <p>Pigmentation:</p> <p>HDTA: 1.06 + 0.95</p> <p>Control: 0.94 + 0.82</p> <p>LDTA: 0.79 + 0.76</p> <p>Control: 0.71 + 0.76</p> <p>Texture:</p> <p>HDTA: 2 + 0.76</p> <p>Control: 1.78 + 0.89</p> <p>LDTA: 2.19 + 0.95<br/>Control: 1.63 + 0.95 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fractional CO<sub>2</sub> Laser versus no treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 RCTS (Azzam 2016: 30 participants; 60 segments, Blome‐Eberwein 2016: 36 participants; 80 scars, Daoud 2019: 23 participants; 46 segments) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azzam 2016: patient satisfaction, as follows:</p> <p>excellent = more than 75 %, good = 50 to 75%, moderate = 25 to 50 % and poor = less than 25 % improvement after 3 months </p> <p> </p> <p>Azzam 2016 and Blome‐Eberwein 2016 used the VSS, including pliability, height, colour, and vascularity </p> <p> </p> <p>Blome‐Eberwein 2016 and Daoud 2019: POSAS</p> <p>including: vascularisation, pigmentation, thickness,</p> <p>relief, pliability, and surface area (observer), itching, colour, and pain not related to treatment </p> <p>stiffness, thickness, and relief (patient)</p> <p>(range 6 to 60) after up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azzam 2016: Number of participants that reported each satisfaction</p> <p>Keloid scar participants</p> <p>Excellent: 6/12</p> <p>Good: 3/12</p> <p>Moderate: 3/12</p> <p>Hypertrophic scar patients<br/>Excellent: 2/7 </p> <p>Good: 1/7</p> <p>Moderate: 2/7</p> <p>Poor: 2/7</p> <p> </p> <p>Azzam 2016:<br/>VSS (Mean + SD) </p> <p>Keloid scar patients</p> <p>Laser: 5.7 + 2.2</p> <p>Control: 7.6 + 1.0</p> <p>Hypertrophic scar patients</p> <p>Laser: 4.6 + 2.5</p> <p>Control: 7.6 + 2.9</p> <p> </p> <p>Blome‐Erbewein 2016</p> <p>VSS (Mean + SD)</p> <p>Hypertrophic scar patients</p> <p>Laser: 6.5 + 2.39</p> <p>Control: 6.41 + 2.31</p> <p> </p> <p>Blome‐Eberwein 2016</p> <p>POSAS</p> <p>Pre‐treatment<br/>Laser: 32.64 ± 12.41<br/>Control: 29.91 ± 13.03 </p> <p>Post‐treatment</p> <p>Laser: 28.51 ± 12.85</p> <p>Control: 24.38 ± 11.41</p> <p> </p> <p>Daoud 2019<br/>POSAS </p> <p>Significant improvements in all categories except for colour (P &lt; 0.001) (results presented in graphs) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fractional CO<sub>2</sub> Laser versus no treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Daoud 2019 23 participants; 46 scar segments)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No definition provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The authors mention that no treatment‐related adverse effects were reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fractional CO<sub>2</sub> Laser versus no treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar size, colour, height, length, width, pliability, skin surface texture, pruritus and pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 RCTS (Azzam 2016: 30 participants; 60 segments;,Blome‐Eberwein 2016: 36 participants; 80 scars) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azzam 2016: pruritus and pain not related to treatment after 3 months</p> <p> </p> <p>Blome‐Eberwein 2016</p> <p>Scar pliability and height evaluated with suction cup and ultrasound, colour; erythema and pigmentation assessed with Dermaspectrometer), sensation, pruritus, and pain not related to treatment evaluated with POSAS after up to 6 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azzam: number of participants complaining of pruritus and pain</p> <p>Pruritus: 16</p> <p>Pain: 5</p> <p>(details not provided)</p> <p> </p> <p>Blome‐Eberwein 2016: pliability, height, recoil Mean and SD – before and after treatment</p> <p>Scar height</p> <p>Pre‐intervention</p> <p>Laser: 3.15 ± 0.37</p> <p>Control: 2.658 ± 0.344</p> <p>Post‐treatment:</p> <p>Laser: 2.34 ± 0.313</p> <p>Control: 2.46 ± 0.342</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><b>HDTA:</b> high‐density treatment arm; <b>HPGA:</b> Health Professional Global Assessment; <b>IQR:</b> interquartile range; <b>LDTA:</b> low‐density treatment arm; <b>PGA:</b> patient global assessment; <b>POSAS:</b> Patient and Observer Scar Assessment Scale; (In POSAS, highest values indicate worse scar or sensation); <b>SD:</b> standard deviation; <b>VAS:</b> visual analogue scale; <b>VSS:</b> Vancouver Scar Scale. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Laser versus no treatment outcome details</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/full#CD011642-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011642-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Laser versus other treatments outcome details</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comparison</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trials (participants)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Definition of outcome in trial/measurement details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>585‐nm PDL versus TAC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 RCTs (Omranifard 2007: 80 participants; 80 scars and Manuskiatti 2002: 10 participants; 20 segments) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Omranifard 2007: Patient Satisfaction assessed by VBS, including pigmentation, vascularity, pliability and height (photographs were taken). Self‐assessment: number of participants who considered their scars better or much better after up to 12 months Manuskiatti 2002: categories of 25% increments of improvement in scar severity after 32 weeks (graded by the participant) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Omranifard 2007:</p> <p>VBS (Mean + SD)</p> <p>Post‐treatment</p> <p>PDL: 4.2 + 1.6</p> <p>TAC: 6.7 + 1.6</p> <p>Self‐assessment</p> <p>PDL: 70%</p> <p>TAC: 30%</p> <p>Manuskiatti 2002:</p> <p>Number of participants with a 50% improvement or higher</p> <p>PDL: 8/10</p> <p>TAC: 10/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>585‐nm PDL versus TAC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 RCTs (Omranifard 2007: 80 participants; 80 scars and Manuskiatti 2002: 10 participants; 20 segments) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Omranifard 2007: complications, such as textural or discolouration (hypo‐ or hyperpigmentation) during up to 12 months Manuskiatti 2002: Immediate treat reactions included mild to moderate pain during treatment, burning sensation, spots of purpura, erosion secondary to blistering. Treatment‐related adverse sequelae including hypopigmentation, telangiectasia, and skin atrophy during 32 weeks. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Omranifard 2007: no complication was observed</p> <p>Manuskiatti 2002:</p> <p>Sequelae:</p> <p>PDL: 0/10<br/>TAC: 5/10 (Hypopigmentation 2, Telangiectasia 2, skin atrophy 1)<br/>Mild to moderate pain related to treatment:<br/>PDL: 9/10 </p> <p>Control: 10/10 (further details not provided)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>585‐nm PDL versus TAC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 RCTs (Omranifard 2007: 80 participants; 80 scars and Manuskiatti 2002: 10 participants; 20 segments) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar size, colour, height, length, width, pliability, skin surface texture, pruritus and pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Omranifard 2007: vascularity, using a transparent tool for blanching the scar. Scar height scores: calliper by measuring the maximum vertical elevation of the scar above the normal skin after up to 12 months Manuskiatti 2002: scar height evaluated using a dial calliper, erythema using a hand‐held colorimeter after 32 weeks. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Omranifard 2007:</p> <p>Vascularity (Mean)</p> <p>Pre‐treatment PDL: 2.3</p> <p>TAC: 2.3</p> <p>Post‐treatment</p> <p>PDL: 1.1</p> <p>TAC: 1.95</p> <p>Height (Mean)</p> <p>Pre‐treatment</p> <p>PDL: 2.16</p> <p>TAC: 2.18</p> <p>Post‐treatment</p> <p>PDL: 1.32</p> <p>TAC: 1.93</p> <p>Manuskiatti 2002: No significant difference between groups in height (results presented only in graphs) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>585‐nm PDL versus 5‐FU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Manuskiatti 2002: 10 participants; 20 segments)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Manuskiatti 2002: categories of 25% increments of improvement in scar severity after 32 weeks (graded by the participant). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Manuskiatti 2002:</p> <p>Number of participants with a 50% improvement or higher</p> <p>PDL: 8/10<br/>5‐FU: 10/10 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>585‐nm PDL versus 5‐FU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Manuskiatti 2002: 10 participants; 20 segments)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Manuskiatti 2002: immediate treatment reactions included mild to moderate pain during treatment and spots of purpura during 32 weeks. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Manuskiatti 2002:<br/>Mild to moderate pain during the injection:<br/>PDL: 9/10<br/>5‐FU: 10/10<br/>  </p> <p>Purpura:<br/>PDL: 10/10 </p> <p>5‐FU: 2/10</p> <p> </p> <p>No permanent sequelae were reported in the areas submitted to laser therapy or 5‐FU.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>585‐nm PDL versus 5‐FU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Manuskiatti 2002: 10 participants; 20 segments)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Manuskiatti2002: scar height evaluated using a dial calliper, erythema using a hand‐held colorimeter after 32 weeks. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant difference between groups in height (results presented only in graphs)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>585‐nm PDL versus TAC plus 5‐FU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Manuskiatti 2002: 10 participants; 20 segments)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Manuskiatti 2002: categories of 25% increments of improvement in scar severity after 32 weeks (graded by the participant). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Manuskiatti 2002:</p> <p>Number of participants with a 50% improvement or higher</p> <p>PDL: 8/10</p> <p>TAC plus 5‐FU: 9/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>585‐nm PDL versus TAC plus 5‐FU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Manuskiatti 2002: 10 participants; 20 segments)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Manuskiatti 2002: immediate treatment reactions included mild to moderate pain during treatment and spots of purpura during 32 weeks. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Manuskiatti 2002:<br/>Mild to moderate pain during the injection:<br/>PDL: 9/10<br/>5‐FU: 10/10<br/>  </p> <p>Purpura:<br/>PDL: 10/10 </p> <p>5‐FU: 3/10</p> <p> </p> <p>No permanent sequelae were reported in the areas submitted to laser therapy or 5‐FU.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>585‐nm PDL versus TAC plus 5‐FU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Manuskiatti 2002: 10 participants; 20 segments)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Manuskiatti2002: scar height evaluated using a dial calliper, erythema using a hand‐held colorimeter after 32 weeks. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild to moderate pain not related to treatment</p> <p>PDL: 9/10</p> <p>TAC plus 5‐FU: 10/10</p> <p>No significant difference between groups in height (results presented only in graphs).</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>585‐nm PDL versus Silicone Gel Sheeting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Wittenberg 1999; 20 participants; 40 segments)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wittenberg 1999: No definition is provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wittenberg 1999: one participant dropped out due to pain during laser treatment. One participant did not use SGS because of skin irritation. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Erbium laser versus TAC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Omranifard 2007: 80 participants; 80 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Omranifard 2007: Patient Satisfaction assessed by VBS, including pigmentation, vascularity, pliability and height. (photographs were taken) Self‐assessment: improvement of the scars severity after up to 12 months. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Omranifard 2007:</p> <p>VBS (Mean + SD)</p> <p>Post‐treatment</p> <p>Erbium: 4.6 + 1.9</p> <p>TAC: 6.7 + 1.6</p> <p>Self‐assessment (number of participants who considered their scars better or much better) </p> <p>Erbium: 65%</p> <p>TAC: 30%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Erbium laser versus TAC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Omranifard 2007: 80 participants; 80 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Omranifard 2007: complications, such as textural or discoloration (hypo‐ or hyperpigmentation) during up to 12 months. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Omranifard 2007: no complication was observed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Erbium laser versus TAC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Omranifard 2007: 80 participants; 80 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Omranifard 2007: vascularity, using a transparent tool for blanching the scar. Scar height scores: calliper by measuring the maximum vertical elevation of the scar above the normal skin after up to 12 months. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Omranifard 2007:</p> <p>Vascularity (Mean)</p> <p>pre‐treatment</p> <p>Erbium: 2.4</p> <p>TAC: 2.3</p> <p>Post‐treatment</p> <p>Erbium: 1.15</p> <p>TAC: 1.95</p> <p>Height (Mean)</p> <p>Pre‐treatment</p> <p>Erbium: 2.18</p> <p>TAC: 2.18</p> <p>Post‐treatment</p> <p>Erbium: 1.39</p> <p>TAC: 1.93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fractional CO<sub>2</sub> Laser versus TAC </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Srivastava 2019; 40 participants; 40 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Srivastava 2019: VSS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Srivastava 2019 Results of full scale were not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fractional CO<sub>2</sub> Laser versus TAC </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Srivastava 2019; 40 participants; 40 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Srivastava 2019: pain at injection site, telangiectasia, skin atrophy and charring were evaluated and reported (when they occurred) during 24 weeks. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Srivastava 2019:</p> <p>Number of participants reporting treatment‐related adverse effects</p> <p>Pain at injection site</p> <p>FCO2: 2/20</p> <p>TAC: 8/20</p> <p>Telangiectasia</p> <p>FCO2: 0/20</p> <p>TAC: 2/20</p> <p>Skin atrophy</p> <p>FCO2: 0/20</p> <p>TAC: 1/20</p> <p>Charring</p> <p>FCO2: 3/20</p> <p>TAC: 0/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fractional CO<sub>2</sub> Laser versus TAC </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Srivastava 2019; 40 participants; 40 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Srivastava 2019: height measured with callipers; vascularity by visual inspection; pliability by palpation; pigmentation after blanching (using a piece of clear plastic sheet till scar flattening occurred) and comparing it with the surrounding skin, pruritus, and pain not related to treatment after 24 weeks. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Srivastava 2019:</p> <p>Height (Mean + SD)</p> <p>Pre‐treatment</p> <p>FCO2: 1.95 + 0.76</p> <p>TAC: 1.75 + 0.64</p> <p>Post‐treatment<br/>FCO2: 0.25 + 0.44 </p> <p>TAC: 0 + 0</p> <p>Vascularity</p> <p>Pre‐treatment</p> <p>FCO2: 2.05 + 0.69</p> <p>TAC: 1.65 + 0.49</p> <p>Post‐treatment<br/>FCO2: 0.45 + 0.51 </p> <p>TAC: 0 + 0</p> <p>Pliability</p> <p>Pre‐treatment</p> <p>FCO2: 1.85 + 0.67</p> <p>TAC: 1.9 + 0.64</p> <p>Post‐treatment<br/>FCO2: 0.9 + 0.31 </p> <p>TAC: 0 + 0</p> <p>Pigmentation</p> <p>Pre‐treatment</p> <p>FCO2: 1.60 + 0.50</p> <p>TAC: 1.7 + 0.47</p> <p>Post‐treatment<br/>FCO2: 0.8 + 0.41 </p> <p>TAC: 0.8 + 0.41</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fractional CO<sub>2</sub> Laser versus Verapamil </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Srivastava 2019; 40 participants 40 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Srivastava 2019: VSS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Srivastava 2019: Results of full scale were not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fractional CO<sub>2</sub> Laser versus Verapamil </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Srivastava 2019; 40 participants 40 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Srivastava 2019: pain at injection site, telangiectasia, skin atrophy and charring were evaluated and reported (when they occurred) during 24 weeks. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Srivastava 2019:</p> <p>Number of participants reporting treatment‐related adverse effects</p> <p>Pain at injection site</p> <p>FCO2: 2/20</p> <p>Verapamil: 0/20</p> <p>Telangiectasia</p> <p>FCO2: 0/20</p> <p>Verapamil: 0/20</p> <p>Skin atrophy</p> <p>FCO2: 0/20</p> <p>Verapamil: 0/20</p> <p>Charring</p> <p>FCO2: 3/20</p> <p>Verapamil: 0/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fractional CO<sub>2</sub> Laser versus Verapamil </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Srivastava 2019; 40 participants 40 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Srivastava 2019: height measured with callipers; vascularity by visual inspection; pliability by palpation; pigmentation after blanching (using a piece of clear plastic sheet till scar flattening occurred) and comparing it with the surrounding skin, pruritus, and pain not related to treatment after 24 weeks. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Srivastava 2019:</p> <p>Height (Mean + SD)</p> <p>Pre‐treatment</p> <p>FCO2: 1.95 + 0.76</p> <p>Verapamil: 2.05 + 0.6</p> <p>Post‐treatment<br/>FCO2: 0.25 + 0.44 </p> <p>Verapamil: 0.05 + 0.22</p> <p>Vascularity</p> <p>Pre‐treatment</p> <p>FCO2: 2.05 + 0.69</p> <p>Verapamil: 1.95 + 0.69</p> <p>Post‐treatment<br/>FCO2: 0.45 + 0.51 </p> <p>Verapamil: 0.1 + 0.31</p> <p>Pliability</p> <p>Pre‐treatment</p> <p>FCO2: 1.85 + 0.67</p> <p>Verapamil: 2.1 + 0.64</p> <p>Post‐treatment</p> <p>FCO2: 0.9 + 0.31</p> <p>Verapamil: 0 + 0</p> <p>Pigmentation</p> <p>Pre‐treatment</p> <p>FCO2: 1.60 + 0.50</p> <p>Verapamil: 1.65 + 0.49</p> <p>Post‐treatment<br/>FCO2: 0.8 + 0.41 </p> <p>Verapamil: 0.55 + 0.51</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><b>5‐FU:</b> Fluorouracil; <b>PDL:</b> Pulsed‐Dye Laser; <b>TAC:</b> Triamcinolone acetonide;<b>VSS:</b> Vancouver Scar scale. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Laser versus other treatments outcome details</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/full#CD011642-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011642-tbl-0006"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Laser plus other treatments versus other treatments outcome details</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comparison</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. of Trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Definition of outcome in trial/measurement details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>585‐nm PDL plus TAC plus 5 FU versus TAC plus 5‐FU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Asilian 2006; 43 participants; 43 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asilian 2006: patient and Observer: no improvement; poor = up to 25% improvement; fair = 26% to 50% improvement; good = 51% to 75% improvement; (for the observer assessment photographs were taken) after 12 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asilian 2006:</p> <p>Number of participants and observers reporting good to excellent improvement OA</p> <p>585‐nm PDL plus TAC plus 5 FU: 14/20</p> <p>TAC plus 5‐FU: 8/20</p> <p>PSA</p> <p>585‐nm PDL plus TAC plus 5 FU: 15/20</p> <p>TAC plus 5‐FU: 11/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>585‐nm PDL plus TAC plus 5 FU versus TAC plus 5‐FU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Asilian 2006; 43 participants; 43 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asilian 2006: treatment‐related adverse effects including the presence of purpuric areas by observer interviews during 12 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asilian 2006:</p> <p>In the TAC plus 5‐FU plus PDL group the lesions became purpuric which lasted from 7 to 10 days </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>585‐nm PDL plus TAC plus 5 FU versus TAC plus 5‐FU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Asilian 2006; 43 participants; 43 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asilian 2006: scar length and width using a dial calliper, height using a calliper, erythema, pliability, and pruritus: graded by the observer on a 5‐point scale: 0 = no; 1 = mild; 2 = moderate; 3 = severe; and 4 = very severe. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asilian 2006:</p> <p>Erythema</p> <p>Pre‐treatment</p> <p>PDL plus TAC plus 5‐FU: 3.2</p> <p>TAC plus 5‐FU: 3.3</p> <p>Post‐treatment</p> <p>TAC plus 5‐FU plus PDL: 1.2</p> <p>TAC plus 5‐FU: 1.9</p> <p>Reduction in height (average lesion)</p> <p>TAC plus 5‐FU: 77%</p> <p>PDL plus TAC plus 5‐FU: 79%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CO<sub>2</sub> Laser plus TAC versus Cryosurgery plus TAC </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Behera 2016: 60 participants; 101 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Behera 2016: patient and observer on a 5‐point scale as, poor = up to 25% improvement; fair = 26% to 50% improvement; good = 51% to 75% improvement; and excellent = 76% to 100% improvement (for the observer assessment photographs were taken) VSS after up to 12 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Behera 2016:</p> <p>Number (%) of participants with an improvement of 50% or higher in the scar:</p> <p>PSA:</p> <p>CO<sub>2</sub> Laser plus TAC: 27 (75%); </p> <p>Cryosurgery plus TAC: 21 (77.78%)</p> <p>OA:</p> <p>CO<sub>2</sub> Laser plus TAC: 22 (61.12%); </p> <p>Cryosurgery plus TAC: 23 (85.18%)</p> <p>VSS: CO<sub>2</sub> Laser plus TAC: 19 (52.78%); </p> <p>Cryosurgery plus TAC: 17 (62.96%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CO<sub>2</sub> Laser plus TAC versus Cryosurgery plus TAC </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Behera 2016: 60 participants; 101 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Behera 2016: no definition was provided (after up to 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Behera 2016:</p> <p>CO<sub>2</sub> Laser plus TAC: 6 (16.66%) </p> <p>Cryosurgery plus TAC: 0 (0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CO<sub>2</sub> Laser plus TAC versus Cryosurgery plus TAC </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Behera 2016: 60 participants; 101 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Behera 2016: no definition was provided (during up to 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Behera 2016:</p> <p>Number (%) of participants with atrophy CO<sub>2</sub> Laser plus TAC: 17 (47.23%); Cryosurgery plus TAC: 15 (55.56%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CO<sub>2</sub> Laser plus TAC versus Cryosurgery plus TAC </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Behera 2016: 60 participants; 101 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Behera 2016: height: using a dial calliper, volume, pruritus, and pain not related to treatment after up to 12 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Behera 2016:<br/>Height (mean percentage reduction + SD): </p> <p>CO<sub>2</sub> Laser plus TAC: 49.31 + 50.42; </p> <p>Cryosurgery plus TAC: 65.46 + 35.63</p> <p>Volume (Mean percentage reduction + SD):</p> <p>CO<sub>2</sub> Laser plus TAC: 54.81 + 47.96; </p> <p>Cryosurgery plus TAC: 72.69 + 37.75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nd:YAG laser plus Intralesional corticosteroid plus 5‐FU versus Intralesional corticosteroid plus 5‐FU </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Chen 2017: 46 participants; 46 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chen 2017: patient and observer on a 5‐point scale as, poor = up to 25% improvement; fair = 26% to 50% improvement; good = 51% to 75% improvement; and excellent = 76% to 100% improvement (for the observer assessment photographs were taken) after 3 months. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chen 2017:</p> <p>OA:</p> <p>Number (%) of participants with an improvement of 51% or higher in the scar:</p> <p>Nd:YAG laser plus Intralesional corticosteroid plus 5‐FU: 16 (69.57%);</p> <p>Intralesional corticosteroid plus 5‐FU: 11 (47.83%)</p> <p>PSA: Nd:YAG laser plus Intralesional corticosteroid plus 5‐FU: 18 (78.26%);</p> <p>Intralesional corticosteroid plus 5‐FU: 13 (56.52%%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nd:YAG laser plus Intralesional corticosteroid plus 5‐FU versus Intralesional corticosteroid plus 5‐FU </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Chen 46 participants; 46 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chen 2017: no definition was provided (during 3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chen 2017:</p> <p>Almost all injections were painful.</p> <p>Nd:YAG plus Intralesional corticosteroid plus 5‑FU: the site treated by Nd:YAG became purpuric, which lasted for 7 to 10 days. </p> <p>No adverse textural or pigmentary alterations, and no ulcers or erosions were observed in either groups. No further information was provided regarding adverse events in the trial. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nd:YAG laser plus Intralesional corticosteroid plus 5‐FU versus Intralesional corticosteroid plus 5‐FU </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Chen 46 participants; 46 scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chen 2017: erythema, pliability, and pruritus were graded by the observer on a 5‐point scale: 0 = no erythema; 1 = mild erythema; 2 = moderate erythema; 3 = severe erythema; and 4 = very severe erythema after 3 months. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chen 2017:</p> <p>Erythema (P &lt; 0.05), pliability (P &lt; 0.05), and pruritus (P &lt; 0.05) were significantly lower in the laser group (data provided only in graphs). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>He‐Ne laser plus Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream versus Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Alsharnoubi 2018: 15 participants; 30 segments)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alsharnoubi 2018: VSS, including skin thickness, pigmentation, and vascularity after 3 months. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alsharnoubi 2018:</p> <p>VSS: median values</p> <p>Pre‐treatment: 9 (value of the whole scar)</p> <p>Post treatment He‐Ne laser plus Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream: 4; </p> <p>Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream: 6;</p> <p>Height score:</p> <p>Pre‐treatment: 2 (value of the whole scar)</p> <p>Post treatment He‐Ne laser plus Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream: 1; </p> <p>Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream: 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>He‐Ne laser plus Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream versus Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Alsharnoubi 2018: 15 participants; 30 scar segments)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Definition was not provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No treatment‐related adverse effects were reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>He‐Ne laser plus Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream versus Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Alsharnoubi 2018: 15 participants; 30 scar segments)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alsharnoubi 2018: scar thickness using an ultrasound imaging system, perfusion (erythema) using a Laser Doppler perfusion imager. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alsharnoubi 2018:</p> <p>Skin thickness (mean ± SD)</p> <p>Pre‐treatment: 0.52 ± 0.17 mm (whole scar)</p> <p>Post treatment He‐Ne laser plus Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream: 0.34 ± 0.09 mm; </p> <p>Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream: 0.43 ± 0.13 mm </p> <p>Perfusion</p> <p>Pre‐treatment: 1.27 ± 0.54 V (whole scar)</p> <p>Post treatment He‐Ne laser plus Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream: 0.8 ± 0.23 V; </p> <p>Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream: 0.77 ± 0.24 V Pigmentation </p> <p>Pre‐treatment: 2 (whole scar)</p> <p>Post Treatment He‐Ne laser plus Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream: 0; </p> <p>Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream: 2;</p> <p>Vascularity</p> <p>Pre‐treatment: 2 (whole scar)</p> <p>Post Treatment</p> <p>He‐Ne laser plus Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream: 1 </p> <p>Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream: 1 (data presented in graphs) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PDL plus intralesional verapamil versus intralesional verapamil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Khattab 2019; 40 participants; 50 keloid scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khattab 2019: VSS, keloid height measured with callipers; pliability by palpation; vascularity by visual inspection, and pigmentation scored after blanching and comparing it with the surrounding skin after 24 weeks. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khattab 2019:</p> <p>Height (Mean + SD)</p> <p>PDL plus verapamil: 0.21 ± 0.56;</p> <p>Verapamil: 3.10±1.85</p> <p>Pliabilty: PDL plus verapamil: 0.20±0.41;</p> <p>Verapamil: 2.07±0.26</p> <p>Vascularity</p> <p>PDL plus verapamil: 0.03 ± 0.70;</p> <p>Verapamil: 0.87±0.74 Pigmentation</p> <p>PDL plus verapamil: 0.13 ± 0.35;</p> <p>Verapamil: 0.27±0.70</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PDL plus intralesional verapamil versus intralesional verapamil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Khattab 2019; 40 participants; 50 keloid scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of treatment‐related adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khattab 2019: treatment‐related adverse effects were regrowth, pain, hyperpigmentation, depigmentation, and purpura during 24 weeks. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khattab 2019:</p> <p>Treatment‐related adverse events:<br/>Regrowth<br/>PDL plus verapamil: 3 (12%)<br/>Verapamil: 2 (8%)<br/>Pain<br/>PDL plus verapamil: 1 (4%);<br/>Verapamil: 0 (0%)<br/>Hyperpigmentation<br/>PDL plus verapamil: 2 (8%)<br/>Verapamil: 0 (0%)<br/>Depigmentation<br/>PDL plus verapamil: 1 (4%)<br/>Verapamil: 1 (4%)<br/>Purpura<br/>PDL plus verapamil: 7 (28%)<br/>Verapamil: 0 (0%)<br/>Total<br/>PDL plus verapamil: 14 (56%)<br/>Verapamil: 3 (12%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PDL plus intralesional verapamil versus intralesional verapamil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT (Khattab 2019; 40 participants; 50 keloid scars)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khattab 2019: height, vascularity, pliability, and pigmentation were assessed at 24 weeks. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khattab 2019:<br/>Height<br/>PDL plus verapamil: 0.21 + 0.56;<br/>Verapamil: 3.1 + 1.85<br/>Vascularity<br/>PDL plus verapamil: 0.03 + 0.07; </p> <p>Verapamil: 0.87 + 0.74</p> <p>Pliability</p> <p>PDL plus verapamil: 0.2 + 0.41;</p> <p>Verapamil: 2.07 + 0.26</p> <p>Pigmentation</p> <p>PDL plus verapamil: 0.13 + 0.35;</p> <p>Verapamil: 0.27 + 0.7</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><b>5‐FU:</b> Fluorouracil; <b>NdYAG:</b> neodymium‐doped yttrium aluminium garnet; <b>PDL:</b> Pulsed‐Dye Laser; <b>SD:</b> standard deviation; <b>TAC:</b> Triamcinolone acetonide;<b>VSS:</b> Vancouver Scar scale. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Laser plus other treatments versus other treatments outcome details</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/full#CD011642-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011642-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">585‐nm Pulsed‐Dye Laser (PDL) versus no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Severity of scar: Patient self‐assessment (32 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [1.11, 3.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Incidence and severity of treatment‐related adverse effects (32 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Mild to moderate discomfort or pain related to treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.62 [1.10, 67.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Purpura</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>21.32 [3.14, 144.86]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">585‐nm Pulsed‐Dye Laser (PDL) versus no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011642-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Non‐ablative Fractional Laser (NAFL) versus no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Severity of scar: Health Professional Global Assessment (3 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Incidence and severity of treatment‐related adverse effects (3 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 High‐Density Treatment Arm (HDTA) versus control, scar worsening (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Non‐ablative fractional Laser (NAFL) versus no treatment, mild hyperpigmentation (3 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Scar size, colour, height, length, width, pliability, skin surface texture, pruritus and pain (3 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 High‐Density Treatment Arm (HDTA) versus control, erythema (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 High‐Density Treatment Arm (HDTA) versus control, pigment (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.3 High‐Density Treatment Arm (HDTA) versus control, texture (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.4 Low‐Density Treatment Arm (LDTA) versus control, erythema (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.5 Low‐Density Treatment Arm (LDTA) versus control, pigment (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.6 Low‐Density Treatment Arm (LDTA) versus control, texture (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Non‐ablative Fractional Laser (NAFL) versus no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011642-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Fractional carbon dioxide (CO2) versus no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Severity of scar: Vancouver Burn Scar (VBS) scale (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Hypertrophic scar</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.30 [‐4.32, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Keloid scar</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.90 [‐3.02, ‐0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Severity of scar: Patient and Observer Scar Assessment Scale (POSAS) (at least one month) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Scar size, colour, height, length, width, pliability, skin surface texture, pruritus and pain (12 to 18 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 Height</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 Erythema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.3 Pigmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.4 Pain not related to treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.5 Pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Fractional carbon dioxide (CO2) versus no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011642-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">585‐nm Pulsed‐Dye Laser (PDL) versus Triamcinolone acetonide (TAC)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Severity of scars: Vancouver Burn Scar (VBS) scale (up to 12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Severity of scars: Patient self‐assessment (up to 12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Split‐scar trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 Parallel trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Incidence and severity of treatment‐related adverse effects (up to 12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 Sequelae (32 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.2 Mild to moderate pain during the intervention (32 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">585‐nm Pulsed‐Dye Laser (PDL) versus Triamcinolone acetonide (TAC)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011642-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">585‐nm Pulsed‐Dye Laser (PDL) versus 5‐Fluorouracil (5‐FU)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Severity of scars: Patient self‐assessment (32 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Incidence and severity of treatment‐related adverse effects (32 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 Mild to moderate discomfort or pain related to treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.2 Purpura</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">585‐nm Pulsed‐Dye Laser (PDL) versus 5‐Fluorouracil (5‐FU)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011642-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">585‐nm Pulsed‐Dye Laser (PDL) versus Triamcinolone acetonide (TAC) plus 5‐Fluorouracil (5‐FU)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Severity of scars: Patient self‐assessment (32 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Incidence and severity of treatment‐related adverse effects (32 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 Mild to moderate discomfort or pain related to treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.2 Purpura</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">585‐nm Pulsed‐Dye Laser (PDL) versus Triamcinolone acetonide (TAC) plus 5‐Fluorouracil (5‐FU)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011642-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">585‐nm Pulsed‐Dye Laser (PDL) versus Silicone Gel Sheeting</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Incidence and severity of treatment‐related adverse effects (24 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.1 Pain during treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.2 Skin irritation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">585‐nm Pulsed‐Dye Laser (PDL) versus Silicone Gel Sheeting</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011642-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Erbium laser versus Triamcinolone acetonide (TAC)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Severity of scars: Vancouver Burn Scar (VBS) scale (up to 12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Severity of scars: Patient self‐assessment (up to 12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Erbium laser versus Triamcinolone acetonide (TAC)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011642-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Fractional carbon dioxide (CO2) laser versus intralesional Triamcinolone acetonide (TAC)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Incidence of treatment‐related adverse effects (24 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.1 Pain at injection site</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.2 Telangiectasia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.3 Skin atrophy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.4 Charring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain (12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.1 Height (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.2 Vascularity (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.3 Pliability (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.3 Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain (24 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.1 Pigmentation (24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Fractional carbon dioxide (CO2) laser versus intralesional Triamcinolone acetonide (TAC)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011642-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Fractional carbon dioxide (CO2) laser versus Intralesional Verapamil</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Incidence of treatment‐related adverse effects (24 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.1 Charring (24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.2 Pain at injection site (24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain (12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.1 Height</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.2 Pigmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.3 Vascularity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.4 Pliability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.3 Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain (24 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3.1 Height</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3.2 Pigmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3.3 Vascularity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Fractional carbon dioxide (CO2) laser versus Intralesional Verapamil</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011642-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">585‐nm Pulsed‐Dye Laser (PDL) plus Triamcinolone acetonide (TAC) plus 5‐Fluorouracil (5‐FU) versus TAC plus 5‐FU</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 Severity of scars (12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.1 Scar improvement good to excellent: observer assessment (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.2 Scar improvement good to excellent: Patient self‐assessment (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">585‐nm Pulsed‐Dye Laser (PDL) plus Triamcinolone acetonide (TAC) plus 5‐Fluorouracil (5‐FU) versus TAC plus 5‐FU</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011642-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Carbon dioxide (CO2) Laser plus Triamcinolone acetonide (TAC) versus Cryosurgery plus TAC</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.1 Severity of scars (12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.1 Mean percentage reduction in Observer Assessment score (12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.2 Mean percentage reduction in Patient Self‐Assessment score (12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.3 Mean percentage reduction in Vancouver Burn Scale (VBS) score (12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.2 Incidence and severity of treatment‐related adverse effects (12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2.1 Atrophy (12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2.2 Erythema (12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2.3 Telangiectasia (12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2.4 Hypopigmentation (12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.3 Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain(12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3.1 Mean percentage reduction of scar height (12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3.2 Mean percentage reduction of scar volume (12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.4 Recurrence of the condition (12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Carbon dioxide (CO2) Laser plus Triamcinolone acetonide (TAC) versus Cryosurgery plus TAC</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011642-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Neodymium‐doped yttrium aluminum garnet (Nd:YAG) laser plus intralesional corticosteroid diprospan plus 5‐Fluorouracil (5‐FU) versus Intralesional corticosteroid diprospan plus 5‐FU</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.1 Severity of scars (3 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.1 Scar improvement good to excellent: Observer assessment (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.2 Scar improvement good to excellent: Patient self‐assessment (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Neodymium‐doped yttrium aluminum garnet (Nd:YAG) laser plus intralesional corticosteroid diprospan plus 5‐Fluorouracil (5‐FU) versus Intralesional corticosteroid diprospan plus 5‐FU</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011642-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Helium–neon (He‐Ne) laser plus Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream versus Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.1 Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain (12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.1 Skin thickness (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Helium–neon (He‐Ne) laser plus Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream versus Decamethyltetrasiloxane, Polydimethylsiloxane and Cyclopentasiloxane cream</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011642-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">595‐nm Pulsed‐Dye Laser (PDL) plus intralesional verapamil versus intralesional verapamil</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.1 Incidence of treatment‐related adverse effects (24 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1.1 Regrowth (24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1.2 Treatment‐related pain (24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1.3 Hyperpigmentation (24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1.4 Depigmentation (24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1.5 Purpura (24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1.6 Total (24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.2 Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain (change from baseline) (12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2.1 Height (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2.2 Vascularity (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2.3 Pliability (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2.4 Pigmentation (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.3 Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain (change from baseline) (24 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3.1 Height (24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3.2 Vascularity (24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3.3 Pliability (24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3.4 Pigmentation (24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">595‐nm Pulsed‐Dye Laser (PDL) plus intralesional verapamil versus intralesional verapamil</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011642.pub2/references#CD011642-tbl-0021">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011642.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011642-note-0018">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011642-note-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011642-note-0017">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD011642-note-0015">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD011642-note-0013">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD011642-note-0014">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD011642-note-0012">Português</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011642-note-0010">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD011642-note-0011">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011642\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011642\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011642\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011642\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011642\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011642\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011642\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011642\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011642\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011642\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011642\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011642\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011642\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011642\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011642\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011642\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011642\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011642\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=FKeXZrqu&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011642.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011642.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011642.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011642.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011642.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727218166"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011642.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727218170"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011642.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ea6ae98999365',t:'MTc0MDcyNzIxOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 